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 i  
ABSTRACT 
Mycobacterium tuberculosis, the etiological agent of tuberculosis, has a unique cell envelope 
which accounts for its unusual low permeability and contributes to resistance against common 
antibiotics. The mycobacterial cell wall consists of a cross-linked network of peptidoglycan 
(PG) in which some of the muramic acid residues are adorned with a complex polysaccharide, 
arabinogalactan (AG), via a unique α-L-rhamnopyranose–(1→3)-α-D-GlcNAc-(1→P) linker 
unit. Whilst the cytoplasmic steps of mycobacterial cell wall biosynthesis have been largely 
delineated, the molecular processes that govern the flux of PG intermediates and the 
mechanism by which PG and AG pathways converge has remained elusive. We identified key 
conserved serine/threonine residues of MurC, as potential candidates for phospho-regulation 
by the cognate protein kinase, PknA. Pseudo-phosphorylated MurC mutants exhibited 
differential enzyme activity, suggesting that M. tuberculosis is capable of tight control of PG 
biosynthesis through phosphorylation of MurC. In addition, we have identified Lcp1, a 
mycobacterial orthologue of the LytR-CpsA-Psr (LCP) family of proteins found in Gram-
positive bacteria, responsible for ligating cell wall teichoic acids to PG. We demonstrate that 
lcp1 is an essential gene required for cell viability and show that recombinant Lcp1 is a 
phosphotransferase capable of ligating AG to PG in a cell free radiolabelled assay. 
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1. INTRODUCTION 
1.1. Tuberculosis 
1.1.1. Etiology of Tuberculosis 
Tuberculosis (TB) is a severe pulmonary disease that is prevalent globally, caused by the 
human pathogen Mycobacterium tuberculosis (Cambau and Drancourt, 2014). Primarily 
affecting the respiratory system, symptoms of active TB disease consist of persistent 
coughing, wasting, exhaustion and finger clubbing (through poor oxygenation). Later signs of 
the disease include coughing with sputum and/or blood and associated chest pain, shortness of 
breath, possible anaemia and potential leucocytosis (due to the immune response causing 
large numbers of leukocytes to migrate to the site of infection) (Knechel, 2009). 
Extrapulmonary TB has also become a problem in recent times, as the increase in incidence of 
Human Immunodeficiency Virus (HIV) allows the disease to take hold in organs, other than 
the lungs, much easier by spreading throughout the lymphatic and circulatory systems after an 
initial pulmonary infection. This kind of TB infection can be difficult to diagnose as 
symptoms are often non-specific, yet will most likely become progressively worse without 
treatment (Elder, 1992). Of all new cases reported in 2014, almost 900,000 were 
extrapulmonary disease cases (WHO, 2015). 
Transmissible through airborne droplet nuclei, M. tuberculosis can infect the lungs once 
inhaled, and initiate innate immune response (Knechel, 2009).  This causes macrophages to 
engulf the mycobacterial cells within phagosomes and try to destroy them through fusion with 
lysosomes, to form phagolysosomes (Smith, 2003). Inside the phagolysosomes, M. 
tuberculosis cells are bombarded with reactive oxygen species (ROS), lysosomal enzymes 
and even acidic pH, however, protection provided by the unique ‘waxy’ cell wall of M. 
tuberculosis allows it to survive, and even continue replicating slowly inside the macrophage 
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(Smith, 2003, Knechel, 2009). Released cytokines and antigen presentation by the 
macrophages begin to recruit T lymphocytes to the site of infection, which then begin to 
attempt to contain the spread of M. tuberculosis cells. The recruitment of monocytes, 
neutrophils as well as the lymphocytes causes the formation of a granuloma, with the infected 
macrophages in the centre (Smith, 2003, Sakamoto, 2012). Eventually, due to the hypoxic 
conditions of the granuloma, the central macrophages die and form necrotic lesions, in which 
the M. tuberculosis cells are able to adapt and survive (e.g. by regulating protein expression) 
(Knechel, 2009). Over time, the necrotic regions become caseous, characterised by low 
oxygen, low pH, limited nutrients as well as toxic fatty acids, where M. tuberculosis cells are 
unable to replicate (Smith, 2003, Knechel, 2009). These non-replicating M. tuberculosis cells 
can then remain in a dormant state for years, being kept in check by the host immune system 
by fibrosis and calcification of the granuloma (Knechel, 2009). However, if the infected host 
becomes immunocompromised or possess a less than adequate immune system to begin with, 
then the stability of the granuloma is compromised. The fibrous walls of the lesion begin to 
degrade, and the calcified tissue becomes liquefied. This allows the semi-liquid necrotic tissue 
to drain into blood vessels, and lesions fill with air. Because of this, the M. tuberculosis cells 
become free, and allow infected hosts to begin to spread the disease to others through droplet 
nuclei, as well as allowing the cells to spread to other areas of the lung and body, where the 
organisms can start new granulomas (Knechel, 2009).   
TB is an extremely old disease, being prevalent for thousands of years. One of the oldest 
known confirmed cases of TB infection in humans is over 7000 years ago, in ancient 
Hungary. The skeletal remains of a young male adult were examined and found to display 
signs of hypertrophic pulmonary osteopathy (HPO) (Masson et al., 2013). A form of 
hypertrophic osteoarthropathy, HPO is characterised by deposit of newer bone upon the 
diaphyses of long bones, which leaves identifiable differences between the two layers. A 
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common cause of HPO in modern times is intrathoracic cancer, but it is also an indicator of 
M. tuberculosis infection (Armstrong et al., 2007, Masson et al., 2013). The remains showed 
bone changes within the ribs and vertebrae also. Because of these symptoms, ancient DNA 
(aDNA) was extracted from various bones via polymerase chain reaction (PCR) amplification 
of specific M. tuberculosis complex regions, and then sequenced. Lipid biomarkers were also 
extracted and analysed from bone samples. Both aDNA and lipid biomarkers confirmed the 
presence of M. tuberculosis, and thus supports the hypothesis that the young male adult did 
have a TB infection (Masson et al., 2013). Similar techniques were used to prove the 
existence of M. tuberculosis within the skeletal remains of a woman and infant who were 
buried over 9000 years ago in an area in the Neolithic eastern Mediterranean (now 
submerged) (Hershkovitz et al., 2008).  This suggests that the bacterium has evolved 
alongside humans for a very long time, and helps to explain why it is such an efficient human 
pathogen.  
1.1.2. Taxonomy of Mycobacterium tuberculosis  
The causative agent of TB in humans, M. tuberculosis, is an acid-fast staining bacterium that 
is part of the Actinomycetales order of the Actinobacteria phylum and class. It is a member of 
the Corynebacterineae suborder and the Mycobacteriaceae family. M. tuberculosis is 
therefore related to other members of the Corynebacterineae suborder (e.g. Corynebacterium 
glutamicum) and other mycobacterial species (e.g. Mycobacterium smegmatis and 
Mycobacterium leprae), and shares some genetic identity with these species. However, M. 
tuberculosis is a member of a group of closely related species, called the Mycobacterium 
tuberculosis complex. Members of this group are mycobacteria that cause TB or TB like 
symptoms in a wide range of hosts and therefore members have similar genetic identity to 
each other (as high as 99 % identity). Some examples of members of this complex are 
Mycobacterium africanum, Mycobacterium canetti (which both cause human TB) 
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Mycobacterium bovis (bovine TB) and Mycobacterium microti (vole TB) (Bouakaze et al., 
2010). Furthermore, mutations can lead to changes in phenotype, giving rise to different 
strains within each species. M. tuberculosis H37Rv and CDC1551 differ in their pathogenic 
capability, since H37Rv can create larger, and a greater number of tubercles than CDC1551, 
which has an impact on the virulence of the latter strain (Manabe et al., 2003).   
Because of the close genetic similarities between strains and species, it is possible to use 
different organisms as model systems to study M. tuberculosis. This is important, as it allows 
for mycobacterial study without the requirement of Biosafety Level (BSL) 3 laboratories and 
training, since non-pathogenic substitutes (such as M. bovis BCG, an attenuated strain) can be 
used in lower BSL laboratories (e.g. BSL 2) (Mahairas et al., 1996). It also means that 
research can proceed much faster with the use of quicker growing model organisms (such as 
M. smegmatis), since M. tuberculosis is extremely slow growing in comparison (M. 
smegmatis doubling time 2-5 h, M. tuberculosis doubling time 18-54 h) (Gill et al., 2009).    
1.1.3. Epidemiology of TB disease 
TB is prevalent worldwide, with both Africa and Asia having the highest incidence 
(approximately 86 % of all cases combined). Globally, there were more than 9.6 million 
estimated new cases of TB during 2014 (Figure 1.1) and 1.5 million deaths (1.1 million from 
HIV negative cases (Figure 1.2) and 390,000 deaths from HIV positive associated cases). Of 
these, 480,000 cases were estimated to be multi-drug resistant (MDR) TB, which resulted in 
190,000 deaths (WHO, 2015). South East Asia and Western Pacific countries reported 58 % 
of all TB cases in 2014. Of these, India, Indonesia and China account for the highest 
incidence, 43 % of TB cases in 2014 (23 % (around 2.2 million), 10 % (around 960,000) and 
10 % (around 960,000) respectively) were reported in these countries alone (WHO, 2015). 
African countries accounted for 28 %, with the remaining cases prevalent in the Eastern 
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Mediterranean (8 %), the Americas (3 %) and European regions (3 %) (Figure 1.1) (WHO, 
2015). However, TB is a severe problem in the so called 22 ‘High Burden Countries’ (HBC) 
(e.g. Russia, African countries such as Ethiopia and Kenya, and Asian countries such as 
Bangladesh), as these account for 83 % of all cases globally. These countries mostly have 
incidence rates of 150-300 per 100,000 of the population; however Mozambique and 
Zimbabwe have incidences of over 500 per 100,000. South Africa and Swaziland have a very 
severe incidence as it is estimated that at least 1 in 100 people will contract TB each year 
(1000+ per 100,000 of the population) (Figure 1.1) (WHO, 2015). However, after 2015 the 
list of HBCs will be increased, and split into 3 new lists for TB, MDR-TB and TB/HIV. These 
will encompass 30 countries in each list, which are defined as incidence of more than 10,000 
cases annually for TB, or 1,000 cases for MDR-TB and TB/HIV (WHO, 2015).  
 
 
Figure 1.1: Map of global incidence of new TB cases in 2014. The highest incidence is found in sub-
Saharan Africa (in particular South Africa), as well as countries in South East Asia. The lowest incidence of new cases are in Western Europe, North America and Australia (WHO, 2015). 
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The highest incidence of TB including both cases and deaths occur in men, but the disease is 
also very prevalent in women, as the number of new cases in women during 2014 was 3.2 
million (33.3% of the total), whereas 1 million cases were in children aged 15 or below (10.4 
% of the total) (WHO, 2015). TB is one of the top 3 causes of death in women in the world 
(along with other lower respiratory infections, the other 2 top causes being ischemic heart 
disease and stroke); with the disease killing around 480,000 (140,000 HIV positive deaths).  
Therefore, nearly half of all deaths by TB in 2014 were women (almost half of all HIV 
positive deaths) (WHO, 2015). However, 140,000 deaths in 2014 were children (55,000 HIV 
positive deaths), which emphasises that TB is a disease that can affect all (WHO, 2015). 
1.1.4. Treatment of TB 
The disease is treatable with a selection of anti-TB agents, but if ignored it can eventually 
cause death (Knechel, 2009). Without an effective treatment program, in cases of sputum 
smear-positive (cases where TB has been confirmed by microscopy of sputum samples) HIV 
Figure 1.2: Map of deaths from HIV negative cases of TB worldwide in 2014. The highest incidence 
of death correlates with incidence of cases (figure 1.1), whereby the most deaths are in sub-Saharan Africa, as well as South East Asia, in particularly Indonesia. The lowest death rates are seen in Western Europe, the Americas and Australia  (WHO, 2015). 
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negative TB, it is likely that 70% of patients will die within 10 years of contracting the 
disease (Tiemersma et al., 2011).  However, the treatment of TB is becoming increasingly 
difficult with the rise of MDR, extensively drug resistant (XDR) and now reported totally 
drug resistant (TDR) strains of the disease becoming globally more common (Udwadia et al., 
2012, Velayati et al., 2009). Drug resistance is believed to be largely due to mismanagement 
of TB cases and is defined as in vivo resistance to isoniazid and rifampicin (MDR) as well as 
any fluoroquinolone and at least one injectable drug (e.g. capreomycin, kanamycin, etc) 
(XDR) (Sotgiu et al., 2011).  
Current front line drug treatments against TB are around 50 years old, but do not have a 100% 
success rate of curing HIV negative TB (WHO, 2012). The current treatment for TB is termed 
Directly Observed Therapy Shortcourse (DOTS), which was introduced by the World Health 
Organisation (WHO) in 1995 as a way to monitor treatment of patients and maintain 
adherence to the drug plan (Davies, 2003). DOTS is defined by WHO as a five element plan, 
consisting of: Political commitment and funding, Case confirmation through microbiological 
services, Standardised observed treatment, Consistent drug supply and Evaluation of the 
treatment (WHO, 2015). However, poor understanding of DOTS, and the underfunding by 
some countries leads to poor adherence to the program (Davies, 2003). The regime of drugs is 
also rigorous, requiring a 6 month course, of rifampicin, isoniazid, ethambutol and 
pyranzidamine for the first 2 months, followed by 4 months of just rifampicin and isoniazid. 
However, in cases of extrapulmonary TB treatment will often be extended to 12 months, and 
any case of drug resistance TB will require 20 months of drug treatment (WHO, 2012). Drug 
resistant TB requires a great deal of time to treat, down to drug susceptibility screening that 
must be performed before treatment can commence. However, delays in this testing can 
exacerbate the disease, not only for the individual, but it can allow for further spreading 
throughout the population, especially in countries designated as high burden (Rifat et al., 
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2015). However, recent research suggests the use of β-lactam antibiotics can be used in 
conjunction with β-lactamase inhibitors to restore antibiotic activity in both MDR and XDR 
TB strains to the same level as susceptible strains of the disease (Hugonnet et al., 2009). This 
is significant as many of these drugs already have FDA approval, so could be put into use 
rapidly. Nevertheless, full compliance with DOTS and the drug treatment regime still only 
provides a survival rate of 85 % (some cases less than 70 %), with MDR-TB survival rates 
being even lower, indicating the urgent requirement for new front line anti-TB agents (Davies, 
2003, WHO, 2015).  
1.1.4.1. Rifampicin 
 
 
 
 
 
 
 
 
 
 
 
 
 
Each of the four front line drugs inhibit the growth of mycobacteria with distinct modes of 
action. The mechanism of action of rifampicin is the inhibition of RNA polymerase (RNAP) 
to block RNA synthesis (Figure 1.3) (McClure and Cech, 1978). This is achieved by the 
Figure 1.3: Structure of Rifampicin. 
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binding of rifampicin to the β-subunit of RNAP, which causes the synthesis of RNA to arrest 
after the first phosphodiester bond is formed, due to steric hindrance in a process termed 
abortive initiation (Wehrli, 1983). Rifampicin additionally causes a 2-3 fold reduction in 
binding affinity of RNAP for nucleotide triphosphates, such as ATP, further reducing the 
ability of the cell to produce RNA (McClure and Cech, 1978). Resistance to rifampicin arises 
through mutations in the β-subunit gene rpoB, specifically within a 81 base pair region 
between codons 504-533 (Somoskovi et al., 2001). The most commonly found mutations 
occur at positions 516, 526 and 533 and are responsible for around 90 % of rifampicin 
resistant strains (Pang et al., 2013). The most frequently seen mutations are Ser531Leu and 
His526Asp, both of which provide high level resistance to rifampicin compared to other 
mutations, increasing the average MIC from 0.2 µg/mL, to >32 µg/mL (Somoskovi et al., 
2001, van Ingen et al., 2011). However, mutations present in other parts of the 81 base pair 
region do not provide such high resistance as these 2 common mutations (however they can 
still provide a 5 fold increase in MIC) (Pang et al., 2013). An additional source of rifampicin 
resistance comes from the use of active efflux pumps by the cell, which can be attributed to 
around 5 % of resistance seen. M. tuberculosis that is rifampicin-resistant is believed to 
upregulate efflux pumps in order to provide additional low level resistance to the drug (Pang 
et al., 2013).  
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1.1.4.2. Isoniazid 
 
 
 
 
 
 
 
Isoniazid is a pro-drug that causes inhibition of mycolic acid biosynthesis, an essential 
component of the mycobacterial cell wall (Figure 1.4) (Section 1.2.4.). Isoniazid becomes 
activated by the catalase-peroxidase KatG, into numerous radicals, one of which (an 
isonicotinyl-acyl radical) binds to NAD+/NADH to form an isoniazid-NADH adduct 
(Timmins and Deretic, 2006). This adduct then binds to the NADH-dependant enoyl-acyl 
carrier protein reductase, InhA (a part of the fatty acid synthase (FAS) II system), which 
causes a disruption to mycolic acid synthesis as fatty acids cannot become elongated 
(Marrakchi et al., 2000, Kremer et al., 2003). Since isoniazid is a pro-drug, there are 
numerous ways that the bacterium can acquire resistance. The most commonly found feature 
within resistant strains is a mutation in katG, Ser315Thr, found within 40 % of resistant 
isolates (Somoskovi et al., 2001). This mutation decreases the catalase-peroxidase ability of 
the enzyme to around 30-40 % activity, which is enough to continue function, but does not 
activate isoniazid (Marttila et al., 1998). An alternative method of resistance to isoniazid 
employed by the cell is mutations within the inhA gene. A biochemical study provides 
evidence that the Ser91Ala mutation in InhA causes a decrease in the binding affinity between 
the enzyme and the isoniazid-NADH adduct, due to a disruption of the hydrogen bonding 
network, showing a 30-fold increase in Ki value (172 nM compared to 5 nM for wild-type). 
Figure 1.4: Structure of Isoniazid. 
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This decrease in binding affinity results in an increase in resistance of Mycobacterium to 
isoniazid (Vilcheze et al., 2006).  
1.1.4.3. Ethambutol 
 
 
 
 
 
 
 
Ethambutol has a unique mode of action, whereby it inhibits proper biosynthesis of 
arabinogalactan, which is a crucial connective cell wall macromolecule (Figure 1.5) (Section 
1.2.3.). The use of ethambutol on replicating mycobacteria showed that it caused an 
immediate accumulation of a major intermediate in arabinan biosynthesis, β-D-
arbinofuranosyl-1-monophosphoryldecaprenol (DPA), as well as a build-up of trehalose 
monomycolates (TMM) and trehalose dimycolates (TDM), with no mycolylation of the cell 
wall occurring (Mikusova et al., 1995). This suggested that the action of ethambutol is to 
prevent the polymerisation of mycobacterial arabinan (which provides the site for mycolate 
attachment), and thus led to the identification of a set of arabinosyltransferases, known as 
EmbA and EmbB, as the target of ethambutol in M. tuberculosis (Belanger et al., 1996). 
Although very little is known about the site of action of ethambutol, EmbA and EmbB are 
known to work as a heterodimer to elongate the arabinan chain and it has been shown that 
overexpression of the embCAB locus of genes conveys resistance to the drug and restores 
arabinan biosynthesis (Belanger et al., 1996, Amin et al., 2008). A mutation in EmbB is 
commonly found at Met306, in around 66.7 % of resistant isolates (Ramaswamy et al., 2004). 
HN
NH
OH
HO
Figure 1.5: Structure of Ethambutol. 
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Changes in this residue can give an MIC value generally twice as high as wild-type, since 
Met306Leu/Val gives an MIC of 40 µg/mL, whereas Met306Ile gives an MIC of 20 µg/mL. 
Cells with wild-type EmbB have an MIC of 5-15 µg/mL, which means these mutations lead to 
an increase in resistance (Sreevatsan et al., 1997). However, it has been shown that mutations 
at EmbB306 have been found in ethambutol sensitive strains, which has led to the suggestion 
that mutations at EmbB306 lead to a predisposition of the cell to acquire further mutations in 
different genes that lead to high-level resistance to ethambutol (Srivastava et al., 2009). In 
particular, mutations in ubiA have been shown to increase production of the intermediate DPA 
(Section 1.2.3.2), whereas mutations in aftA can lead to overexpression of embC (since aftA is 
immediately upstream of embC), both of which can interact with mutations in embB and lead 
to an increase in MIC value above that of wild-type (Safi et al., 2013). 
1.1.4.4. Pyrazinamide 
 
 
 
 
 
 
The mechanism of action of pyrazinamide is yet to be elucidated, however there are currently 
a number of theories behind how it takes action. Pyrazinamide (Figure 1.6) is known to be a 
pro-drug that is activated by pyrazinamidase into pyrazinoic acid (Konno et al., 1967).  This 
accumulation of pyrazinoic acid is thought to cause disruption to the plasma membrane due to 
the acidic pH and disrupt membrane transport, although the significance of this remains 
unsolved (Zhang et al., 2003). More recent research has suggested a downstream target of 
pyrazinoic acid as ribosomal protein S1, RpsA, which has a role in trans-translation (the 
N
N
NH2
O
Figure 1.6: Structure of Pyrazinamide. 
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rescue of ribosomes that have stalled mid-translation) (Shi et al., 2011). Resistance to 
pyrazinamide is usually associated with mutations within pncA, the gene encoding the 
pyrazinamidase (72-97 % of isolates) (Somoskovi et al., 2001). This is further evidenced due 
to the natural resistance of M. bovis and M. bovis BCG to pyrazinamide, since these bacteria 
carry a mutation within pncA (Cys169Gly) that prevents the drug from becoming activated 
(Scorpio and Zhang, 1996). However, pncA in M. tuberculosis has been found with mutations 
throughout the sequence that prevent activation of pyrazinamide (Scorpio and Zhang, 1996). 
Despite these mutations being highly prevalent, mutations have been identified within rpsA in 
isolates that do not contain any pncA mutations, yet still display pyrazinamide resistance (2-3 
fold increase in MIC value) (Shi et al., 2011). This provides further evidence of RpsA as a 
target of the drug, but also shows a risk for an increase in resistance routes to pyrazinamide.   
Each front line drug plays a crucial part in the combinational therapy against TB. Rifampicin 
is the most important drug within the regime, as it is bactericidal against both metabolically 
active and stationary M. tuberculosis cells, which therefore targets the majority of the 
infection (Arbex et al., 2010). As a cell wall targeting prodrug, isoniazid is effective in killing 
rapidly growing bacteria, yet slower growing cells are relatively unaffected (Zhang, 2005). 
Likewise, ethambutol has a bacteriostatic effect on rapidly growing M. tuberculosis (both 
intracellular and extracellular cells), but does not have any real effect on slower growing cells 
(Zhang, 2005). Finally, pyrazinamide is bactericidal against stationary M. tuberculosis and is 
used to sterilise the persistent bacterial populations within macrophages and prevents relapse 
of the disease from these cells (Arbex et al., 2010). The inclusion of pyrazinamide within the 
drug regime reduces the length of time of rifampicin treatment to 6 months overall (Arbex et 
al., 2010). The inclusion of isoniazid with rifampicin during the final 4 months of the regime, 
despite isoniazid only being active against rapidly growing bacteria, is because of the 
different stages of granulomas found within the lungs (Sakamoto, 2012). Some granulomas 
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will degrade sooner than others, meaning M. tuberculosis cells will become metabolically 
active at different times during the drug regime, therefore isoniazid must be present in order 
to combat these active persistent bacteria throughout treatment (Zhang, 2005, Arbex et al., 
2010).  
Such a complex combinational therapy is required against TB in order to avoid the rise of 
drug resistance and still be able to combat the disease even if it does arise (Cottarel and 
Wierzbowski, 2007). Each front line drug has a distinct target and mode of action, which 
prevents cross-resistance from becoming an issue. If a drug is used on its own, then M. 
tuberculosis would likely become resistant to it very quickly, whereas the combination of 
drugs reduces the likelihood of this occurring (Bakker-Woudenberg et al., 2005). However, 
new anti-tuberculosis drugs are urgently required, not just to try and tackle persistent cells in 
order to reduce the length of therapy, but also drugs that target some aspect of mycobacterial 
cell wall biosynthesis, in order to replace isoniazid or ethambutol in cases where resistance is 
found. In order to develop such antimicrobials, it is therefore incredibly important for us to 
understand the molecular architecture of such a complex structure as the mycobacterial cell 
wall, as well its biosynthesis, so that it may be exploited in the future.  
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1.2. Mycobacterial cell wall 
1.2.1. Molecular architecture of the cell wall 
The cell wall is an essential component to almost all prokaryotes, as it serves to protect the 
cell against a hostile external environment, as well as excessive osmotic turgor (Silhavy et al., 
2010). Bacterial cell walls have historically been classified into one of two groups, depending 
upon if they retain Crystal violet during Gram staining, those that do are referred to as Gram-
positive, and those that do not are known as Gram-negative (Bartholomew and Mittwer, 
1952). However, in recent times the use of molecular genetics and cryo-electron microscopy 
are becoming increasingly more popular as methods of identification and classification of 
bacteria (Doolittle, 2005, Sani et al., 2010). The bacteria that are classified as Gram-negative 
(such as Escherichia coli) possess a cell wall that is comprised of a thin peptidoglycan (PG) 
layer, found within the periplasmic space, with a phospholipid/glycolipid (primarily 
lipopolysaccharide) outer membrane surrounding the cell (Silhavy et al., 2010). Both the 
periplasmic space and outer membrane are highly protein rich, many of these proteins are 
involved in nutrient transport both into and out of the cell (Rassam et al., 2015). The major 
difference between Gram-negative and Gram-positive cell walls is the lack of outer 
membrane in Gram-positive bacteria (such as Bacillus subtilis). Because of this, the cell is 
less protected from the environment and compensates by having a much thicker layer of PG 
(Silhavy et al., 2010). Anionic cell wall polymers (CWP) are found throughout the PG layer, 
making up 60 % of the total cell wall mass. These CWPs consist mostly of glycerol phosphate 
or ribitol phosphate bound to glycosyl and D-alaninyl ester residues, known as teichoic acids. 
Cell wall teichoic acids are covalently attached to PG, whereas lipoteichoic acids are 
intercalated into the inner membrane and extend into the PG (Neuhaus and Baddiley, 2003). 
However, the lack of outer membrane means that extracellular proteins need to be bound or 
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anchored to the inner plasma membrane to keep them in place. Alternatively proteins become 
associated with the PG layer, or teichoic acids to prevent them from diffusing away from the 
cell (Silhavy et al., 2010). 
The cell wall of mycobacteria shares some structural features with Gram-positive species, but 
since they do not retain Gram stain, mycobacteria are classified as Gram-indeterminate 
bacteria. As such, mycobacteria resist de-colourisation of the Ziehl-Neelsen stain using acidic 
solvents after being heated and are therefore termed “Acid-fast”. This is due to the relative 
impermeability of the mycolate matrix preventing the stain being removed (Chen et al., 
2012). The M. tuberculosis cell wall possesses a thick PG layer surrounding the inner 
membrane, similar to Gram-positive species. However, in M. tuberculosis it is covalently 
attached to a branched macromolecule called arabinogalactan (AG), which is in turn bound to 
a range of mycolic acids (MA) on the non-reducing end of arabinan chains which cover the 
surface of the cell. Overall, this structure is known as the mycolyl-arabinogalactan-
peptidoglycan (mAGP) complex (Figure 1.7) (Jankute et al., 2015). The mycolic acids on the 
outer most layer of the wall form a bilayer (with free unbound lipids) known as the 
mycobacterial outer membrane (MOM). Although not a true outer membrane like those 
possessed by Gram-negative bacteria, the MOM provides a waxy, largely impermeable barrier 
creating a periplasmic space between the inner membrane and the MOM (Hett and Rubin, 
2008, Cook et al., 2009). The cell wall is further elaborated with the addition of lipomannan 
(LM) and lipoarabinomannan (LAM), which are intercalated glycolipids that are important to 
mycobacteria. These large structures begin with glycosylphosphatidylinositol (GPI), an 
acylated lipid anchor into either the inner membrane or outer membrane, which is bound to a 
branched mannan, further elongated by arabinan chains in the case of LAM. The arabinan 
branches are capped with units of mannose to complete the molecule, which are believed to 
be important in the virulence of mycobacteria, and M. tuberculosis in particular, such as 
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having a role in preventing apoptosis of the infected macrophage, as well as inhibiting 
phagosome-lysosome fusion (Briken et al., 2004, Jankute et al., 2012, Mazurek et al., 2012).  
Recent work using cryo-electron microscopy had shed light on the dimensions of the 
mycobacterial cell wall, as well as its arrangement. It has been shown that overall size of the 
cell wall is around 30 nm in length, broken down to the MOM (7-8 nm), arabinogalactan-
peptidoglycan (AGP) (6-7 nm) and then a region of periplasmic space, rich in LM and LAM, 
that has not been considered in previous models (14-17 nm) (Figure 1.7) (Meroueh et al., 
2006, Hoffmann et al., 2008, Zuber et al., 2008, Sani et al., 2010). NMR data of synthetic PG 
fragments have suggested that rather than the traditional parallel to the plasma membrane 
structure of PG, it actually forms right handed helices consisting of 3 N-acetylglucosamine-N-
acetylmuramic acid repeats per turn (Meroueh et al., 2006). This arrangement of PG suggests 
that the AGP of the mycobacterial cell wall adopts a “scaffold” structure, whereby the 
backbone of the PG and the galactan moiety is perpendicular to the plasma membrane and 
provides rational sites for arabinan attachment (and therefore mycolate attachment) within the 
dimensions of the cell wall (Figure 1.7) (Kaur et al., 2009, Minnikin et al., 2015).  
However, despite a helical structure of PG being proposed, it remains controversial as 
numerous reports dispute this model in Gram-positive bacteria. Experiments performed using 
atomic-force microscopy (AFM) have shown evidence of a planar topography of PG glycan 
strands in both Staphylococcus aureus and Lactococcus lactis, similar to Gram-negative PG 
(Turner et al., 2010, Andre et al., 2010), whereas the same technique showed the PG glycan 
strands in the rod-shaped B. subtilis as 50 nm wide coiled-coils running around the short axis 
of the cell (Hayhurst et al., 2008). Yet, more recently AFM was combined with electron cryo-
tomography (ECT) and in silico modelling, which showed that the cell wall of B. subtilis is 
uniformly dense, not organised into hollow coils, as well as a distinct lack of ~50 nm gaps for 
new coils to be inserted into the cell wall, casting doubt upon the coiled-coil model (Beeby et 
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al., 2013). Through further examination of the orientation of peptide cross-links within the B. 
subtilis PG, which were seen to run in parallel to the long axis of the cell, as well as molecular 
dynamic simulations of the way the PG folds once broken, it was concluded that the glycan 
strands more likely run in a circumferential planar topography (Beeby et al., 2013). However, 
this model does not seem capable of accommodating the long glycan strand lengths seen in 
previous AFM data, suggesting that further research is required before a definitive model is 
produced (Hayhurst et al., 2008). 
Nonetheless, the overall architecture of rod-shaped M. tuberculosis PG remains elusive. Since 
there may not be one over-arching model that pertains to every instance of bacterial PG 
(Lovering et al., 2012, Turner et al., 2014), it is possible that with the spatial constraints of 
the cell wall, as well as the relatively heavy cross-linking in mycobacterial PG, the previously 
mentioned proposed helical model could be likely (Minnikin et al., 2015). Not only does this 
newly proposed model of the M. tuberculosis cell wall take into account the dimensions of 
each “layer” of the cell wall, as well as a periplasmic space between the mycobacterial inner 
membrane (MIM) and AGP, it also proposes an initial anchorage of LM and LAM within the 
MIM based upon a common lipid anchorage to phosphatidylinositol mannosides (PIMs) 
found within the MIM (Figure 1.7) (Minnikin et al., 2015). Previous studies suggest that a 
potential transfer to the MOM at a later date, by an as of yet undefined mechanism, could 
occur since lipoglycans have been found at the cell surface of mycobacteria, but they are also 
present in the membranes of other Actinobacteria which do not possess mycolic acids or an 
outer membrane (Pitarque et al., 2008, Minnikin et al., 2015). However, it should be noted 
that the proposed model structure is made up of data from various members of the 
Corynebacterineae, which despite their many structural similarities, may not pertain to M. 
tuberculosis cell wall structure in the long run (Figure 1.7) (Minnikin et al., 2015).  
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Figure 1.7: Structural representation of the mycobacterial cell wall, showing dimensions and interactions 
between each section. The mycobacterial inner membrane (MIM) is 6-7 nm in size and is interspersed with 
varying phosphatidylinositol mannosides (PIM). Within the periplasmic space (14-17 nm) LM and LAM are anchored to the MIM and extend throughout the space. The “scaffold” structure of AGP spans 6-7 nm and sits perpendicular to the MIM. Helical PG is bound to helical galactan through a unique linker region (α-L-Rhap(1→3)-α-D-GlcNAc-(1→P)), further bound to arabinan chains, which extend outwards and specific non-reducing ends become esterified with mycolic acids. These mycolates (α, keto (K) and methoxy (M)) of varying shapes (U,S and W) form a bilayer with free lipids (diacyl trehalose (DAT), pentaacyl trehalose (PAT), sulfoglycolipid (SGL) and phthiocerol dimycocerosate (PDIM)) on the outside of the cell which is referred to as the mycobacterial outer membrane (MOM) (7-8 nm). GalN and succinyl modifications are made to specific 3,5-Araf residues of arabinan chains of AG and LAM. The whole cell envelope spans roughly 30 nm in total from the cell surface. Figure adapted from Minnikin et al., 2015.  
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1.2.2. Peptidoglycan 
1.2.2.1. Structure of Peptidoglycan 
Present in almost all bacteria, PG is an important component of the cell wall, providing shape, 
rigidity and protection from internal osmotic pressure (Schleifer and Kandler, 1972). In 
addition, mycobacterial PG provides a foundation for additional covalently attached 
molecules that eventually form the mAGP complex (Figure 1.7). The glycan backbone of PG 
typically consists of N-acetylglucosamine (GlcNAc) bound to N-acetylmuramic acid 
(MurNAc) through β(1→4) glycosidic linkages, in a repeating fashion (Figure 1.8) (Brennan 
and Nikaido, 1995). However, it has been identified that mycobacterial PG can incorporate a 
hydroxylated version of MurNAc, N-glycolylmuramic acid (MurNGlyc), providing a mixture 
of two versions within the backbone structure (Figure 1.8) (Mahapatra et al., 2005, Raymond 
et al., 2005). The reason behind the modification of MurNAc to MurNGlyc is yet to be fully 
elucidated, but it is thought to be involved in increasing the overall strength of the PG by 
providing increased sites for hydrogen bonding, as well as reducing the susceptibility of the 
PG to lysozyme, providing enhanced protection to the cell (Brennan and Nikaido, 1995, 
Raymond et al., 2005). Nevertheless, the presence of MurNGlyc within the PG structure 
stimulates mammalian NOD-2 receptors more so than MurNAc, and therefore has a role in 
increasing NOD-2 related immunogenicity within the host (Coulombe et al., 2009). 
Attached to the muramyl components of the backbone, tetrapeptide side chains provide the 
mesh-like structure of PG through cross-linkages. The side chains in M. tuberculosis PG are 
L-alaninyl-D-isoglutaminyl-meso-diaminopimelyl-D-alanine, typically cross-linked (3→4) 
meso-diaminopimelate (m-DAP) to D-alanine (D-ala) (Figure 1.8) (Wietzerbin et al., 1974). 
M. tuberculosis PG shares many features with that of E. coli, being within the same PG group, 
A1γ, based upon the classification system of Schleifer and Kandler (1972). However, 
Chapter 1   Introduction  
22  
HO
O
OH
O
CH3
NH
O
O
NH
CH2
O
OH
O
OCH3
O
HO
O
OH
O
CH3
NH
O
O
NH
CH3
O
OH
OCH3
O HO
-Glycolyl Muramic acid(MurNGlyc)-Acetyl Muramic acid(MurNAc)
RR
-Acetyl Glucosamine(GlcNAc) -Acetyl Glucosamine(GlcNAc)
L-Ala
D-Glu
DAP
D-Ala
L-Ala
D-Glu
DAP
D-Ala D-Ala
DAP
D-Glu
L-Ala
O
O
CH3 O
OH
O
CH3
NH
O
O
NH
CH3
O
OH
O
HO
O
CH3 O
O
OH
O CH3
NH
O
O
NH
CH3
O
OH
HO
RR
mycobacterial PG also contains a high number of (3→3) cross-linkages between m-DAP and 
m-DAP throughout its structure, which increase in number (up to 80 % of all cross-linkages) 
upon entering stationary phase (Figure 1.8) (Lavollay et al., 2008). M. tuberculosis has the 
ability to adjust these cross-linkages from (3→4) to (3→3) without requiring it to perform de 
novo synthesis of PG, which could help to protect the cell from endopeptidase action 
(Lavollay et al., 2008). A further feature that makes mycobacterial PG unique is that it 
provides the site for AG attachment. Hydroxyls at the 6 position of muramyl residues within 
the PG backbone offer a site for a phosphodiester bond to the AG ‘linker unit’, α-L-
Rhamnopyranose-(1→3)-α-D-GlcNAc-(1→P) (McNeil et al., 1990).  
 
 
 
 
 
 
 
 
 
 
 Figure 1.8: The structure of M. tuberculosis PG. Glycan backbone consists of repeating units of GlcNAc and MurNAc, with incorporated MurNGlyc (R side chains represent continuing glycan backbone). Tetrapeptide side chains consisting of L-ala, D-Glu, m-DAP and D-ala are cross-linked both m-DAP to D-ala (3→4) and m-DAP to m-DAP (3→3).  
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1.2.2.2. Synthesis of Peptidoglycan 
An extensive number of proteins are utilised to synthesise PG (Table 1.1), being similar in 
most bacteria. Biosynthesis largely takes part within the cytoplasm, often proposed to start 
with UDP-GlcNAc. However, before this, UDP-GlcNAc is synthesised by 3 enzymes, 
initiated by GlmS which converts D-fructose-6-phosphate to D-glucosamine-6-phosphate 
(Badet et al., 1987). This is then acted on by the mutase GlmM/MrsA, which transfers the 
phosphate group from D-glucosamine-6-phosphate to D-glucosamine-1-phosphate (Li et al., 
2011). The bifunctional action of GlmU is responsible for converting D-glucosamine-1-
phosphate to N-acetylglucosamine-1-phosphate, via acyltransferase activity, and subsequently 
producing UDP-GlcNAc via uridylyltransferase activity, in order to produce the traditional 
‘starting point’ for PG synthesis (Zhang et al., 2008). 
 
 
 
Figure 1.9: Mur ligase pathway showing the synthesis of PG on both sides of the plasma 
membrane. UDP-GlcNAc becomes converted into UDP-MurNAc through the action of MurA and MurB. At this point MurC begins the sequential addition of amino acids, followed by MurD, MurE and MurF to form UDP-MurNAc-pentapeptide. MurX then causes UDP-MurNAc-pentapeptide to become decaprenyl-phosphate linked, known as “Lipid I”. The action of MurG adds GlcNAc to “Lipid I” to form “Lipid II”, which then becomes translocated across the plasma membrane by the action of MurJ/FtsW. Once on the outside of the cell, “Lipid II” becomes transglycoslated and then transpeptidated by the PBP1/PBP2 (PonA1/PonA2) proteins, forming nascent PG.   
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From this point, substrates enter the sequential Mur ligase pathway (Table 1.1, Figure 1.9). 
UDP-GlcNAc is converted to enoylpyruvyl-UDP-N-acetylglucosamine (UDP-
enoylpyruvylGlcNAc) by UDP-N-acetylglucosamine enolpyruvyl transferase activity of 
MurA, using phospho-enoyl-pyruvate as a substrate. This product is then reduced by UDP-N-
acetylpyruvyl-glucosamine reductase (MurB), with the use of NADPH, to form UDP-
MurNAc by conversion of the enolpyruvyl moiety to a lactoyl ether moiety (Benson et al., 
1996). This completes the first ‘stage’ of the pathway. At this point, NamH can hydroxylate 
the methyl group of the MurNAc moiety of UDP-MurNAc into UDP-MurNGlyc to feed into 
the rest of the pathway (Raymond et al., 2005).  From here amino acids are systematically 
adjoined to UDP-Muramyl (either MurNAc or MurNGlyc) to form a pentapeptide, by the 
ATP-dependent Mur ligases. The first of these being the addition of L-alanine (L-ala) by 
UDP-N-acetylmuramyl:L-alanine ligase (MurC) to form UDP-Muramyl-L-ala. The next step 
involves linking up D-isoglutamate (D-isoglu) to form UDP-Muramyl-L-ala-D-isoglu by the 
UDP-N-acetylmuramyl-L-alanine:D-isoglutamate ligase activity of MurD. The D-isoglu 
required by MurD is provided to the cell by the stereochemical conversion of L-glutamate to 
D-isoglu by the racemase MurI (Morayya et al., 2015). Next, m-DAP is attached by UDP-N-
acetylmuramyl-L-alaninyl-D-isoglutamate: meso-diaminopimelate ligase (MurE) to form 
UDP-Muramyl-L-ala-D-isoglu-m-DAP. The final amino acid attached to the chain is the 
dipeptide D-alaninyl-D-alanine (D-ala-D-ala) by the UDP-N-acetylmuramyl-L-alaninyl-D-
isoglutaminyl-meso-diaminopimelate: D-alaninyl-D-alanine ligase activity of MurF (Munshi 
et al., 2013). However, in order to provide the substrate for MurF, L-alanine must first be 
stereochemically inverted into D-alanine, by the racemase Alr (Strych et al., 2001). The D-
alanine is then attached to another D-alanine, by the ligase Ddl, to produce D-ala-D-ala for 
attachment to the growing peptide chain (Figure 1.9) (Feng and Barletta, 2003). This final 
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addition gives rise to ‘Park’s nucleotide’, UDP-Muramyl-L-ala-D-isoglu-m-DAP-D-ala-D-ala 
(Kurosu et al., 2007).  
The third and final ‘stage’ of the Mur pathway involves linking the UDP-Muramyl-
pentapeptide to the cell membrane and flipping it to the outside of the cell (Figure 1.9). A 50-
carbon membrane bound lipid carrier containing 10 isoprenoid units (decaprenyl-phosphate) 
becomes attached to the UDP-Muramyl-pentapeptide via a transferase reaction performed by 
the integral membrane bound enzyme phospho-N-acetylmuramyl-pentapeptide-transferase 
(MraY/MurX), to create “Lipid I”, a membrane bound pentapeptide precursor. GlcNAc is 
then transferred onto “Lipid I” by decaprenyldiphospho-muramylpentapeptide β-N-
acetylglucosaminyltransferase (MurG) to create “Lipid II”, a β 1-4 linked GlcNAc-Muramyl-
pentapeptide. “Lipid II” will become the final monomeric unit of PG structure, and its 
synthesis is the last known step in the Mur ligase pathway (Smith, 2006, El Zoeiby et al., 
2003, Bouhss et al., 1999).  
The process which flips the monomer across the plasma membrane to the outside of the cell is 
currently a debated topic. It was initially thought that the protein involved in this mechanism 
was MurJ in E. coli (Ruiz, 2008), but this has since been debated to be the enzyme FtsW, as 
this has been shown to perform “Lipid II” flippase activity in vitro (Mohammadi et al., 2011). 
However, the Ruiz group have since shown data that shows MurJ having in vivo “Lipid II” 
flippase activity in E. coli (Sham et al., 2014). Nonetheless, further research is required for 
both proteins in order to truly identify and characterise the “Lipid II” flippase. 
Once the monomeric units are outside the cell, they become polymerised by 
transglycosylation reactions, performed by the bifunctional proteins PonA1/PBP1 and 
PonA2/PBP2 (Table 1.1). This process involves the GlcNAc moiety of the “Lipid II” 
monomer becoming attached to the muramyl moiety of the growing PG backbone (Hett et al., 
Chapter 1   Introduction  
26  
2010). The second function of both PonA1 and PonA2 is D,D-transpeptidase activity, which 
form classical (3→4) cross-linkages between m-DAP and D-ala residues of neighbouring 
peptide chains, at the expense of cleavage of the terminal D-ala (Chang et al., 1990). Both 
PonA1 and PonA2 have additional domains, including a transmembrane helix, as well as a 
PASTA (PBP and Serine/Threonine associated) domain. However, these do not behave as 
traditional PASTA domains, as they do not bind to typical ligands such as β-lactams, 
muropeptides or nascent PG (Calvanese et al., 2014). Therefore further characterisation of 
these domains is required. 
When M. tuberculosis enters a non-replicating phase, the cell rearranges the PG in order to 
increase the number of (3→3) cross-linkages between m-DAP and m-DAP, through the action 
of nonclassical L,D-transpeptidases (Table 1.1) (Cordillot et al., 2013). Within the M. 
tuberculosis genome, five paralogues have currently been identified, known as LdtMt1-5, 
however, only LdtMt1 and LdtMt2 depleted strains showed any phenotypic difference within 
their PG structure, since LdtMt3, LdtMt4 and LdtMt5 deficient strains showed no difference in 
growth rate or colony phenotype when compared to wild-type (Schoonmaker et al., 2014). 
These L,D-transpeptidases convert (3→4) cross-linkages to (3→3) through the cleavage of the 
remaining D-alanine residue on the donor peptide chain. This leaves behind a tripeptide side 
chain in the stationary phase PG (Sacco et al., 2010). 
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Gene name Rv number Role Reference glmS*  Rv3436c Converts D-fructose-6-P to  D-GlcN-6-P (Badet et al., 1987) glmM /mrsA* Rv3441c Converts D-GlcN-6-P to D-GlcN-1-P (Li et al., 2011) glmU*  Rv1018c Converts to D-GlcN-1-P to GlcNAc-1-P, then to UDP-GlcNAc (Zhang et al., 2008) murA Rv1315 Converts UDP-GlcNAc to UDP-enoylpyruvylGlcNAc (Kim et al., 1996) murB Rv0482 Converts UDP-enoylpyruvylGlcNAc to UDP-MurNAc  (Benson et al., 1996) murC Rv2152c Attaches L-ala to UDP-MurNAc  (Mahapatra et al., 2000) murD  Rv2155c Adds D-isoglu to L-ala in peptide chain (Smith, 2006) murE Rv2158c Adds m-DAP to D-isoglu in peptide chain (Basavannacharya et al., 2010) murF Rv2157c Adds D-ala-D-ala to m-DAP in peptide chain (Munshi et al., 2013) murX /mraY Rv2156c Attaches lipid to MurNAc-pentapeptide chain (‘Lipid I’) (Bouhss et al., 1999) murG Rv2153c Adds UDP-GlcNAc to MurNAc-pentapeptide-lipid (‘Lipid II’) (Trunkfield et al., 2010) murJ♦  Rv3910 (probable) Translocates ‘Lipid II’ across plasma membrane (Ruiz, 2008) ftsW♦ Rv2154c Translocates ‘Lipid II’ across plasma membrane (Mohammadi et al., 2011) ponA1 /pbp1 Rv0050 Bifunctional: transglycosylation of GlcNAc to MurNAc. Also transpeptidation to cross-link m-DAP to D-ala (3→4) 
(Hett et al., 2010) 
ponA2 /pbp2 Rv3682 (Chang et al., 1990) ldtmt1  Rv0116c    Nonclassical L,D-transpeptidase action, converts (3→4) m-DAP to D-ala cross-linkages to (3→3) m-DAP to m-DAP 
(Schoonmaker et al., 2014) ldtmt2  Rv2518c (Schoonmaker et al., 2014) ldtmt3  Rv1433 (Schoonmaker et al., 2014) ldtmt4  Rv0192 (Schoonmaker et al., 2014) ldtmt4  Rv0483 (Schoonmaker et al., 2014) namH  Rv3808 Converts UDP-MurNAc to UDP-MurNGlyc (Raymond et al., 2005) murI*  Rv1338 Converts L-glutamate to D-isoglu (Morayya et al., 2015) alr*  Rv3423c Converts L-ala to D-ala (Strych et al., 2001) ddl*  Rv2981c Ligates D-ala to D-ala (Feng and Barletta, 2003)  
Table 1.1: List of genes, and their function, involved in the synthesis of Peptidoglycan (PG). 
*Genes are involved the synthesis of precursors to the pathway. ♦Genes are debated to have same role. 
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1.2.3. Arabinogalactan 
1.2.3.1. Structure of Arabinogalactan 
Mycobacterial PG is further elaborated with a unique heteropolysaccharide termed 
arabinogalactan (AG) (Figure 1.7). AG is a branched polysaccharide, covalently attached to 
around 10-12 % of the muramyl units of PG via a phosphodiester bond between the C-6 
hydroxyl of the muramyl residue and the GlcNAc of the AG ‘linker unit’ (LU) (McNeil et al., 
1990). AG is comprised mostly of arabinose and galactose monomer units found only in their 
furanose configuration (Araf and Galf), and can be broken down into 3 seperate components, 
arabinan, galactan and the LU (Figure 1.10) (Crick et al., 2001, McNeil et al., 1987). The LU 
is comprised of P-GlcNAc (bound to decaprenyl-monophosphate before attachment to PG), in 
turn covalently bound to L-rhamnopyranose (Rhap) through an α(1→3) glycosidic bond 
(McNeil et al., 1990). The linear galactan constituent is made up of approximately 30 Galf 
residues alternating β(1→5) and β(1→6) linkages, with the first Galf unit bound to the Rhap 
residue of the LU in an α(1→4) fashion (McNeil et al., 1987, McNeil et al., 1990).   
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Araf residues were found to be attached to specific β(1→6) Galf residues at the 8th, 10th and 
12th positions of the galactan chain within the AG of C. glutamicum, which has largely been 
believed to be the case in M. tuberculosis AG, since mAGP architecture is largely conserved 
across members of the Corynebacterineae (Figure 1.10) (Besra et al., 1995, Alderwick et al., 
2005, Dianiskova et al., 2011). However, more recent research has suggested that M. 
tuberculosis cell walls have only two arabinan chains that are attached to the galactan 
polymer, rather than three, a topic which remains debated (Bhamidi et al., 2011). Nonetheless, 
attached Araf residues are elongated by α(1→5) linkages, with α(1→3) linkages introducing 
3,5-Araf branch points, which become further elongated themselves by additional α(1→5) 
linkages (Figure 1.10) (Amin et al., 2008, Birch et al., 2008). The highly branched arabinan 
chains are terminated at the nonreducing ends by a β(1→2) linkage, with the final structural 
Figure 1.10: The structure of mycobacterial AG. PG bound linker unit (α-L-Rhap(1→3)-α-D-GlcNAc-
(1→P)) is elaborated with approximately 30 Galf units in alternating β(1→5), β(1→6) linkages to form mature galactan. At positions 8, 10 and 12 of the galactan chain, highly branched arabinan is attached, formed of α(1→5) linked Araf residues, with 3,5 branch points introduced by α(1→3) linkages. The non-reducing termini are β(1→2) linked, forming Araf6 terminal motif, which provides the site for mycolate attachment. AG is further modified by addition of GalN or succinyl residues at the 3,5-Araf branch points. Figure adapted from Minnikin et al., 2015 
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motif being [β-Araf-(1→2)-α-Araf]2-3,5-α-Araf-(1→5)-α-Araf, a characteristic hexa-
arabinofuranoside (Araf6) (McNeil et al., 1994). Of this motif, the available C-5 hydroxyls 
represent a site for mycolic acid attachment (Figure 1.7, Figure 1.10). However, only around 
two thirds of these motifs become mycolylated in the final cell wall (McNeil et al., 1991). AG 
is further adorned with a single galactosamine (GalN) residue at the C-2 position of some 
inner 3,5-Araf residues (often the penultimate residue of the Araf6 motif), found as a single 
residue side chain on around one third of chains (Draper et al., 1997, Peng et al., 2012). 
Another substituent found on AG is the addition of succinyl residues, found attached at the 
same locations as GalN residues. These succinyl residues appear on a further one third of 
arabinan chains (Bhamidi et al., 2008). It is suggested that these substituents may have a role 
in strengthening anionic interactions between AG and rest of the cell wall, as well as 
potentially having a role in the orchestration of mycolylation of arabinan chains (Draper et al., 
1997, Bhamidi et al., 2008). 
1.2.3.2. Synthesis of Arabinogalactan 
Biosynthesis of AG requires a plethora of biosynthetic machinery (Table 1.2) and is initiated 
within the cytoplasm, with the formation of the linker region by the enzyme WecA/Rfe. This 
enzyme catalyses the addition of GlcNAc-P (from UDP-GlcNAc) to decaprenyl-
monophosphate (C50-P), to form GlcNAc-P-P-C50, known as glycolipid 1 (GL-1) (Mikusova 
et al., 1996). The linker is completed by the further addition of Rhap (from dTDP-β-L-Rhap) 
by the enzyme WbbL1, to form α-L-Rhap-(1→3)-α-D-GlcNAc-(1→P) (Rha-GlcNAc-P-P-
C50), known as glycolipid 2 (GL-2) (Figure 1.11) (Birch et al., 2008, McNeil et al., 1990). 
The dTDP-Rha that is required for completion of the LU comes from a series of reactions, 
which arise from the action of the products from the gene cluster rmlABCD. Firstly, dTTP is 
attached to α-D-glucose-1-P to form dTDP-α-D-glucose, and release inorganic pyrophosphate 
(PPi), due to the action of the enzyme RmlA (Ma et al., 1997). In the next step, dTDP-α-D-
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glucose 4,6-dehydratase (RmlB) action forms dTDP-α-6-deoxy-D-xylo-4-hexulose which in 
turn becomes epimerised by RmlC to dTDP-β-6-deoxy-L-lyxo-4-hexulose (Stern et al., 1999, 
Ma et al., 2001). Finally, the action of RmlD forms dTDP-β-L-Rhap, which is ready for 
incorporation into the growing LU (Hoang et al., 1999). 
 
 
 
The precursor to galactan synthesis, the high energy donor UDP-Galf, is made through a two-
part reaction (Table 1.2). Firstly, UDP-glucopyranose is converted to UDP-galactopyranose 
(UDP-Galp) through the epimerase action of GalE1. UDP-Galp is then further converted to 
the furanose ring form UDP-Galf by the enzyme Glf (Weston et al., 1997). UDP-
Figure 1.11: Structures of Glycolipid (GL) 1, 2, 3 and 4. GL-1 consists of decaprenyl-P-P-GlcNAc, 
which then becomes GL-2 with the addition of Rhap by Wbbl1. GlfT1 then adds a Galf to form GL-3 and immediately adds an additional Galf to form GL-4. 
Chapter 1   Introduction  
32  
galactofuranosyl transferases (GlfT) then begin to build the galactan chain upon the LU, 
through the enzyme GlfT1, which begins with the catalysis of two units of UDP-Galf onto the 
linker, in a bifunctional capacity. It attaches one Galf to Rha-GlcNAc-P-P-C50 (known as 
glycolipid 3 (GL-3)), then immediately adds another to form Galf-Galf-Rha-GlcNAc-P-P-C50 
(known as glycolipid 4 (GL-4)) (Figure 1.11) (Mikusova et al., 1996, Mikusova et al., 2006). 
GlfT2 then continues to add Galf residues to the growing galactan chain, in a linear fashion of 
alternating 5-linked and 6-linked β-D-Galf, until 30 Galf residues are reached (Kremer et al., 
2001a). The linear galactan is then translocated across the plasma membrane to the outside of 
the cell, by a conserved ABC transport system, the enzymes Wzt and Wzm (Dianiskova et al., 
2011) (Table 1.2).  
Once the completed galactan chain is outside the cell, the highly-branched arabinan can be 
added to the complex. All arabinose within the cell is attained from a single donor molecule, 
β-D-arabinofuranosyl-1-monophosphoryldecaprenol (DPA) (Alderwick et al., 2005) (Table 
1.2). The synthesis of DPA begins with 5-phosphoribosyl-1-pyrophosphate (pRpp), itself 
synthesised by the addition of pyrophosphate from ATP to ribose-5-phosphate by the enzyme 
PrsA (Alderwick et al., 2011b). Ribose-5-phosphate from the donor pRpp is attached to 
decaprenyl-phosphate by UbiA to form decaprenylphosphoryl-5-β-D-phosphoribose (DPPR) 
(Huang et al., 2005). Rv3807c is then believed to cause dephosphorylation of DPPR to give 
rise to decaprenylphosphoryl-5-β-D-ribose (DPR). An epimerisation reaction then occurs, 
catalysed by DprE1 (to form the keto-intermediate DPX) and DprE2, to create DPA (Batt et 
al., 2012, Grover et al., 2014). DprE1 oxidises the hydroxyl moiety at the C-2 of ribose of 
DPR, to form decaprenylphosphoryl-2-keto-β-D-erythro-pentofuranose (DPX). DprE2 then 
reduces the C-2 keto moiety of DPX to form the final donor, DPA (Mikusova et al., 2005). 
The initial Araf residues taken from DPA are attached to the C-5 hydroxyls of Galf residues of 
galactan, at positions 8, 10 and 12, by the first arabinosyltransferase, AftA (Alderwick et al., 
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2006). The arabinan chain is then prolonged by the heterodimer of EmbA and EmbB, which 
cause α(1→5) linkage between Araf monomers (Amin et al., 2008). Internal α(1→3) 
branching is introduced by AftC, and also by the largest arabinosyltransferase AftD, which is 
thought to have other functions (e.g. acting as a scaffold for other multienzymatic complexes) 
due to its large size (Birch et al., 2008, Jankute et al., 2012). The arabinan chains are then 
capped by β(1→2) linkages that form the non-reducing Araf6 motif, catalysed by AftB (Seidel 
et al., 2007). GalN residues are synthesised through a pathway beginning with PpgS, which 
utilises polyprenyl-phosphate and UDP-N-Acetylgalactosamine (UDP-GalNAc) to form 
polyprenyl-P-GalNAc. This then becomes deacetylated and translocated across the membrane 
by an as of yet unknown mechanism. Finally, Rv3779 transfers GalN onto the C-2 position of 
3,5-Araf residues of the arabinan chains (Skovierova et al., 2010). The enzymes and 
mechanisms involved in the attachment of succinyl residues to arabinan chains, currently 
remain unknown (Jankute et al., 2015).  
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Gene name Rv number Role Reference rmlA* Rv0334  Addition of dTTP + α-D-glucose-1-P to form dTDP-α-D-glucose + PPi (Ma et al., 1997) rmlB* Rv3464  Converts dTDP-α-D-glucose to dTDP-α-6-deoxy-D-xylo-4-hexulose (Ma et al., 2001) rmlC* Rv3465  Converts dTDP-α-6-deoxy-D-xylo-4-hexulose to dTDP-β-6-deoxy-L-lyxo-4-hexulose (Stern et al., 1999) rmlD* Rv3266  Uses NADH to convert dTDP-β-6-deoxy-L-lyxo-4-hexulose to dTDP-β-L-Rhap (Hoang et al., 1999) wecA /rfe Rv1302 Attaches GlcNAc-P (from UDP-GlcNAc) to decaprenyl-monophosphate (C50-P) (McNeil et al., 1990) wbbL1  Rv3265c Addition of dTP-β-L-Rhap to GlcNAc-P-P-C50 to form ‘linker unit’ (Birch et al., 2008) galE1* Rv3634c  Conversion of UDP-glucosep to UDP-Galp (Weston et al., 1997) glf* Rv3809c  Conversion of UDP-Galp to UDP-Galf (Weston et al., 1997) glfT1  Rv3782 Addition of initial Galf residues onto linker unit (Mikusova et al., 2006) glfT2  Rv3808c Continuation of Galf addition up to Galf30 – linker unit (Kremer et al., 2001a) wzt  Rv3781 Flips Galf30 - linker unit across membrane alongside Wzm.  (Dianiskova et al., 2011) wzm  Rv3783 Flips Galf30 - linker unit across membrane alongside Wzt. (Dianiskova et al., 2011) aftA  Rv3792 Transfers the first Araf unit onto the Galactan domain (Alderwick et al., 2006) aftB  Rv3805c β(1→2) branching and capping of arabinan (Seidel et al., 2007) aftC  Rv2673 Introduces α(1→3) branching in arabinan (Birch et al., 2008) aftD  Rv0236c α(1→3) branching and potential scaffolding properties (Skovierova et al., 2009) embA  Rv3794 Heterodimer with EmbB, α(1→5) addition of araf to arabinan (Amin et al., 2008) embB  Rv3795 Heterodimer with EmbA, α(1→5) addition of araf to arabinan (Amin et al., 2008) prsA Rv1017c  Transfers PPi from ATP onto ribose-5-P to form pRpp (Alderwick et al., 2011b) ubiA*  Rv3806c Transfer of ribose-phosphate to decaprenyl-phosphate (Huang et al., 2005) ?*  (unknown) Rv3807c  (Believed) Dephosphorylation of DPPR to form DPR  (Grover et al., 2014) dprE1*  Rv3790 First step of DP epimerisation DPR→DPX intermediate (Batt et al., 2012) dprE2*  Rv3791 Second step of DP epimerisation  DPX intermediate→DPA (Batt et al., 2012) ppgS* Rv3631  Addition of polyprenyl-P and UDP-GalNAc to form polyprenyl-P-GalNAc (Skovierova et al., 2010) ? (unknown) Rv3779 Attachment of GalN residues to arabinan chain at C-2 of 3,5-Araf (Skovierova et al., 2010) 
Table 1.2: List of genes, and their function, involved in the synthesis of Arabinogalactan (AG). 
*Genes are involved the synthesis of precursors to the pathway. 
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1.2.4. Mycolic Acids 
1.2.4.1. Structure of Mycolic Acids 
The AG of mycobacteria is decorated with a variety of MAs. In M. tuberculosis, the MAs are 
involved in the permeability of the cell wall, as well as the ability of the cell to form biofilms 
(Ojha et al., 2005, Sambandan et al., 2013). They also have a role in the pathogenicity of M. 
tuberculosis (Glickman et al., 2000, Vander Beken et al., 2011). There are 3 types of MAs 
produced by M. tuberculosis, those being α-, methoxy- and keto- structures. The α-mycolates 
are by far the most abundant within the cell wall, at around 70 %, whereas the methoxy- and 
keto- forms account for 10-15 % each (Takayama et al., 2005). However, all MAs share the 
same basic structure of an alpha-alkyl chain (C26 in length) branching from a meromycolic 
backbone (up to around C60 in length) (Figure 1.12) (Marrakchi et al., 2014). The “mycolic 
motif” at the juncture of the two chains consists of a β-hydroxy acid group (consisting of both 
a carboxylic acid group as well as a hydroxyl group, separated by two carbon atoms) and is a 
conserved characteristic of MAs across the Corynebacterineae (Figure 1.12) (Lea-Smith et al., 
2007). The α-mycolates are found only in a cis-cyclopropane configuration, whereas the 
methoxy- and keto-mycolates can be found as either cis- or trans-cyclopropane 
configurations, with a distal methyl group attached (Watanabe et al., 2002, Jankute et al., 
2015). MAs become modified post-synthesis, with the blend of subtypes altering the fluidity 
and as a result the permeability of the MOM and therefore the cell wall if needed, as well as 
increasing the resistance of the cell wall to oxidative stresses (Yuan et al., 1995).  
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1.2.4.2. Synthesis of Mycolic Acids 
Both Acyl-CoA and Malonyl-CoA act as initial substrates for MA synthesis. Acyl/Malonyl-
CoA is used by the Fatty Acid Synthase (FAS)-I system, a multifunctional enzyme complex, 
for de novo fatty acid synthesis (Figure 1.13) (Bhatt et al., 2007). The FAS-I system can be 
found in eukaryotes and higher prokaryotes, and is comprised of several domains, each with a 
separate enzymatic activity. The order of discreet protein domains begins with an 
acyltransferase, and progresses with an enoyl reductase, dehydratase, malonyl/palmitoyl 
transferase, acyl carrier protein, β-ketoacyl reductase and finally a β-ketoacyl synthase. 
Elongation of the fatty acid chains proceeds by addition of 2 carbons at a time, and all 
intermediate products remain bound to the complex until being released (either at C12-18 for 
further elongation, or C24-26 for use in the complete mycolate) (Bhatt et al., 2007, Smith et al., 
2003). 
Figure 1.12: Basic structure of MAs from M. tuberculosis. Chain 1 represents the meromycolic 
backbone chain (up to C58) containing cis-cyclopropane modifications and additional methoxy- and keto- groups within the corresponding MA subtype. Chain 2, the alpha-alkyl chain (C26), is connected via the β-hydroxy acid “mycolic motif” (in red box). 
Chain 1 
Chain 2 
α- 
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Chapter 1   Introduction  
37  
In order to shuttle FAS-I system products to further elongation, FabH binds to shorter (C12-18) 
acyl-CoA chains and catalyses a condensation reaction with malonyl-AcpM (Mycobacterial 
Acyl carrier protein) to produce acyl-AcpM chains, elongated by C2 (i.e. C14-20). FabH then 
transports its product into the FAS-II system (Figure 1.13) (Bhatt et al., 2007). Malonyl-
AcpM is generated by the transacylation of malonate from malonyl-CoA to holo-AcpM by 
FabD (Kremer et al., 2001b). The FAS-II pathway is, unlike FAS-I, a set of soluble enzymes 
found in prokaryotes and plants that perform fatty acid elongation (Table 1.3). However, 
unlike other bacteria, the M. tuberculosis FAS-II is not capable of de novo synthesis of fatty 
acids, and thus relies on the FAS-I system (Marrakchi et al., 2014, Bhatt et al., 2007). The 
FAS-II enzymes work in a similar fashion to the regions of FAS-I, with both systems utilising 
a C2 group from malonyl-CoA/AcpM for additional elongation, however FAS-II can elongate 
the carbon chain to a much greater extent (Marrakchi et al., 2014). The first enzymes in the 
system are the condensing β-ketoacyl-Acp synthases, KasA and KasB (Figure 1.13). 
Although similar in sequence and function, it is believed that KasA catalyses the inital 
addition of carbons to the chain, whereas KasB is involved in the latter stages of elongation of 
longer meromycolate chains, due to them having different chain length specificities (Bhatt et 
al., 2007). After this, the β-ketoacyl-Acp reductase, MabA, reduces the β-ketoacyl-AcpM to 
β-hydroxyacyl-AcpM, which can then be used as a substrate for the heterodimeric β-
hydroxyacyl-Acp dehydratases, HadAB and HadBC (Figure 1.13) (Marrakchi et al., 2014). 
The action of these enzymes produces an enoyl-AcpM, which is then reduced by NADH-
dependent trans-2-enoyl-Acp reductase, InhA, to once again produce an acyl-AcpM which 
can undergo further elongation by KasB, etc (Figure 1.13) (Marrakchi et al., 2014).  
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Meromycolate chains become modified through the addition of double bonds, a feature of all 
MAs across each MA containing species (Marrakchi et al., 2014). However, the mechanism 
in which M. tuberculosis introduces double bonds into its MAs remains elusive. In 
Streptococcus pneumoniae the enzymes FabM (a trans-2-cis-3-enoyl-ACP isomerase) along 
with FabZ (a dehydratase) were identified as being responsible for shunting fatty acid 
Figure 1.13: Synthesis pathway of MAs in M. tuberculosis. Acetyl-CoA and Malonyl-CoA are fed into 
the FAS-I system for de novo fatty acid synthesis. The products of FAS-I are then shuttled into the FAS-II system by FabH for further elongation. The long chain meromycolate product from FAS-II is then modified, before a condensation reaction performed by Pks13 combines the shorter α-alkyl chain from FAS-I to the meromycolate chain to form an intermediatary mycolic β-ketoester (3-oxo-C78-mycolate). CmrA finally reduces the β-ketoester to form a secondary alcohol and mature mycolate. The mycolate is then conjugated to trehalose to form trehalose monomycolate (TMM), before being transported out of the cell by MmpL3 and finally attached to the cell wall by the antigen 85 complex to complete the mAGP complex. 
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synthesis towards an unsaturated state (Marrakchi et al., 2014). Two potential homologs of 
FabM were identified in M. tuberculosis as EchA10 and EchA11, which are proposed to 
perform the isomerisation of the trans-2 intermediate of the FAS-II system to the hypothetical 
cis-3-enoyl fatty acid, ultimately leading to a cis-double bond at the distal end of the 
meromycolate chain after further elongation (Takayama et al., 2005, Marrakchi et al., 2014). 
However, the fact that both EchA10 and EchA11 are both predicted to be non-essential 
enzymes casts doubt as their role as isomerases, since MAs are essential, the proteins that 
provide isomerase activity should also be essential, leaving the identity of a true 
mycobacterial FabM homolog currently unknown (Griffin et al., 2011, Marrakchi et al., 
2014). An alternative method of introducing double bonds would be through aerobic 
desaturation of the meromycolate chain during synthesis, by an oxidative desaturase utilising 
both molecular oxygen and NADH (Marrakchi et al., 2014). Three potential desaturases have 
been identified within the M. tuberculosis genome, encoded by desA1, desA2 and desA3 
respectively (Cole et al., 1998, Takayama et al., 2005). Through overexpression and 
biochemical analysis, DesA3 has been shown to be responsible for the synthesis of the 
unsaturated fatty acid oleic acid in M. bovis BCG, proving its capability of insertion of double 
bonds to long carbon chains (Phetsuksiri et al., 2003). However, no function has yet been 
elucidated for either DesA1 or DesA2 (Marrakchi et al., 2014). 
The meromycolate chains become further modified by the action of a set of S-adenosyl-
methionine-dependant methyltransferases (SAM-MTs). CmaA2, MmaA2 and PcaA all have 
roles in introducing cyclopropanation (cis- and trans-) at both the distal and proximal ends of 
the chain (George et al., 1995, Glickman et al., 2000, Glickman, 2003) (Table 1.3). MmaA3 
and MmaA4 are SAM-MTs that are responsible for both forming methyl and hydroxyl 
branches and methoxylation of these to form methoxy- and keto-mycolate derivatives 
(Boissier et al., 2006). Once the meromycolate has matured, a condensation reaction 
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involving the type I polyketide synthase, Pks13, and a specific fatty-acyl-AMP ligase, 
FadD32, completes the synthesis of MAs. FadD32 converts the meromycoyl-S-AcpM into 
meromycoyl-AMP, whilst the C26-acyl-CoA from FAS-I is carboxylated by Acyl-CoA 
carboxylase (ACCase) into 2-carboxyl-C26-CoA (Figure 1.13) (Gago et al., 2006). Pks13 then 
binds both components of MA at its N terminus, and then transfers and condenses functional 
groups of the mycolate components within different domains of the enzyme via nucleophilic 
attack. The product of these reactions yields the intermediate 3-oxo-C78-mycolate and CO2. 
The intermediate is finally reduced by CmrA, into a secondary alcohol and thus the completed 
C78-mycolate (Figure 1.13) (Bhatt et al., 2007, Lea-Smith et al., 2007). Completed MAs are 
conjugated to trehalose to form trehalose monomycolate (TMM) in a yet to be elucidated 
pathway. TMM is then transported across the plasma membrane by MmpL3 (Grzegorzewicz 
et al., 2012). Finally, MAs from TMM are attached to the AG at the Araf6 non-reducing 
termini, by the fibronectin-binding proteins (Fbp) (known as the antigen 85 complex), 
antigens 85A, 85B and 85C, thus completing the mAGP complex (Jackson et al., 1999, Puech 
et al., 2000).  
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Gene name Rv number Role Reference fas Rv2524c  Complex of all components of FAS-I pathway of mycolic acid synthesis (Smith et al., 2003) fabD  Rv2243 Transacylation of malonate from malonyl-CoA to holo-AcpM to form malonyl-AcpM (Kremer et al., 2001b) fabH Rv0533c  Condensation of C12/14-Acyl-CoA with Malonyl-ACP to initiate FAS-II pathway (Bhatt et al., 2007) kasA  Rv2245 Initial addition of carbon to acyl-CoA primers in FAS-II pathway (Bhatt et al., 2007) kasB  Rv2246 Addition of carbon to longer acyl-CoA chains in FAS-II pathway (Bhatt et al., 2007) mabA  Rv1483 Reduction of β-ketoacyl-AcpM to β-hydroxyacyl-AcpM in FAS-II (Takayama et al., 2005) hadAB  Rv0635 Rv0636 Dehydration of β-hydroxyacyl-AcpM to enoyl-AcpM in FAS-II (Marrakchi et al., 2014) hadBC  Rv0636 Rv0637 Dehydration of β-hydroxyacyl-AcpM to enoyl-AcpM in FAS-II (Marrakchi et al., 2014) inhA  Rv1484 Reduction of enoyl-AcpM to acyl-AcpM in FAS-II (Marrakchi et al., 2014) fadD32  Rv3801c Converts meromycolyl-S-AcpM to meromycolyl-AMP (Bhatt et al., 2007) pks13  Rv3800c Condensation of 2-carboxyl-C26-CoA and meromycolyl-AMP (Bhatt et al., 2007) cmrA Rv2509 Reduction of 3-oxo-C78-mycolate into C78-mycolate (Lea-Smith et al., 2007) cmaA2 Rv0503c  Introduction of trans-cyclopropanation to MAs (George et al., 1995) mmaA2 Rv0644c  Introduction of distal cyclopropanation of α-MAs (Glickman, 2003) pcaA Rv0470c  Introduces proximal cyclopropanation of α-MAs (Glickman et al., 2000) mmaA3 Rv0643c  Methoxylation of methyl branches of mycolate chains (Boissier et al., 2006) mmaA4 Rv0642c  Introduction of methyl and adjacent hydroxyl branches to mycolate chains (Boissier et al., 2006) mmpL3 Rv0206c  Transports MAs (as TMM) across the plasma membrane (Grzegorzewicz et al., 2012) fbpA/ a 85A Rv3804c   Attachment of MAs to non-reducing termini of AG 
  (Jackson et al., 1999) fbpB/ a 85B Rv1886c fbpC/ a 85C Rv0129c  
  
Table 1.3: List of genes, and their function, involved in the synthesis of Mycolic Acids (MA). 
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1.3. Aims and Objectives 
Our understanding of crucial aspects of mycobacterial cell wall biosynthesis remains 
fragmented; particularly those associated with the regulation of the cytoplasmic assembly of 
peptidoglycan precursors and how AG is covalently attached to PG. 
This thesis can be split into two major objectives: 
1. Bioinformatics and biochemical analysis of pseudo-phosphorylated mutants of M. 
tuberculosis MurC, the first of the ATP-dependent Mur ligases involved in PG 
biosynthesis. This will assess whether phosphorylation of this enzyme has any impact 
upon the activity of the protein and therefore PG biosynthesis as a whole in M. 
tuberculosis. 
 
2. Bioinformatic analysis to identify a putative phosphotransferase in M. tuberculosis 
responsible for attachment of AG to PG. We will adopt a molecular genetic approach 
to determine the essentiality of this phosphotransferase by generating a conditional 
deletion of its orthologue in M. smegmatis. We will also perform a comprehensive 
biochemical analysis on recombinant protein. 
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2. INVESTIGATION INTO PHOSPHOREGULATION OF MURC LIGASE 
2.1. Introduction 
The Mur ligase pathway is a vital component in the biosynthesis of PG, responsible for the 
generation of the final PG ‘monomer unit’, “Lipid II”, within the cytoplasm before its 
translocation across the plasma membrane and addition into the growing PG polymer (Figure 
1.9) (Section 1.2.2.2.). ATP-dependent Mur ligases are a division of these proteins which are 
responsible for the addition of amino acid residues to UDP-MurNAc or UDP-MurNGlyc (in 
M. tuberculosis) to form a pentapeptide side chain, which later becomes cross-linked on the 
outside of the cell (Chang et al., 1990, Smith, 2006). These enzymes consist of MurC which 
catalyses the addition of the first residue L-alanine (L-ala), MurD which then adds D-
glutamine (D-glu), MurE then attaches meso-diaminopimelate (m-DAP) and MurF which 
completes the side chain with D-alanine-D-alanine (D-ala-D-ala) attachment (Section 
1.2.2.2.).  
The ATP-dependent Mur ligases from E. coli exhibit similar structural features and have a 
high degree of sequence similarity. Each of these four enzymes consist of three different 
domains, each responsible for binding one of the three substrates involved in catalysis. The N-
terminal domains (domain 1) show similarity to known dinucleotide binding Rossmann-fold 
like domains, which differ slightly in the orientation of β-sheets between MurC/D (mixed) 
and MurE/F (parallel) (Figure 2.1). Structural studies of these proteins have shown that 
domain 1 binds to the UDP-MurNAc moiety for each of the substrates utilised in this pathway 
(Smith, 2006). The central domain (domain 2) is consistent with ATP and GTP binding 
domains and the C-terminal domain (domain 3) has been shown to bind to the incoming 
amino acid residue to be attached to the growing peptide (Figure 2.1) (Smith, 2006, El Zoeiby 
et al., 2003). The active site for these enzymes is found at the junction between all 3 domains, 
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which is assisted by the ability of the protein to adjust the angle of its domains via hinge 
residues (such as phenylalanine-321 in MurC) (Smith, 2006). Because of the increasing chain 
length of the growing pentapeptide, MurE/F contains an extended loop within domain 1 that 
protrudes towards domain 3; which is absent in MurC/D (Figure 2.1). This loop interacts with 
UDP-MurNAc and is thought to provide additional space to accommodate the binding of a 
substrate with two or more additional amino acids (Smith, 2006).  
 
 
 
 
Figure 2.1: Comparison of E. coli ATP-dependent Mur ligase binding moieties. Domain 1 (red) is the 
UDP-MurNAc binding domain, domain 2 (green) is the ATP binding domain and domain 3 (blue) is the amino acid residue binding domain. A) MurC (PDB: 2F00) B) MurD (PDB: 2UAG) C) MurE (PDB: 1E8C) and D) MurF (PDB: 1GG4). All proteins share a similar overall structure, increasing in width as the size of the substrate increases throughout the pathway. 
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All of the ATP-dependent Mur ligases are believed to utilise the same mechanism to catalyse 
the addition of amino acid residues onto the growing peptide chain. Each of these enzymes 
sequentially bind substrates, beginning with the binding of ATP, followed by UDP-
MurNAc/NGlyc (with any attached peptides) and finally the amino acid residue to be added, 
each binding to their specific sites within the protein (Figure 2.2) (Eveland et al., 1997). From 
here, the γ-phosphate group from ATP becomes covalently attached to the terminal 
carboxylate group of the UDP-Muramate (or equivalent carboxylate group of the attached 
amino acid residue), liberating ADP and creating an activated acyl-phosphate intermediate. 
Interestingly, both enzymatic and structural characterisation of these enzymes has implicated 
Mg2+ as playing an important role in stabilising the negative charges within the active site 
(Smith, 2006). Nucleophilic attack by the incoming amino acid then replaces the phosphate 
group, producing a peptide bond and therefore releasing both inorganic phosphate and the 
enzymatic product of the Mur ligase (Figure 2.2) (Falk et al., 1996, Bertrand et al., 1999). In 
the presence of high concentrations of ADP, it is possible for these ATP-dependent Mur 
ligases (such as MurC) to perform the reverse reaction and remove the amino acid residue 
from the UDP-MurNAc/NGlyc-peptide molecule (Liger et al., 1995). 
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Figure 2.2: Mechanism of action of ATP-dependent MurC ligase. Substrates are bound in sequential 
order of ATP, then UDP-MurNAc (or UDP-MurNGlyc) and finally L-alanine. The γ-phosphate group from ATP then binds to terminal carboxylate group of UDP-MurNAc, creating an activated acyl-phosphate intermediate. Nucleophilic attack by the incoming L-alanine forms a tetrahedral intermediate before it replaces the phosphate group, producing a peptide bond and therefore creating UDP-MurNAc-L-alanine. 
Inorganic phosphate and ADP are released as by-products of the reaction. 
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Mycobacterial ATP-dependent Mur ligases have the ability to utilise UDP-MurNGlyc, as well 
as UDP-MurNAc, therefore integrating the hydroxylated backbone molecule into the structure 
of PG (Raymond et al., 2005). The first of these enzymes, MurC, has a preference for L-ala as 
its natural substrate, but is capable of utilising glycine (Gly) as well as L-serine (L-ser) in 
vitro, in the same way as MurC from other bacteria such as E. coli. However, the affinity of 
M. tuberculosis MurC for both Gly and L-ser is much lower than that for L-ala, suggesting the 
reason that L-ala is the preferred substrate (Munshi et al., 2013). The X-ray crystal structure 
of M. tuberculosis MurC is yet to be elucidated, however, homologous structures have been 
published from other bacteria such as Haemophilus influenzae and E. coli, with both 
structures consisting of the usual three domains as seen in other ATP-dependent Mur ligases 
(Mol et al., 2003, Deva et al., 2006). In E. coli, it was seen that MurC crystallises as a dimer, 
yet exists in solution in a dynamic equilibrium of both monomeric and dimeric forms, both of 
which show activity (Deva et al., 2006, Das et al., 2011).  
The fact that MurC is at the start of the sequential ATP-dependent Mur ligase biosynthetic 
pathway, as well as that there is no eukaryotic equivalent, makes it a very attractive drug 
target. A series of compounds known as phosphinate transition-state analogues were tested as 
inhibitors against MurC (from E. coli), with the most potent compound providing an IC50 
value of 49 µM (Reck et al., 2001). Unfortunately in vivo testing of these phosphinate 
compounds indicate that they have little antibacterial activity, presumably due to the inability 
of these compounds to cross the cytoplasmic membrane in order to reach their target 
destination (El Zoeiby et al., 2003).  
In C. glutamicum, it has been observed that MurC is phosphorylated by a specific 
serine/threonine kinase called PknA. Radiochemical analysis indicated that Cg-MurC is 
intermittently phosphorylated at several locations which include Thr-51, Thr-120, Thr-133, 
Thr-167, Thr-362 and Thr-365 (Fiuza et al., 2008). This study also demonstrated that MurC 
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phosphorylation correlates with regulation of enzymatic activity using a radiochemical 
endpoint assay (Fiuza et al., 2008). The addition of phosphate onto a protein can have a wide 
variety of effects (including up and down-regulation of activity). It can also have an effect in 
signalling pathways and protein degradation (Stock et al., 1989, Burnett and Kennedy, 1954). 
Phosphorylation is a useful mechanism of control by cells, as the addition of phosphate onto a 
protein residue, through phosphokinase action, can easily be reversed by removal of the 
phosphate by phosphatases (Burnett and Kennedy, 1954). This allows cells to maintain 
control over pathways that need to be tightly regulated, in order to prevent damage to the cell. 
This is important as it means that the cell has a means to regulate essential pathways such as 
PG biosynthesis. However, research into PknA activity on M. tuberculosis enzymes showed 
only MurD as a phosphorylation target through in vitro binding assays (Thakur and 
Chakraborti, 2008). Conversely, it has recently been shown by protein-protein interaction 
studies that both PknA and a different kinase, PknB, have the ability to interact with all of the 
ATP-dependent Mur ligases in M. tuberculosis, to varying degrees of intensity (Munshi et al., 
2013). In contrast, Streptococcus pneumoniae uses StkP to phosphorylate MurC, which is a 
multiple PASTA-domain containing phosphokinase. It has been suggested that there are 
multiple Ser/Thr sites within the C. glutamicum and M. tuberculosis MurC/D and so these 
species use PknA in order to phosphorylate the sites on all 3 domains (Falk and Weisblum, 
2013).  
PknA (as well as PknB) belongs to a family of 11 proteins in M. tuberculosis, known as 
Serine/Threonine Protein Kinases (STPKs), which phosphorylate specific serine and 
threonine residues on various proteins within the cell (Prisic and Husson, 2014). The M. 
tuberculosis phosphoproteome is vast and STPKs have been found to be responsible for at 
least 500 phosphorylation events across 301 proteins, involved in a variety of different 
activities within the cell (Prisic et al., 2010). Of the 11 STPKs in M. tuberculosis, PknG and 
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PknK are two proteins that are distinct from the other nine as they do not contain a 
transmembrane domain, suggesting that these genes were acquired elsewhere than those 
transmembrane spanning STPKs, which likely all derived from a single common ancestral 
gene (Prisic and Husson, 2014). However, the extracellular sensor domains of the nine 
receptor-type STPKs share no sequence homology, indicating that they bind to distinctive 
signal molecules to each other (Prisic and Husson, 2014). Yet six of these STPKs 
(PknA,B,D,E,F and H), do share a similar core phosphorylation motif to each other found 
within an intracellular N-terminal kinase domain, with differences arising in proteins that 
require higher substrate specificity (Prisic and Husson, 2014). PknA and PknB are both 
encoded by adjacent genes within an operon that contains numerous cell wall synthetic gene 
products, such as PBPA (also a probable substrate of PknB) and RodA, which are involved in 
cell shape and division. Both PknA and PknB have been shown as essential in mycobacteria 
through transposon mutagenesis, with this essentially and their location within the genome 
suggesting that PknA and PknB have an important role in the regulation of cell growth, shape 
and cell wall biosynthesis (Sassetti et al., 2003, Prisic and Husson, 2014). Although PknB has 
been suggested to activate multiple STPKs, it has recently been shown that PknA is activated 
independently of PknB in vivo and its activation loop is likely to be autophosphorylated by 
PknA itself, indicating that PknA is not reliant on PknB activity (Baer et al., 2014, Nagarajan 
et al., 2015).  
In this study, we have identified several homologous candidate residues for phosphorylation 
in M. tuberculosis MurC, based upon phosphorylation sites from the C. glutamicum protein, 
through extensive bioinformatic analysis. We therefore created pseudo-phosphorylated MurC 
mutants and biochemically analysed the effect of creating a negatively-charged region at these 
residues when compared to wild-type.   
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2.2. Results 
2.2.1. In silico analysis of MurC and identification of candidate phosphorylation sites  
A multiple protein sequence alignment (Section 5.17.) was used to compare MurC protein 
sequences between various bacteria including mycobacterial, Gram positive and Gram 
negative species (Figure 2.3). The varying mycobacterial MurC proteins show at least around 
80 % sequence identity to M. tuberculosis MurC, whereas C. glutamicum MurC shows around 
52 % identity (Figure 2.3, Table 2.1). The MurC sequences from Pseudomonas aeruginosa, S. 
aureus and E. coli all share around 30 % sequence identity to M. tuberculosis MurC. A 
second protein sequence alignment was performed between MurC sequences from M. 
tuberculosis and C. glutamicum in order to identify homologous residues between the two 
(Figure 2.4). Based upon reported phosphorylated residues in C. glutamicum MurC by Fiuza 
et al., 2008, five homologous residues were identified in M. tuberculosis MurC. These 
residues selected as possible phosphorylation sites were Thr-116, Thr-129, Ser-163, Thr-357 
and Ser-360 (Figure 2.4). There was no homologous residue to Thr-51 (from C. glutamicum 
MurC (Fiuza et al., 2008)) in M. tuberculosis MurC, since the corresponding residue is Gly-
47, which is unable to be phosphorylated by STPKs. 
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Figure 2.3: Protein sequence alignment of MurC from different bacterial species. M. tuberculosis, 
M. smegmatis, M.bovis BCG, Mycobacterium. leprae, C. glutamicum, H. influenzae, Psuedomonas aeruginosa, Staphylococcus aureus and E. coli display a high level of homology between sequences, indicated by residues in red. Residues highlighted in red indicate identity across all species aligned, showing conserved residues. Secondary structure information is seen above all sequences. 
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Species Identity (%) 
M. smegmatis 79.25 
M. bovis BCG 100 
M. leprae 80.61 
C. glutamicum 52 
H. influenzae 37.5 
P. aeruginosa 36.93 
S. aureus 30.07 
E. coli 35.74 
 
 
 
 
 
 
 
 
 
Table 2.1: Protein sequence identity of M. tuberculosis MurC with MurC from multiple 
different species. Highest identity is seen between M. tuberculosis and M. bovis BCG, as they have the exact same sequence (100 % identity), whereas the lowest identity is seen when compared to S. aureus (30.07 %). However, reasonably high identity is seen between all the mycobacterial species and C. glutamicum. There is still reasonable identity between the Gram positive and negative 
species, due to conserved residues between all species.   
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The sequences for both C. glutamicum (Cg) and M. tuberculosis (Mtb) MurC proteins were 
submitted for 3D homology modelling using the I-TASSER server (with a C-score of 1.11 
and 0.785 respectively) (Section 5.17.). These homology models were then analysed in 
comparison to each other and also to the H. influenzae MurC crystal structure model bound to 
a non-hydrolysable ATP analogue, AMPPNP (PDB ID: 13P1), in order to identify where 
ATP would bind to the homology models (Figure 2.5) (Section 5.17.). We made use of the 
reported phosphorylation sites of Cg-MurC to identify the equivalent (putative) 
phosphorylation sites in Mtb-MurC (Figure 2.4) (Fiuza et al., 2008). In addition, we mapped 
Figure 2.4: Protein sequence alignment of MurC from both M. tuberculosis and C. glutamicum. 
Residues highlighted in red are conserved residues, whereas residues highlighted blue represent phosphorylation sites identified in C. glutamicum by Fiuza et al., 2008 and homologous residues identified in the M. tuberculosis protein. The identified residues in M. tuberculosis MurC were Thr116, Thr129, Ser163, Thr357 and Ser360.  
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these phosphorylation sites into the I-TASSER homology models to investigate the surface 
exposure of the amino acids that ultimately become phosphorylated (Figure 2.5A,B Bottom). 
Structural alignment of both the Cg-MurC and Mtb-MurC homology models demonstrate that 
four of the five putative Mtb-MurC phosphorylation sites appear on the surface of the protein, 
with one (T129) being buried within the protein (Figure 2.5A,B Bottom). 
 
 
 
 
Figure 2.5: An overlay of I-TASSER generated homology models of Cg-MurC (blue) and Mtb-MurC 
(brown) showing location of ATP (AMPPNP) bound. Phosphorylated residues are highlighted green in the 
Cg-MurC model and selected residues are highlighted red in the Mtb-MurC model. A) Top – shows ‘front’ image of ribbon overlay of Cg and Mtb models, the highlighted residues overlay nearly identically and all show a close spatial proximity to the bound ATP analogue. Bottom – a spacefilling model of the ‘front’ of Mtb MurC showing surface selected residues in red. B) Top – shows ‘back’ image (180°) of ribbon overlay of Cg and Mtb models. Bottom – ‘back’ image (180°) of spacefilling model of Mtb MurC, showing selected surface residues in red. The only residue that is not found on the surface of the protein is T129. 
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The close spatial proximity between the selected phosphorylation residues in both the Cg-
MurC and Mtb-MurC homology models and the bound ATP analogue suggest that alteration 
of these residues will have an effect on ATP binding by the enzyme (Figure 2.5A,B, Top). 
Both T116 and S163 are situated at the top of neighbouring loops that extend down toward 
the ATP binding site (Figure 2.5A). T116 is located at the start of β-strand 5, whereas S163 is 
found just before the start of β-strand 7, both of which form a part of a β-sheet (Figure 2.4). 
T129 is positioned within the middle portion of α-helix 6, which is embedded within the 
protein at the base of the ATP binding moiety (Figure 2.4, Figure 2.5). Both T357 and S360 
residues are found within α-helix 11, which itself is actually situated within the L-ala binding 
moiety of Mtb-MurC (Figure 2.4). However, both residues are orientated on the outside edge 
of the α-helix which faces the ATP binding site, suggesting interaction with this substrate 
(Figure 2.5).  
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2.2.2. Purification of recombinant MurC protein 
An N-terminally His-tagged M. tuberculosis MurC expression vector (pET28b-MurC) was 
constructed (Section 5.18.1.) and the selected homologous phosphorylation site residues 
(Section 2.2.1.) were mutated into aspartate through site-directed mutagenesis (SDM) 
(Section 5.6.). This gave rise to the constructs pET28b-MurC T116D, T129D, S163D, T357D 
and S360D alongside the MurC WT construct. All of these vectors were overexpressed in E. 
coli BL21 (DE3) (Section 5.4.1.) and purified through immobilised metal ion affinity 
chromatography (IMAC) (Figure 2.6) and subsequent anion exchange chromatography, if 
required (Section 5.11.). 
 
 
 
Figure 2.6: SDS-PAGE of MurC proteins. A) MurC WT, B) MurC T116D, C) MurC S163D, D) MurC 
T357D E) MurC S360D. MurC T129D was unable to be expressed or purified despite numerous attempts of optimisation. Lanes shown are protein marker (M), clarified lysate flow through (1), 50 mM imidazole elution (2), 75 mM imidazole elution (3), 125 mM imidazole elution (4), 150 mM imidazole elution (5) and 500 mM imidazole elution (6). Bands visible around 50-60 kDa in lane 5 represent recombinant MurC. 
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MurC WT as well as T116D, S163D, T357D and S360D pseudo-phosphorylated site-directed 
mutants all purified well and were stable in MurC ‘storage’ buffer (Section 5.1.11.) at 
concentrations up to 2.3 mg/mL. However, despite numerous attempts at optimising 
expression and purification, it was not possible to obtain recombinant MurC T129D, despite 
cells appearing phenotypically healthy.  
 
2.2.3. Kinetic analysis of MurC pseudo-phosphorylation 
In order to biochemically characterise each MurC pseudo-phosphorylated mutant, a kinetic 
assay was developed to assess the rate of MurC action (Section 5.16.). An enzyme-coupled 
assay was used, whereby the rate of MurC activity was directly linked to the action of the 
enzymes pyruvate kinase and lactate dehydrogenase. This was achieved through the 
utilisation of the ADP by-product of the reaction catalysed by MurC (Figure 2.2), being fed 
into a secondary reaction scheme which converts phosphoenolpyruvate (PEP) into pyruvate 
(catalysed by pyruvate kinase and the turnover of ADP to ATP), which in turn becomes 
converted into lactate (by lactate dehydrogenase) and the oxidation of NADH to NAD+ 
(Figure 2.7). This turnover of ADP to ATP and NADH to NAD+ occurs at a 1:1 ratio, 
meaning the rate of NADH conversion to NAD+ is directly correlated to the rate of ADP 
release from the MurC reaction. Furthermore, the oxidation of NADH to NAD+ can be 
directly monitored by a continuous spectrophotometric analysis at 340 nm, as a decrease in 
absorbance and the rate of the reaction observed as Δ340 nm vs time (Jenkins, 1991) (Section 
5.16.). 
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We hypothesised that because M. tuberculosis MurC can utilise both UDP-MurNAc and 
UDP-MurNGlyc, as well as the fact that the pseudo-phosphorylation sites surround the ATP 
binding cleft (Figure 2.5), that there could be differences in MurC kinetics between substrates. 
Therefore we decided to assess the difference between the Michaelis-Menten kinetics of WT 
MurC and pseudo-phosphorylated MurC using UDP-Muramyl dependent as well as ATP 
dependent triplicate assays (Section 5.16.).  
 
 
 
 
 
 
 
Figure 2.7: A reaction scheme for biochemical analysis of MurC pseudo-phosphorylated mutants. 
MurC utilises ATP to attach L-alanine to UDP-MurNAc/NGlyc and releases ADP and inorganic phosphate as by-products. The released ADP is then used by pyruvate kinase to convert PEP to pyruvate and releasing ATP. Pyruvate is then converted into lactate by lactate dehydrogenase through the oxidation of NADH to NAD+. This reaction can be monitored by Δ340 nm. 
Figure 2.8: Michaelis-Menten graph of MurC WT with UDP-MurNAc (A) and UDP-MurNGlyc (B). 
The affinity of MurC WT for UDP-MurNGlyc was shown to be 30-fold more than for UDP-MurNAc, with Km values of 52.98 ± 5.64 µM and 1,555 ± 272 µM respectively. R2 values of A) 0.9661 and B) 0.9473. 
A B 
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The reaction velocity (V) of MurC was found to be hyperbolically dependent on both UDP-
MurNAc and UDP-MurNGlyc at saturating levels of ATP and L-ala (Section 5.16.). This 
allowed for the Michaelis constant (Km) to be deduced for each UDP-Muramyl substrate 
(using equation ܸ = ௏೘ೌೣ × [ௌ௨௕௦௧௥௔௧௘]௄೘ା[ௌ௨௕௦௧௥௔௧௘] ) with WT MurC, revealing a Km for UDP-MurNAc of 
1,555 ± 272 µM and a Km of 52.98 ± 5.64 µM for UDP-MurNGlyc (Figure 2.8). Since there 
was a 30-fold difference in Km between the two substrates, we decided to assess the UDP-
Muramyl dependence of all pseudo-phosphorylated mutants using UDP-MurNGlyc.  
The assay was repeated using each pseudo-phosphorylated mutant of MurC with UDP-
MurNGlyc and saturating ATP and L-ala, with each MurC mutant displaying similar 
hyperbolic dependence to UDP-Muramyl as WT MurC. The reaction velocities (V, mM.min-
1) of each mutant were converted into specific activity of the enzymes (mM.min-1mg-1) to 
normalise the assays and allow for direct comparison between each protein (using equation 
ܵܣ = ௏೘ೌೣ (௠ெ.௠௜௡షభ)௠௚ ௣௥௢௧௘௜௡ ) (Figure 2.9). The turnover number (Kcat) and the specificity constant 
(Kcat/Km) were calculated for each MurC mutant (using equation ܭ௖௔௧ = ௏೘ೌೣ (ெ)[௉௥௢௧௘௜௡](ெ)) (Table 
2.2).  
 
 
 
 
 
 Figure 2.9: Michaelis-Menten graph displaying specific activities (mM.min-1mg-1) of MurC WT, T116D, 
S163D, T357D and S360D for UDP-MurNGlyc dependence. The Km for each MurC variant is shown in Table 2.2. R2 values for each MurC variant are 0.9473, 0.9094, 0.8427, 0.9608 and 0.9251 respectively, indicating high goodness of fit. 
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MurC Variant Km (µM) Vmax  (mM.min-1) Specific Activity  (mM.min-1mg-1) Kcat (min-1) Kcat/Km (min-1M-1) WT 52.98 (±7.631) 0.0348 (±0.00135) 20.81 212.84 4.02×10
6 
T116D 40.99 (±7.282) 0.0127 (±0.00055) 12.22 124.51 3.04×10
6 
S163D 40.47 (±10.05) 0.0119 (±0.00072) 20.81 212.88 5.26×10
6 
T357D 1728 (±989.4) 0.0376 (±0.01776) 6.38 67.47 3.91×10
4 
S360D 46.78 (±7.598) 0.0148 (±0.00062) 25.67 263.11 5.62×10
6 
 
All MurC pseudo-phosphorylation mutants (apart from T357D) display a higher affinity for 
UDP-MurNGlyc than WT MurC. T116D, S163D and S360D all show a Km within the range 
of 40-47 µM compared to 52.98 ±7.631 µM for WT (Table 2.2). The Km of T357D of 1728 
±989.4 µM is more comparable to the WT Km for UDP-MurNAc of 1555 µM. However, the 
specific activities of the MurC mutants correlate with this trend of affinities, apart from MurC 
T116D, which shows a specific activity of 12.22 mM.min-1mg-1, around half that of MurC 
WT (20.81 mM.min-1mg-1) indicating that each mg of MurC T116D displays around half the 
rate of that of MurC WT (Figure 2.9, Table 2.2). MurC T357D has a much lower specific 
activity than MurC WT, at 6.38 mM.min-1mg-1, around a third lower (Table 2.2). However, 
MurC S360D shows a higher specific activity than MurC WT, of 25.67 mM.min-1mg-1, 
indicating an increase of around a fifth in activity (Table 2.2). This disparity between MurC 
WT, S163D and S360D to both T116D and T357D is seen even clearer when both the Kcat 
and Kcat/Km is considered. The Kcat indicates the maximum amount of reactions that can be 
performed by the enzyme active site per minute. MurC WT has a Kcat of 212.84 min-1, 
whereas T116D is around half, at 124.51 min-1, indicating around half the number of reactions 
Table 2.2: Kinetic values for MurC WT and pseudo-phosphorylated mutants with UDP-MurNGlyc 
dependence. All mutants (except for T357D) display a higher affinity for the substrate than WT, however the specific activity for T116D is around half that of the other MurC variants. T357D has much lower affinity and activity than all of the other variants. 
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being performed by T116D. Again, T357D (67.47 min-1) is around a third of that of MurC 
WT, showing a much lower number of reactions performed per minute (Table 2.2). Again, 
MurC S360D displays a higher Kcat (263.11 min-1) than MurC WT (Table 2.2). Finally, the 
Kcat/Km shows the efficiency of the enzyme, with a higher specificity constant meaning an 
enzyme shows a higher preference for the particular substrate. Interestingly, both MurC 
S163D and S360D show a higher Kcat/Km than MurC WT, indicating a higher preference for 
UDP-MurNGlyc with pseudo-phosphorylation of these residues (Table 2.2). However, as 
expected, MurC T116D shows a lower Kcat/Km (3.04×106 min-1M-1) than WT (4.02×106 min-
1M-1), suggesting MurC T116D is less efficient than MurC WT (Table 2.2). MurC T357D 
shows a much lower Kcat/Km than MurC WT of 3.91×104 min-1M-1, which is around 100 times 
lower, showing that MurC T357D is highly inefficient with UDP-MurNGlyc when compared 
to MurC WT (Table 2.2). 
The assay was then repeated in order to assess the kinetic relationship of MurC WT and 
pseudo-phosphorylated mutants to ATP. This was initially performed using saturating 
concentrations of UDP-MurNGlyc and L-ala (Section 5.16.). Each MurC variant displayed 
hyperbolic dependence to ATP, similar to that of UDP-MurNGlyc (Figure 2.10). The kinetic 
parameters were calculated as before (Table 2.3). 
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MurC Variant Km (µM) Vmax  (mM.min-1) Specific Activity  (mM.min-1mg-1) Kcat (min-1) Kcat/Km (min-1M-1) WT 46.80  (±5.70) 0.0272 (±0.00093) 16.30 166.36 3.56×10
6 
T116D 56.76 (±13.29) 0.0068 (±0.00047) 6.53 66.67 1.18×10
6 
S163D 43.09  (±9.03) 0.0080 (±0.00045) 13.99 143.11 3.32×10
6 
T357D 142.6 (±35.29) 0.0018 (±0.00017) 0.30 3.23 2.27×10
4 
S360D 66.42 (±12.51) 0.0110 (±0.00066) 19.05 195.56 2.94×10
6 
 
All MurC mutants (except S163D, which is comparable to WT) show lower affinity for ATP 
in the presence of UDP-MurNGlyc than WT MurC (Table 2.3). T357D once again shows a 
much lower affinity (142.6 ±35.29 µM) than all other MurC variants, with a Km around three 
times larger than that of WT. However, the specific activities of MurC WT, S163D and S360D 
are similar, ranging between 13.99-19.05 mM.min-1mg-1, whereas MurC T116D has a specific 
activity just under half of those including WT (6.53 mM.min-1mg-1). The specific activity of 
Figure 2.10: Michaelis-Menten graph displaying specific activities (mM.min-1mg-1) of MurC WT, 
T116D, S163D, T357D and S360D for ATP dependence in the presence of UDP-MurNGlyc. The Km for each MurC variant is shown in Table 2.3. R2 values for each MurC variant are 0.9391, 0.8814, 0.8939, 0.8924 and 0.8847 respectively, indicating high goodness of fit. 
Table 2.3: Kinetic values for MurC WT and pseudo-phosphorylated mutants for ATP dependence in the 
presence of UDP-MurNGlyc. All MurC mutants show lower or similar affinity to ATP as WT, however they all show similar specific activity apart from both T116D and T357D, which are much lower than WT MurC. This is correlated by both Kcat and Kcat/Km values. 
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MurC T357D is almost non-existent (0.30 mM.min-1mg-1), indicating very little activity by 
this protein (Figure 2.10, Table 2.3). Once again, MurC S360D displays the highest specific 
activity (19.05 mM.min-1mg-1), higher than MurC WT by around 15 % (Figure 2.10, Table 
2.3). These figures are echoed by the Kcat values, which indicate that MurC T116D turns over 
just under half that of WT MurC (66.67 min-1 for T116D compared to 166.36 min-1 for WT), 
whereas T357D (3.23 min-1) performs around 50 times less reactions per minute than WT 
MurC (Table 2.3). MurC S360D displays a higher Kcat than MurC WT (195.56 min-1), 
performing more reactions per minute (Table 2.3). The efficiency of these enzymes shown by 
Kcat/Km also corresponds with the rest of the kinetic figures for this assay. Once again, MurC 
WT and S163D show similar specificity constants to one another, however T116D (1.18×106 
min-1M-1) is around three times lower than MurC WT (3.56×106 min-1M-1) (Table 2.3), 
indicating that MurC T116D shows lower preference to ATP in the presence of UDP-
MurNGlyc than WT. MurC T357D shows even lower preference and very high inefficiency 
with ATP, since the Kcat/Km for this protein is more than 150 times lower (at 2.27×104 min-
1M-1) than MurC WT (Table 2.3). Interestingly, despite showing a higher activity and Kcat 
than MurC WT, MurC S360D actually displays a lower Kcat/Km (2.94×106 min-1M-1), 
indicating that the protein is less efficient overall with ATP in the presence of UDP-
MurNGlyc than MurC WT (Table 2.3). 
The assay was repeated a final time to assess the kinetic relationship of MurC WT and 
pseudo-phosphorylated mutants to ATP dependence, this time in the presence of UDP-
MurNAc and L-ala (Section 5.16.). However, due to a limited amount of UDP-MurNAc 
available for assay, as well as the high amount required per experiment, we were unable to 
assay MurC S163D with this substrate. Nonetheless, each assayed MurC variant once again 
displayed hyperbolic dependence to ATP (Figure 2.11) and the kinetic parameters were once 
again calculated (Table 2.4). 
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MurC Variant Km (µM) Vmax  (mM.min-1) Specific Activity  (mM.min-1mg-1) Kcat (min-1) Kcat/Km (min-1M-1) WT 55.46 (±5.635) 0.0129 (±0.00036) 7.70 78.90 1.42×10
6 
T116D 36.70 (±7.192) 0.0042 (±0.00019) 3.99 41.18 1.12×10
6 
T357D 113.6 (±98.52) 0.0010 (±0.00031) 0.17 1.79 1.58×10
4 
S360D 66.79 (±10.97) 0.0057 (±0.00028) 9.92 101.33 1.52×10
6 
 
The affinity of MurC T116D (36.70 ±7.192 µM) is higher for ATP in the presence of UDP-
MurNAc than MurC WT (55.46 ±5.635 µM), whereas both S360D and T357D display higher 
Km values than WT (Table 2.4). The specific activities of all assayed MurC variants show a 
similar trend as the previous assays, wherein MurC T116D displays a specific activity around 
half that of MurC WT and T357D shows an extremely low specific activity, whereas MurC 
Figure 2.11: Michaelis-Menten graph displaying specific activities (mM.min-1mg-1) of MurC WT, 
T116D, T357D and S360D for ATP dependence in the presence of UDP-MurNAc. The Km for MurC WT, T116D, T357D and S360D are shown in Table 2.4. R2 values for each MurC variant are 0.9692, 0.8596, 0.3644 and 0.9284 respectively, indicating high goodness of fit for each variant (apart from T357D as values are too low to provide a better fit). 
Table 2.4: Kinetic values for MurC WT and pseudo-phosphorylated mutants for ATP dependence 
in the presence of UDP-MurNAc. MurC T116D shows a higher affinity for ATP than WT, yet both S360D and T357D show a lower affinity than WT. MurC S360D shows the highest specific activity, being slightly higher than WT. However, T116D has specific activity just under half of that of WT, whereas T357D once again displays very low activity. These figures are correlated by both Kcat and Kcat/Km. 
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S360D shows an activity almost a third higher than MurC WT (Figure 2.11, Table 2.4). This 
trend is followed by the Kcat, showing a turnover number for MurC T116D (41.18 min-1) 
again around half that of WT (78.90 min-1). MurC T357D is shown to turnover 44 times less 
reactions (1.79 min-1) than MurC WT (Table 2.4). MurC S360D displays a Kcat of 101.33 min-
1, showing an ability to perform more reactions per minute than MurC WT (Table 2.4). This is 
finally corroborated by the specificity constant values for these proteins, whereby the Kcat/Km 
for both MurC WT and S360D are comparable (1.42×106 min-1M-1 and 1.52×106 min-1M-1 
respectively) showing a similar efficiency to one another, but the Kcat/Km for MurC T116D is 
slightly lower (1.12×106 min-1M-1), indicating a lower preference for ATP than WT (Table 
2.4). However, the Kcat/Km for MurC T357D is 90-fold lower than WT (1.58×104 min-1M-1) 
indicating the inefficiency of this pseudo-phosphorylated mutant.  
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2.2.4. Ligand binding of ATP to MurC pseudo-phosphorylated mutants 
We utilised intrinsic tryptophan fluorescence (ITF) in order to investigate how pseudo-
phosphorylation of MurC affects the binding of ATP to the protein (Section 5.15.). MurC WT 
and each pseudo-phosphorylated mutant displayed a varying degree of sigmoidal binding, 
indicating co-operative binding of ATP to MurC. Therefore, the data was fitted to a single site 
saturation model with a Hill slope, yielding both an equilibrium binding constant (Kd) and 
Hill coefficient/slope (h) for each protein. The Hill equation is used when a multi-site protein 
displays co-operative binding, with the Hill coefficient being derived from the equation (ܻ =
[௅௜௚௔௡ௗ]೓
௄೏ା[௅௜௚௔௡ௗ]೓). If h>1 the protein shows positive co-operative binding, whereas if h<1 the 
protein displays negative co-operative binding. However, if h=1 then the binding is non-co-
operative and the protein obeys the usual single site saturation binding equation (Stefan and 
Le Novere, 2013). 
 
 
 
 
 
 
 
 
 
Figure 2.12: Saturation binding experiments to using ITF to assess ATP binding to MurC 
pseudo-phosphorylated mutants. Each protein displays a sigmoidal binding curve, indicative of co-operative binding. MurC WT, T116D, S163D, T357D and S360D gave Kd values of of 419 µM, 261.4 µM, 340.9 µM, 407.8 µM and 302.7 µM respectively. They each gave a Hill coefficient (h) of 1.121, 1.86, 2.109, 1.298 and 2.129 respectively, indicating that each protein exhibits positive co-operative binding. R2 values for each MurC variant are 0.9451, 0.9610, 0.9360, 0.9731 and 0.9682 respectively, indicating high goodness of fit for each curve. 
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MurC WT shows a Kd of 419 µM for ATP and shows that h = 1.121, which indicates that 
MurC WT does show some positive co-operative binding of ATP (Figure 2.12). However, 
MurC T116D has almost twice the binding affinity for ATP than MurC WT, with a Kd of 
261.4 µM. This correlates with an h value of 1.86, almost twice that of MurC WT (Figure 
2.12). MurC S163D displays a Kd of 340.9 µM, which is still an increased binding affinity for 
ATP when compared to WT, yet this mutant has an h value of 2.109 indicating much higher 
positive co-operation of binding sites (Figure 2.12). MurC T357D behaves much more like 
MurC WT, with a comparable Kd of 407.8 µM and h = 1.298, showing less co-operative 
binding than the previous two mutants (Figure 2.12). However, MurC S360D displays a lower 
Kd of 302.7 µM, indicating a higher binding affinity for ATP, but a high h value of 2.129, 
showing the most positive co-operation between binding sites of all MurC variants (Figure 
2.12). Therefore, MurC T116D, S163D and S360D show both higher binding affinity for ATP 
and also much higher positive co-operation between binding sites than MurC WT or T357D 
(Figure 2.12). 
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2.3. Discussion 
The essential MurC enzyme is a key component in M. tuberculosis PG biosynthesis. As the 
first member of the sequential ATP-dependent Mur ligase pathway, it represents an interesting 
research topic, since disruption of any point in the pathway will cause PG biosynthesis to halt 
and will result in cell death (Munshi et al., 2013). The murC gene is among a cluster of genes 
known as the division/cell wall (dcw) operon, which contains each ATP-dependent Mur ligase 
(murCDEF), along with murX and murG in close proximity to each other, as well genes 
involved in cellular division processes, such as ftsZ and ftsQ (Munshi et al., 2013). MurC and 
the ATP-dependent Mur enzymes are thought to be a part of a wider superfamily of ATP-
dependent amide ligases which include folyl-γ-polyglutamate ligases, which add glutamate to 
folate or folate derivatives in humans and the poly-γ-glutamate synthetase CapB (from B. 
subilitis) (Candela and Fouet, 2006, Lawrence et al., 2014). These enzymes share mechanistic 
similarities and some sequence homology to the Mur ligases across various bacterial and 
mammalian species (Eveland et al., 1997). As the first of the ATP-dependent Mur ligases, it 
has been shown in C. glutamicum that the kinase PknA is utilised to phosphorylate specific 
sites of MurC in order to regulate its activity (Fiuza et al., 2008). We therefore hypothesised 
that M. tuberculosis, as a relative of C. glutamicum, would likely be capable of regulating 
MurC and therefore PG biosynthesis by phosphorylation of similar specific residues.  
The site-directed mutagenesis of specific Ser/Thr sites to a negatively-charged amino acid can 
be performed to create phospho-mimics at these residues. This is particularly useful in 
situations such as this study, whereby the phosphorylation of specific individual residues is to 
be investigated, as well as the fact that definitive phosphorylation of MurC by PknA is yet to 
be shown. To assess the effect of phosphorylation of MurC, we decided to generate site-
directed mutants of homologous specific Ser/Thr residues and substitute them with 
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negatively-charged aspartate residues. This approach to pseudo-phosphorylation has been 
performed successfully in the past, particularly in the analysis of the effects of 
phosphorylation at specific sites of the neuronal microtubule-associated protein tau. These 
previous studies showed that the substitution of Ser/Thr for Asp not only simulated the effects 
of phosphorylation upon tau, but also showed little difference between Asp or glutamate (a 
larger negatively-charged residue) substitutions (Leger et al., 1997, Gohar et al., 2009, Sun 
and Gamblin, 2009).  
Through extensive bioinformatic analysis of MurC, homologous Ser/Thr residues were 
identified in the M. tuberculosis protein, comparable to those phosphorylated in the C. 
glutamicum enzyme (Figure 2.4). These residues were then mapped onto 3D homology 
models of both Mtb-MurC and Cg-MurC, then compared to one another (Figure 2.5). The two 
models overlay with a TM-score of 0.93544, indicating a good fit (since a TM-score of 1 
means a perfect fit (Zhang and Skolnick, 2004)), with the selected phosphorylation sites 
occupying almost the exact same area in space between the two models (Figure 2.5A,B Top). 
Importantly, all of the selected residues in the Mtb MurC model appear to have a function in 
the binding of ATP, based on the location of bound AMPPNP, from the overlay of the H. 
influenzae MurC crystal structure. Both T116 and S163 appear to be the furthest from the 
bound ATP analogue, however, they are found at the opposite ends of two loops that appear 
to directly interact with ATP, which suggests they are likely candidates for phosphorylation in 
vivo (Figure 2.5). These residues also appear to be surface exposed by the use of a spacefilling 
model of Mtb-MurC (Figure 2.5A Bottom). Along with both T357 and S360, which also 
appear to be surface exposed, it increases the likelihood of these residues being 
phosphorylated in vivo, since any potential kinase that would act on these residues can reach 
them easier. T129 (and its Cg homolog T133) appears to be buried within the structure of 
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both Mtb and Cg spacefilling models, so it is unknown how any kinase would be capable of 
reaching this residue in vivo (Figure 2.5A,B Bottom). 
The initial Michaelis-Menten kinetic data for WT MurC showed a high preference of the 
protein for UDP-MurNGlyc over UDP-MurNAc, with a 30-fold difference of affinity between 
the two (Figure 2.8). The Km value of 1,555 ± 272 µM for UDP-MurNAc differs to the Km of 
23.5 ± 0.5 µM reported by Munshi et al., 2013, believed to be due to fact that they performed 
stopped assays for phosphate release after 30 min, whereas we performed assays that recorded 
the initial linear rates of reaction where the rate is proportional to the enzyme concentration. It 
is unlikely that they recorded initial rates, since it can be shown using their conditions and 
kinetic constants that MurC WT would have fully consumed all of the substrate before a 
measurement of activity could be made, which would lead to an inaccurate Km being 
suggested. The acidic nature of the assay employed by Munshi et al., 2013 could also result in 
false positives in regard to activity, since UDP-Muramyl precursors tend to be susceptible to 
instability under these conditions. Both of these discrepancies are likely to account for the 
difference between the reported Km and our data. Nonetheless, the significant difference in 
our affinities between UDP-Muramyl substrates led us to utilise UDP-MurNGlyc to perform 
UDP-Muramyl dependent assays using each pseudo-phosphorylated mutant of MurC (Figure 
2.9). The same major trend was seen when the assays were repeated for ATP dependency 
using both UDP-MurNGlyc and UDP-MurNAc, whereby the activity of MurC T116D was 
reduced to around half that of WT, whereas the activity of MurC T357D was all but abrogated 
(Figure 2.10, Figure 2.11). Due to the vast quantities of UDP-MurNAc required for each 
assay, we were unable to perform any ATP dependency assays using MurC S163D and UDP-
MurNAc, due to limiting substrate. However, since each of the other pseudo-phosphorylated 
mutants followed similar trends across each assay, we expect that MurC S163D would behave 
in a similar fashion to MurC WT. 
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The binding of ATP to MurC WT and pseudo-phosphorylated mutants was further probed 
using ITF. Each protein displayed a sigmoidal binding curve, indicative of co-operative 
binding between multiple binding sites, when at saturation with a defined Bmax and binding 
affinity at the µM range (Figure 2.12). Because of the sigmoidal binding nature shown in 
these assays, we were also able to deduce a Hill coefficient from the binding of ATP to each 
MurC variant, which gives an insight into the co-operation between binding sites (Stefan and 
Le Novere, 2013). Each pseudo-phosphorylated MurC mutant displayed higher binding 
affinity for ATP, as well as increased positive co-operation between binding sites, than MurC 
WT, except for MurC T357D which behaved in a similar manner to MurC WT (Figure 2.12). 
Since MurC has been shown to exist in solution as both monomeric and dimeric forms, in E. 
coli, it is possible that the alteration of T116, S163 and S360 to aspartate increases the 
presence of dimerised MurC in solution, which would then afford these mutants a secondary 
ATP binding site and help to explain the increase in positive co-operative binding (Das et al., 
2011). The increase in dimerisation of these MurC mutants is further supported by the fact 
that both T116 and S163 lie close to the dimer interface, between two MurC molecules 
(Figure 2.13). The negative charges introduced by these residues may cause an increase of 
interactions between opposing residues of the proteins or conformational change that favours 
dimerisation of the protein, for instance, T116 seemingly interacts with the N-terminal region 
of the opposing monomeric unit, so mutation of T to D may lead to an increase of non-
covalent interactions (Figure 2.13). S360D may also cause a conformational change that 
resonates throughout the protein leading to an increased preference for dimers to form. 
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This study provides a comprehensive biochemical insight into the outcomes of 
phosphorylation of M. tuberculosis MurC. Given the kinetic data results and the positions of 
the residues within the homology model, it is likely that M. tuberculosis could phosphorylate 
T116 and T357 in order to augment the activity of MurC. Phosphorylation of T116 would 
likely regulate the activity of the enzyme by around 50 %, whereas the modification of T357 
would likely lead to an almost complete halt in enzymatic activity. It is likely that in vivo 
multiple residues are phosphorylated at once in order to maintain the level of activity of MurC 
that the cell requires at a particular time, since pseudo-phosphorylation of S360 displayed a 
very slight increase in activity of 15-20 %, compared to WT. Therefore by phosphorylating 
multiple sites at one time M. tuberculosis can possibly fine tune the activity of MurC beyond 
simply around 50 % activity, but to the level required. 
Figure 2.13: 3D-homology model representation of Mtb-MurC dimer. Both T116 and S163 are 
situated near to the dimer interface, suggesting that alteration of these residues may have an effect on dimerisation. The mutation of these residues to aspartate increases positive co-operation between binding sites suggesting that an increase of dimerisation has occurred when compared to MurC WT. The mutation of S360 to aspartate also increases co-operative binding, suggesting that a conformational change may result in an increase in dimer formation. Dimer model based upon E. coli MurC dimer crystal structure (PDB: 2f00).  
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It has been shown previously in C. glutamicum MurC that multiple threnonine 
phosphorylation sites are required for activity. Successive site-directed mutagenesis by Fiuza 
et al. (2008) revealed that the loss of more than three phosphorylation sites at once greatly 
decreased the activity of MurC, with a mutation of all six residues at once abolishing activity, 
in both in vitro assays as well as in vivo functional complementation experiments. It is 
therefore likely that each phosphorylation of MurC, at one or more sites, could differentially 
regulate the protein. This could potentially be investigated in Mtb-MurC by producing 
proteins containing multiple pseudo-phosphorylation mutations, including double, triple and 
quadruple mutations of T116, S163, T357 and S360, with multiple permutations of each 
mutant. These proteins would then require assaying in the same manner as the single site 
mutants (Section 2.2.3.) in order to compare the activity of MurC with increasing pseudo-
phosphorylated residues and identify whether the regulation of MurC can be fine-tuned in M. 
tuberculosis by multiple phosphorylation sites. 
The severe reduction in enzymatic activity caused by the pseudo-phosphorylation of T357 can 
be attributed to the location of the residue within the protein (Figure 2.14). Situated near to 
the enzymatic active site and ATP binding cleft, the change in charge at this position would 
more than likely cause a change in the electrostatic charges between neighbouring residues, in 
particular His124 and Glu192. The probable position of Asp357 (57.8% likelihood) is also a 
likely candidate for the position of a phosphate group attached to the native Thr357 (Figure 
2.14). This means that the introduced negative charge would be closer to the negatively 
charged Glu192 than before, which would likely introduce repulsion between the residues and 
cause conformational and electrostatic disruption to the neighbouring active site, diminishing 
enzymatic activity (Figure 2.14).  
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The increased affinity for UDP-MurNGlyc is an important consideration concerning the 
phosphorylation of MurC. Non-replicative (dormant) M. tuberculosis cells inhabit granulomas 
within the host lungs, where the conditions are hypoxic and the bacilli halt growth. This is 
ended when granulomas break down through a compromise of the host immune system and 
the atmospheric oxygen rises (Section 1.1.1.). The increase in molecular oxygen would result 
in production of UDP-MurNGlyc through the hydroxylation of UDP-MurNAc by NamH 
(Raymond et al., 2005). We propose that during dormancy M. tuberculosis tightly regulates 
MurC activity by phosphorylation of the identified residues (e.g. T116 or T357) in order to 
maintain a low activity and along with phosphorylation of MurD, reduce PG biosynthesis. 
This low activity is also maintained by the lack of up-regulation of MurC during dormancy 
keeping protein abundance low (Murphy and Brown, 2007). Once the granuloma begins to 
break down and oxygen becomes introduced, MurC (and MurD) is de-phosphorylated in 
order to increase activity and the high affinity for the newly converted UDP-MurNGlyc drives 
Figure 2.14: 3D-homology model of Mtb-MurC residue 357 with ATP bound. A) The predicted 
position of Thr357 in relation to nearby side chains. His124 and Glu192 are near to the enzyme active site. B) Mutation of Thr357 to Asp357 in the most probable position (57.8% likely) is also likely a very similar position of a phosphate group attached to Thr in the native protein. The introduction of a negative charge at this position would have an effect on the electrostatic charges within the protein, in particular the proximity to Glu192 and could easily cause disruption to the nearby active site. 
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PG production forward in order to help push cell growth and to exit dormancy. We do not 
suggest that this is the only mechanism of M. tuberculosis to resume a replicative state, nor 
the only function of hydroxylation of UDP-MurNAc or phosphorylation of MurC. For 
instance, incorporation of MurNGlyc into the PG structure has been shown to increase the 
resistance of the cell wall to lysozyme assault (Section 1.2.2.1.). It is probable that M. 
tuberculosis could slow the rate of PG biosynthesis through phosphorylation of MurC, to 
allow time for NamH action to increase the pool of UDP-MurNGlyc for incorporation into the 
cell wall and increase the protection from lysozyme, therefore regulating the level of 
MurNGlyc found within the PG structure. 
The discovery that pseudo-phosphorylation of specific sites of M. tuberculosis MurC has an 
effect on activity of the enzyme does raise a key issue, that of the identification of a potential 
M. tuberculosis MurC kinase. As previously mentioned (Section 2.1.), PknA has been shown 
to phosphorylate M. tuberculosis MurD, rather than MurC, but has recently been identified as 
capable of interacting with MurC (Thakur and Chakraborti, 2008, Munshi et al., 2013). 
However, it has not yet been proven that PknA is actually capable of phosphorylating MurC 
in M. tuberculosis, so the identity of a potential MurC kinase remains elusive. 
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3. IDENTIFCATION OF A PUTATIVE MYCOBACTERIAL AG/PG LIGASE 
3.1. Introduction 
Much is known about the biosynthetic pathway that leads to the formation of mycobacterial 
AG and PG (Section 1.2.), however knowledge of the final steps of AGP construction, namely 
how AG and PG are covalently tethered, is missing. It is recognised that AG is covalently 
attached to 10-12 % of muramyl residues of PG, specifically at the C6-hydroxyl via a unique 
LU, also that AG only becomes bound to PG once the latter becomes fully matured through 
peptide cross-linkages by transpeptidase action (Amar and Vilkas, 1973, McNeil et al., 1990, 
Hancock et al., 2002). However, the enzymatic process of this final “ligation” of AG to PG 
via a phosphodiester bond remains unsolved.   
Recently, a novel superfamily of proteins was identified called the LytR-CpsA-Psr (LCP) 
family, which are involved in the covalent attachment of anionic CWPs to the PG of Gram-
positive bacteria (Kawai et al., 2011). Anionic CWPs consist of both cell wall teichoic acids 
(CWTAs), which are bound directly to PG via a phosphodiester bond and lipoteichoic acids 
(LTAs) which are membrane-anchored and span throughout the PG layer (Weidenmaier and 
Peschel, 2008). Both of these CWPs have important roles in orchestrating the placement of 
cell division machinery, as well as being directly involved in host-pathogen interactions 
(Weidenmaier and Peschel, 2008). Interestingly, Gram-positive CWPs share a strikingly 
similar chemical phenotype to the homologous AG and LM/LAM polysaccharides from the 
mycobacterial cell wall (Crick et al., 2001, Jankute et al., 2012). CWTAs also share a similar 
biosynthetic pathway to AG, being initially synthesised within the cytoplasm as a lipid-linked 
polymer, translocated across the plasma membrane, before being attached to the PG 
(Swoboda et al., 2010). The LU of Gram positive CWTAs are also very similar to the unique 
LU of mycobacterial AG (Figure 3.1). The disaccharide LU of Gram-positive bacteria, such 
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as B. subtilis, consists of β-D-N-acetylmannosamine (ManNAc)-(1→4)-α-D-GlcNAc-(1→P), 
which is similar to α-L-Rhap-(1→3)-α-D-GlcNAc-(1→P) of AG, notably they both share D-
GlcNAc-(1→P) linking to PG (Kaya et al., 1984, McNeil et al., 1990, Weidenmaier and 
Peschel, 2008). 
 
OP
OH
O
O
O
OH
O
CH3
NH
O
O
OHHO
H3C
O
OH
OH
OHO OO
OH
OHO
HO
O
P
OH
O
O
OP
OH
O
O
HO
OP
OH
O
O
OH
O
CH3
NH
O
HO
HO
A
B
PG
PG
O
HO
O
OH NH
O
CH3
15
1-3
HO
40
OR OH
 
 
 
 
A recently characterised LCP protein identified in Streptococcus pneumoniae, Cps2A, acts as 
a phosphotransferase in the addition of CWTAs onto the PG (Kawai et al., 2011, Eberhardt et 
al., 2012). The crystal structure of Cps2A (solved to 1.69 Å) is described as having 2 
domains, an LCP domain that is conserved across species (30% sequence identity with 3 LCP 
Figure 3.1: Comparison of LU structures. A) B. subtilis 168 CWTA showing (Glycerol-P(GroP))40-(GroP)1-3-β-D-ManNAc-(1→4)-α-D-GlcNAc-(1→P). R side chain represents H, D-Ala or Glucose B) M. tuberculosis AG showing ((1→6)-Galf-(1→5)-Galf)15-α-L-Rhap-(1→3)-α-D-GlcNAc-(1→P). The two structures vary, but both LUs comprise of a disaccharide, comprising of either D-ManNAc (CWTA) or L-Rhap (AG) and a common D-GlcNAc-(1→P) forming a phosphodiester bond between the LU and C6-hydroxyls of muramyl residues of PG (boxed).  
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family proteins from B. subtilis) and an accessory domain, with a sequence and structure that 
is not conserved at all, to the point where it is not present in the sequence of some other LCP 
proteins (Kawai et al., 2011). The core of the LCP domain of Cps2A is an α-β-α structure, a 
5-stranded β-sheet surrounded by 2 α-helices, with 2 β-strands that extend from the protein 
core to form the interface between the domains. A highly conserved polyisoprenoid binding 
pocket containing hydrophobic residues was identified and it was noted that Cps2A co-eluted 
and crystallised with a bound decaprenyl-phosphate (from E. coli expression host), with the 
phosphate head group held in place by a variety of conserved charged residues (Kawai et al., 
2011). Beyond this hydrophobic pocket there is a space available that would accommodate an 
oligosaccharide LU, in a cleft on the surface of the protein, which is then likely to interact 
with the conserved arginine pair Arg362 and Arg244 (Kawai et al., 2011). A groove was also 
identified between β-strands that was suggested to accommodate PG, at an almost 90° angle 
to CWTA (Kawai et al., 2011). Observed structural data also showed that Cps2A is 
magnesium dependent, with Mg2+ binding between 2 aspartate residues (Asp234 and 
Asp246). Mg2+ is suggested to stabilise the transition state intermediate, by neutralising the 
emerging negative charge (Kawai et al., 2011). The absence of Mg2+ (or the removal of 
Asp234 by site-directed mutagenesis to alanine) in colourimetric assays showed far less 
liberation of inorganic phosphate, indicating a reduction of enzyme activity and the 
importance of Mg2+ as well as key catalytic residues (such as Asp234) to enzymatic function 
(Kawai et al., 2011).   
It has been identified that there are multiple LCP proteins present in various Gram-positive 
bacteria, which appear to have semi-redundant roles (Eberhardt et al., 2012). It has been 
shown that some of these homologs have a non-specific function (in S. pneumoniae), such as 
LytR and Psr, which can assist in the addition of polymers to the cell wall in the absence of 
Cps2A. However, it was noted that the homologous LCP genes cannot fully compliment the 
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function of genetically-altered strains depleted of a single LCP gene, as reduced cell wall 
material was recorded (Eberhardt et al., 2012). It was also shown that all 3 of these homologs 
are involved in some aspect of cell wall biosynthesis due to GFP-fused proteins aggregating at 
the mid-cell, where pneumococcal cell wall synthesis takes place, which in turn supports the 
hypothesis that these LCP proteins complete cell envelope maturation by attachment of 
CWTAs to PG (Eberhardt et al., 2012).  
The cpsA gene was investigated in Mycobacterium marinum (one of four LCP-like proteins), 
by the use of a transposon insertion mutant, which had a kanamycin resistance cassette 
inserted into the predicted LCP domain of CpsA, which resulted in loss of protein action 
(Wang et al., 2015). The resulting mutant displayed phenotypes unlike the wild-type, such as 
altered colony morphology, sliding motility, reduced cell wall hydrophobicity and 
permeability and reduced virulence (Wang et al., 2015). Of note is that this cpsA mutant 
contained reduced AG within its cell walls, indicating a potential reduction, but not total 
abolition, of attachment to the cell wall (Wang et al., 2015). It is therefore highly probable 
that M. tuberculosis has a similar set of proteins that belong to the LCP family, in particular 
one which can identify the common D-GlcNAc-(1→P) of the LU and act as a peptidoglycan-
arabinogalactan ligase (Figure 3.1). 
In this study, we have identified Rv3267 as being a direct homolog of Cps2A. Our results 
demonstrate that the M. smegmatis orthologue (MSMEG1824) is an essential gene as 
determined using Conditional Expression-Specialised Transduction Essentiality Test 
(CESTET). Furthermore, a comprehensive biochemical characterisation of recombinant 
Rv3267 (henceforth termed Lcp1) demonstrates its ability to “ligate” AG to PG in a 
radiolabelled cell-free assay.  
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3.2. Results 
3.2.1. Identification and in silico analysis of Lcp1 
A bioinformatic analysis (Section 5.17.) of mycobacterial and corynebacterial genomes using 
S. pneumoniae Cps2A as a query revealed Rv3267 (MtbLcp1) as a primary LCP homolog in 
M. tuberculosis showing 20 % sequence identity to Cps2A. A homologous protein was also 
identified in M. smegmatis, as MSMEG1824 (MsLcp1) with 71 % sequence homology to 
MtbLcp1 (Figure 3.2).  An alignment of lcp1 and its surrounding genes (from M. tuberculosis, 
M. smegmatis, Mycobacterium leprae and C. glutamicum) showed close genetic synteny, 
indicating conserved functionality between these species (Figure 3.3A). Interestingly, the fact 
that the gene cluster is conserved in the degenerate genome of M. leprae indicates an 
important conserved function for these genes to the survival of mycobacteria (Sassetti et al., 
2003). Furthermore, lcp1 is found immediately upstream of several genes involved in cell 
wall biosynthesis, importantly rmlD and wbbL1, both of which encode for proteins involved 
in the biosynthesis of the AG LU (Section 1.2.3.). 
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 Figure 3.2: Multiple protein sequence alignment of Lcp1 from different bacterial species. M. tuberculosis (Rv3267), M. smegmatis (MSMEG1824), C. glutamicum (NCgl0708) and homologous proteins from B. subtilis (LytR) and S. pneumoniae (Cps2A) (minus 140 N-terminal residues representing non-conserved accessory domain) share some sequence homolgy. The predicted secondary structure of MtbLcp1 is shown along the top of the alignment. Completely conserved residues are highlighted red, whereas homologous residues mostly conserved are in red font. Residues in blue indicate conserved residues believed to be involved in polyisoprenoid binding.  
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A 3D homology model was produced from the MtbLcp1 protein sequence (UniProtKB - 
P96872_MYCTU) using the I-TASSER server (C-score of -2.36) with a predicted single 
transmembrane helix (between residues 1 and 36) omitted (Figure 3.3B,C) (Section 5.17.). 
The homology model was then analysed in comparison to the S. pneumoniae Cps2A crystal 
structure model (PDB ID: 2xxp) (Section 5.17.). The predicted N-terminal α-helix 
corresponds with what has been observed in other LCP proteins, such as S. pneumoniae 
Cps2A (Kawai et al., 2011), however the sequence and model of MtbLcp1 does not contain the 
non-conserved accessory domain as Cps2A. The LCP domain of MtbLcp1 is indicated to 
contain a 5-stranded β-sheet, surrounded by α-helices forming the core of the protein, similar 
to the structure of the LCP domain of Cps2A. The homology model also retains the highly 
conserved polyisoprenoid binding hydrophobic pocket (Figure 3.3C). Numerous amino acid 
residues were identified as catalytically important in Cps2A by Kawai et al. (2011), in 
particular the arginine residues Arg267, Arg362, Arg364 and Arg374, as well as Asp371 and 
Gln378. Using both the multiple sequence alignment and positions of residues within the 
homology model (Figure 3.2, 3.3C) we identified four residues in MtbLcp1 (Arg70, Arg118, 
Arg236 and Arg238) which were believed to be involved in polyisoprenoid-pyrophosphate 
binding and therefore catalytically important.  
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Figure 3.3: Comparison of the lcp1 locus and in silico analysis of Lcp1 by TMHMM and I-TASSER. A) 
Mycobacterial lcp1 locus alignment, where lcp1 is black. The locus tags are Rv3267 in M. tuberculosis, MSMEG1824 in M. smegmatis, ML0756 in M. leprae and NCgl0708 in C. glutamicum. Each species shows genetic synteny, since lcp1 is consistently immediately upstream of both rmlD (dark grey) and wbbL1 (light grey). B) TMHMM server prediction of the hydrophobicity of MtbLcp1 (Section 5.17.). Predicted membrane toplogy showed an N-terminal transmembrane α-helix between residues 1 and 36, with the majority of the protein being extracellular. C) I-TASSER 3D model of MtbLcp1, positioned in relation to the plasma membrane, showing transmembrane domain between residues 1 and 36. Model also shows bound decaprenyl-phosphate.    
Chapter 3                                                                    Identification of a putative AG/PG ligase   
86  
3.2.2. Essentially of MsLcp1 in M. smegmatis  
Since Lcp1 is suspected to have an important role in the attachment of AG to PG, we 
hypothesised that lcp1 is likely to be an essential gene in mycobacteria. To test this 
hypothesis, we created a knockout phage (phΔMslcp1) (Section 5.19.) in order to replace 
MSMEG1824 (Mslcp1) with a hygromycin resistance cassette in M. smegmatis (Bhatt and 
Jacobs, 2009). As expected, there were no direct transductants, indicating an inability to 
directly generate a ΔMslcp1 null mutant. Therefore, a merodiploid strain of M. smegmatis 
harbouring a secondary acetamide inducible copy of Mslcp1 (Section 5.18.2.) was used for 
transduction with phΔMslcp1 by CESTET (Bhatt and Jacobs, 2009). Only when acetamide was 
present in the growth media were ΔMslcp1 knockout mutants generated.  
To confirm that a conditional ΔMslcp1 mutant had been created, cells were grown in the 
presence of acetamide and genomic DNA was extracted (Section 5.9.). As previously 
explained, if the genomic copy of Mslcp1 had been successfully knocked out, then it would be 
replaced with a larger hygromycin resistance cassette (Figure 3.4A). Therefore, PCR was 
performed on the extracted genomic DNA using primers that flank either side of genomic 
Mslcp1, which was then analysed by agarose gel electrophoresis (Section 5.5., Section 5.7.) 
(Figure 3.4B). Primers for murC amplification were also used as a control experiment to 
confirm presence of M. smegmatis template DNA (Section 5.5.1.) (Figure 3.4B). This PCR 
showed a band at around 3.5 kb using primers for the flanking regions of Mslcp1 from M. 
smegmatis WT genomic DNA (Figure 3.4B, Lane 2). However, the same experiment using 
genomic DNA from the ΔMslcp1 mutant revealed a band at around 6 kb, corresponding to the 
larger size of the hygromycin resistance cassette replacing Mslcp1 (Figure 3.4A, B, Lane 3). 
The ΔMslcp1 mutant DNA also showed a band for murC, at around 1.5 kb, confirming that the 
DNA is indeed from M. smegmatis cells (Figure 3.4B, Lane 4). The increase in size between 
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the bands from both M. smegmatis WT and ΔMslcp1 genomic DNA indicate that Mslcp1 was 
successfully knocked out in this conditional mutant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Confirmation of generation of a ΔMslcp1 conditional knock-out mutant. A) Using primers 
Mslcp1-Van91I L-LL and R-RR (Section 5.5.1.), the amplified region from M. smegmatis WT would be 3482 bp, whereas in the M. smegmatis ΔMslcp1 conditional mutant, the increased size of the hygromycin resisitance cassette would cause this region to be 6121 bp in size. B) Agarose gel electrophoresis of PCR from both M. smegmatis WT and ΔMslcp1. Lane 1 shows a 1 kb DNA ladder, Lane 2 shows M. smegmatis WT with flanking primers, Lane 3 shows M. smegmatis ΔMslcp1 with flanking primers and Lane 4 shows M. smegmatis ΔMslcp1 with murC amplifying primers. Lane 2 shows the correct sized band of around 3.5 kb, whereas Lane 3 corresponds to the size of the region containing the hygromycin resistance cassette. Lane 4 shows the correct sized band for murC, indicating that the conditional mutant DNA is indeed M. smegmatis and that the conditional mutant is indeed a true ΔMslcp1 knock out. 
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The M. smegmatis ΔMslcp1 mutant cells grown on agar plates in the presence of acetamide 
showed a difference in colony morphology when compared to M. smegmatis WT cells on the 
same plates (Figure 3.5A). The essentiality of Mslcp1 was further investigated through 
subsequent passages in liquid media, in the absence of the acetamide inducer (Figure 3.5B). In 
the absence of acetamide, there was a visibly rapid loss in cell viability, indicating the 
requirement of the second pMV306-ACET- Mslcp1 copy of the gene is required for cell 
growth, which supports the hypothesis of the essentiality of Mslcp1 (Figure 3.5B).  
 
 
 
 
 
 
 
The M. smegmatis ΔMslcp1 mutant was grown both in the presence and absence of acetamide 
over 55 h, with samples of both periodically being plated on TSA containing acetamide in 
order to check for colony forming units (CFU) (Figure 3.6). The ΔMslcp1 cells in the absence 
of acetamide rapidly begin to decline in CFU count after 20-25 h, whereas those grown in the 
presence of acetamide continue to grow unhindered (Figure 3.6). After around 24 h, there is a 
whole log difference in CFU between the ΔMslcp1 and WT cells. After the 55 h growth period 
the there is a 4 log difference between CFU counts for both samples, with WT cells reaching 
108 CFU, whereas ΔMslcp1 cells drop to a CFU count of below 104 (Figure 3.6). Since the 
Figure 3.5: Essentiality of Mslcp1 in M. smegmatis on solid and liquid media. A) The growth and colony 
formation of M. smegmatis WT and ΔMslcp1 mutant on tryptic soy agar (TSA). Pictures show a clear difference in shape and fitness of colonies, even though the mutant is grown in the presence of acetamide, inducing the second copy of Mslcp1. B) Growth of M. smegmatis ΔMslcp1 mutant in tryptic soy broth (TSB) in the presence (+) and the absence (−) of acetamide. Without acetamide, the ΔMslcp1 mutant rapidly declines in cell viability, shown by lack of growth in TSB.  
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number of CFU is decreasing over time in the absence of acetamide, it suggests that the cells 
are dying rather than becoming static, indicating that the loss of MsLcp1 to the cell is lethal 
(Figure 3.6). Because of the rapid loss in cell viability of the the ΔMslcp1 mutant in the 
absence of acetamide, it was not possible to phenotypically characterise the expected resultant 
lesions in the cell wall, due to a lack of available cellular material. We therefore decided to 
biochemically characterise recombinant MtbLcp1. 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.6: M. smegmatis ΔMslcp1 CFU growth curve, in both the presence and absence of 
acetamide. When acetamide is removed from the growth medium, the cells immediately begin to die, as evidenced by the rapid reduction of CFU over the first 20 h. After 55 h, the cells in the absence of acetamide are well in decline, whereas the cells grown with acetamide continue to grow unhindered across the entire timespan, indicating that the cells are healthy and in optimum growth conditions, showing that the lack of acetamide and therefore MsLcp1, results in increased cell death. 
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3.2.3. Purification of recombinant MtbLcp1 protein 
An N-terminally His-tagged MtbLcp1 (minus transmembrane domain) expression vector 
(pET28b-MtbLcp1) was constructed (Section 5.18.1.). Four identified amino acid residues with 
a predicted role in polyisoprenoid-phosphate binding (Section 3.2.1.) were mutated into 
alanine through site-directed mutagenesis (SDM) of the pET28b-MtbLcp1 vector (Section 
5.6.). This gave rise to the constructs pET28b-MtbLcp1 WT, R70A, R118A, R236A and 
R238A. All of these vectors were overexpressed in E. coli BL21 (DE3) (Section 5.4.1.) and 
purified through immobilised metal ion affinity chromatography (IMAC) (Figure 3.7) and 
subsequent anion exchange chromatography, if required (Section 5.11.).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: SDS-PAGE of MtbLcp1. A) MtbLcp1 WT, B) MtbLcp1R70A, C) MtbLcp1 R118A, D) 
MtbLcp1 R236A. MtbLcp1 R238A was unable to be expressed or purified despite numerous attempts of optimisation. Lanes shown are protein marker (M), clarified lysate flow through (1), 50 mM imidazole elution (2), 75 mM imidazole elution (3), 100 mM imidazole elution (4), 200 mM imidazole elution (5), 250 mM imidazole elution (6) and 500 mM imidazole elution (7). Bands visible around 50-60 kDa represent recombinant MtbLcp1. 
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MtbLcp1 WT, R70A, R118A and R236A all purified abundantly (Figure 3.7) and were stable 
at concentrations of 50 mg/mL and higher, however, it was not possible to obtain recombinant 
MtbLcp1 R238A, despite numerous attempts at optimising expression and purification. 
Recombinant purified MtbLcp1 WT and the site-directed mutants (SDMs) (R70A, R118A and 
R236A) were all stable when dialysed into 100 % dH2O for a period of 1 to 2 weeks at 4 °C.  
Since it was observed that S. pneumoniae Cps2A co-eluted with a polyisoprenoid-phosphate 
(Section 3.1.) and the MtbLcp1 homology model predicted a hydrophobic binding cavity 
(Section 3.2.1.), we investigated whether MtbLcp1 also co-eluted with a polyisoprenoid. We 
performed an organic solvent extraction of MtbLcp1 and analysed the extracted sample by TLC 
(Figure 3.8), which revealed a spot with the same Rf value as the known standard decaprenyl-
monophosphate (Section 5.21.). These extractions were also submitted for mass spectrometric 
analysis (Section 5.21.), which clearly indicated an m/z of 777, which directly correlates with 
the expected mass of decaprenyl-1-monophosphate (Figure 3.9). This indicates that MtbLcp1 
also co-purifies with a bound polyisoprenoid-phosphate, in a similar fashion to other LCP 
proteins (Section 3.1.). We repeated an identical extraction and analysis approach for each of 
the three recombinant mutant MtbLcp1 proteins using the same amount of protein as the 
original experiment. Surprisingly, all three mutants also co-eluted with decaprenyl-
monophosphate as indicated by TLC and mass spectrometric analysis (Figure 3.8, Figure 3.9). 
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Figure 3.8: TLC plate showing MtbLcp1 WT and SDM bound lipid. Decaprenyl-monophosphate (Lane 
1, C50-P) and undecaprenyl-monophosphate (Lane 2, C55-P) shown running alongside solvent extracted samples from MtbLcp1 WT (Lane 3), R70A (Lane 4), R118A (Lane 5) and R236A (Lane 6) using the solvent system CHCl3:CH3OH:NH4OH:H2O (65:25:0.5:3.6, v/v/v/v) (Section 5.14.). All MtbLcp1 extractions ran at the same Rf value as decaprenyl-monophosphate, indicating that MtbLcp1 WT and SDMs co-purify with a bound polyisoprenoid, likely to be decaprenyl-monophosphate. 
Figure 3.9: Mass spectra of MtbLcp1 WT and SDM. A single peak at 777 m/z is seen, which 
corresponds to the expected mass of decaprenyl-1-monophosphate in the negative ion mode. A) MtbLcp1 
WT. B) MtbLcp1 R70A. C) MtbLcp1 R118A. D) MtbLcp1 R236A. 
Chapter 3                                                                    Identification of a putative AG/PG ligase   
93  
Since the MtbLcp1 SDMs harbour mutated residues that are predicted to be important for the 
binding of decaprenyl-monophosphate, it was important for us to eliminate the possibility that 
these mutated recombinant proteins were folded incorrectly. Therefore we conducted a far-
UV circular dichroism (CD) (Section 5.22.) analysis of both MtbLcp1 WT and each of the 
three SDMs.  
An overlay of the spectra from each sample of MtbLcp1 (Figure 3.10) indicated that each 
protein was folded with the same degree of secondary structure. The only major differences in 
spectra were at the low wavelength end (190 nm) and were attributed to system noise.   
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Figure 3.10: Far-UV CD spectra of MtbLcp1 WT (black) and SDMs (R70A red, R118A blue, R236A 
green), between 260 and 190 nm. Each spectrum overlays extremely well, indicating that each protein is folded into the same secondary structure as MtbLcp1 WT, and thus each SDM protein is folded correctly.    
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Further biophysical characterisation of MtbLcp1 could be obtained through analytical 
ultracentrifugation (AUC), in order to probe how MtbLcp1 self-assembles in solution (Section 
5.22.). We performed a set of sedimentation velocity experiments using MtbLcp1 WT and 
SDMs alone, and also MtbLcp1 WT in the presence of varying concentrations of a synthetic 
carbohydrate ligand, compound 1, one of a panel of analogues representing various stages of 
the mycobacterial LU (Figure 3.13), synthesised to investigate MtbLcp1 and its interaction 
with its chemically complex and labile natural substrate (Section 3.2.4.). When the MtbLcp1 
proteins were in solution on their own, the distribution (c (s)) of the sedimentation coefficient 
(S) indicated a single major molecular species for all samples at 3.2-3.3 S (Figure 3.11), 
which correspond to apparent molecular weights (Table 3.1) fitting the calculated molecular 
weight of MtbLcp1, of around 48.5 kDa, indicating MtbLcp1 WT and SDMs are likely 
monomeric in solution. When increasing ligand concentration was added to MtbLcp1 WT, 
there was a slight increase in S with increased ligand concentration (from 3.2 S to 3.5 S) 
(Figure 3.12), however, this did not cause a significant change in apparent molecular weights 
(Table 3.2) and it is probable that MtbLcp1 remains a monomer in solution in the presence of 
carbohydrate ligands, such as the AG LU.    
 
 
 
 
 
 
Chapter 3                                                                    Identification of a putative AG/PG ligase   
95  
 
 
 
 
Sample Molecular Weight (kDa) 
MtbLcp1 WT 50.8 
MtbLcp1 R70A 47.5 
MtbLcp1 R118A 48.4 
MtbLcp1 R236A 50.0 
Figure 3.11: Self-assembly analysis of MtbLcp1 WT (black) and SDMs (R70A red, R118A blue, 
R236A green) by AUC in sedimentation velocity mode. The peaks for each protein fell within 3.2 S and 3.3 S and gave apparent molecular weights (Table 3.1) that fit to the calculated molecular weight of MtbLcp1 in its monomeric state. 
Table 3.1: Apparent molecular weights of MtbLcp1 WT and SDMs calculated through sedimentation 
velocity experiments by AUC. Each molecular weight can be fitted to the calculated molecular weight of 
MtbLcp1, 48.5 kDa.  
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Sample Molecular Weight (kDa) 
MtbLcp1 WT 50.8 
MtbLcp1 WT + 2 mM compound 1 54.5 
MtbLcp1 WT + 4 mM compound 1 49.8 
MtbLcp1 WT + 4 mM compound 1 51.2 
  
Figure 3.12: Self-assembly analysis of MtbLcp1 WT (black) and increasing carbohydrate ligand 
(compound 1) concentration (2 mM green, 4 mM purple, 6 mM blue) by AUC in sedimentation velocity mode. The peak for WT protein on its own was at 3.2 S, with increasing ligand concentration raising the sedimentation coefficient to 3.5 S. However, the apparent molecular weight of protein with each ligand concentration (Table 3.2) did not significantly alter from the calculated molecular weight of monomeric MtbLcp1. 
Table 3.2: Apparent molecular weights of MtbLcp1 WT with increasing concentration of 
carbohydrate ligand (compound 1) calculated through sedimentation velocity experiments by AUC. Each molecular weight can be fitted to the calculated molecular weight of MtbLcp1, 48.5 kDa.  
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3.2.4. Carbohydrate binding of linker unit mimetics to MtbLcp1 
Our laboratory has previously synthesised neo-glycolipid acceptors, modelled upon motifs 
found within mycobacterial AG, in order to probe the ligand binding abilities of proteins 
involved in cell wall structure, as well as any enzymatic function associated with them 
(Alderwick et al., 2008, Alderwick et al., 2011a). Therefore, it was possible to synthesise an 
array of analogues of the mycobacterial LU (Compounds 1-4) (Figure 3.13), which could be 
used to investigate MtbLcp1 and its interaction with its putative natural substrate decaprenyl-
pyrophosphoryl-GlcNAc-Rhap-Galf30. Compounds 1-4 are LU mimetics synthesised to 
represent a variety of stages of LU biosynthesis (Section 1.2.3.2.), since the physiological 
substrate is chemically complex and labile, they offered an alternative means to assess this 
important biochemical interaction. Unstable decaprenyl-pyrophosphate groups were 
substituted with C8 alkyl chains, since compounds containing these have previously been 
shown to be successful acceptors (Lee et al., 1997). Compound 1 (Rha-GlcNAc-O-C8) is a 
representation of glycolipid (GL)-2 and resembles the disaccharide L-Rhap-(1→3)-α-D-
GlcNAc of the mycobacterial LU, with a shortened representation of the decaprenyl-
pyrophosphoryl moiety. Compound 2 (Galf2-Rha-GlcNAc-O-C8) represents GL-4 and 
compound 3 (Galf3-Rha-GlcNAc-O-C8) contains a single Galf residue addition to compound 
2, representing the increasing galactan chain. However, compound 4 (Galf-Rha-O-C8) 
represents the terminal L-Rhap of the LU, attached to a single Galf residue (Figure 3.13). 
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We used intrinsic tryptophan fluorescence (ITF) to probe the binding of MtbLcp1 WT with 
compounds 1-4 (Section 5.15.). Binding data was fitted to a single site saturation model to 
yield equilibrium binding constants (Kd) for each compound (Figure 3.14). The Kd for 
compound 1 was 57.68 µM, which increased ~10 fold in affinity with the addition of 2 Galf 
residues, providing a Kd of 5.13 µM for compound 2.  Further elongation of the galactan 
chain with a third Galf residue in compound 3 resulted in a Kd of 20.39 µM. Compound 4 
displayed a much lower binding affinity, providing a Kd of 97.61 µM, as well as ~10 fold 
decrease in binding capacity (Bmax).  
Figure 3.13: Structures of novel chemical scaffolds used as ligands to probe MtbLcp1 interaction 
with mycobacterial LU. Compounds 1 and 2 represent GL-2 and GL-4 of LU/galactan assembly respectively (Section 1.2.3.2.). Compound 3 represents an extension of GL-4 by a single Galf residue. Compound 4 represents the terminal Rhap of the mycobacterial LU bound to a single Galf residue.   
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The data shows that MtbLcp1 is capable of binding the disaccharide compound 1, representing 
the LU. It also shows that MtbLcp1 has a high affinity for LU with additional Galf residues 
attached (compound 2 and 3), suggesting that the presence of Galf residues is important in 
substrate binding. The fact that compound 4 displays a significantly lower binding affinity to 
MtbLcp1 suggests that D-GlcNAc is an important component of MtbLcp1 substrate recognition 
(Figure 3.14). However, when the selected arginine residues were mutated to alanine, a 
change in binding was seen for both compounds 1 and 4 (compounds 2 and 3 were omitted 
due to depletion of available ligands) (Figure 3.15). 
Figure 3.14: Saturation binding experiments using ITF to assess MtbLcp1 WT ligand binding. Each 
experiment  used 26 nM MtbLcp1, all experiments performed in triplicate. (1) Binding of compound 1 (Rha-GlcNAc-O-C8) gives a Kd of 57.68 µM. (2) Compound 2 (Galf2-Rha-GlcNAc-O-C8) binding gives a Kd of 5.13 µM. (3) Binding of compound 3 (Galf3-Rha-GlcNAc-O-C8) gives a Kd of 20.39 µM. (4) Compound 4 (Galf-Rha-O-C8) gives no significant binding affinity, providing a Kd of 97.61 µM and a much reduced binding capacity (Bmax).  
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The mutation at R70 resulted in a binding affinity around three fold lower for compound 1 
(161.5 µM) than for MtbLcp1 WT, as well as a lower Bmax of 1,102, compared to that of 1,448 
for WT (Figure 3.15A). MtbLcp1 R70A shows a similar trend in binding compound 4, 
whereby it displays a higher Kd than WT of 150.1 µM and a slight reduction in the already 
significantly reduced binding capacity (Figure 3.15B). Interestingly, MtbLcp1 R118A displays 
Figure 3.15: Saturation binding experiments using ITF to assess MtbLcp1 SDM binding. For compound 1 
(A), the Kd of each of the MtbLcp1 variants were 57.68 µM for WT, 161.5 µM for R70A, 27.76 µM for R118A and 82.43 µM for R236A. However, the Bmax for each mutant was lower than the 1,448 that WT displayed, with R70A being 1,102, R118A being 744.5 and R236A being 1,077. For compound 4 (B), the Kd of each of the MtbLcp1 variants were 97.61 µM for WT, 150.1 µM for R70A, 99.07 µM for R118A and 206.4 µM for R236A. Again, each mutant MtbLcp1 displayed a lower Bmax than the 177.6 for WT, with R70A being 135.4, R118A being 38.61 and R236A being 92.79. The data for both compounds with each MtbLcp1 variant shows that mutation of these residues results in a decrease in overall binding of the LU mimetics. 
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a Kd of almost half that of WT when binding compound 1 (27.76 µM), yet also shows a Bmax 
of around half that of WT (744.5), suggesting that this mutation increases the binding affinity, 
whilst lowering the overall binding capacity (Figure 3.15A). When MtbLcp1 R118A binds 
compound 4, the Kd remains similar to that of WT (99.07 µM), however the binding capacity 
is again dramatically reduced to 38.61 (Figure 3.15B). Finally, MtbLcp1 R236A displays a 
lower binding affinity than WT (82.43 µM) and a lower Bmax of 1,077 when binding 
compound 1, behaving in a similar fashion to MtbLcp1 R70A (Figure 3.15A). Yet when 
binding compound 4, MtbLcp1 R236A shows a Kd around twice that of WT of 206.4 µM and a 
binding capacity almost half of WT (92.79) (Figure 3.15B). All of these results suggest that 
mutation of these specific residues in MtbLcp1 has a detrimental effect on LU binding. 
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3.2.5. MtbLcp1 cell-free activity assay 
We developed a cell-free biochemical assay in order to assess whether MtbLcp1 was capable of 
ligating AG to PG. Since MtbLcp1 was predicted to contain an N-terminal transmembrane 
helix (Section 3.2.1.), attachment is likely to occur at or around the cytoplasmic membrane, 
we therefore proposed that membranes prepared from mycobacteria would contain some 
endogenous AG to PG attachment activity, which could be investigated by using a [14C]-
carbohydrate radiolabelled assay. A previous method used to monitor the synthesis of 
radiolabelled decaprenyl-pyrophosphoryl intermediates of mycobacterial cell wall 
biosynthesis in our laboratory was modified to directly investigate the attachment of [14C]-AG 
intermediates to PG, in vitro (Birch et al., 2009). Mycobacterial membranes (Section 5.23.1.) 
and cell wall fraction (rich in endogenous cell wall biosynthetic enzymes) (Section 5.23.2.) 
were mixed with [14C]-galactopyranose, with the endogenous Glf mutase activity within the 
assay mix enough to allow for direct incorporation of [14C]-Galf into cell wall intermediates, 
as was previously demonstrated (Birch et al., 2009). Purified PG (PPG) from M. smegmatis 
(Section 5.23.3.), free of any covalently bound AG, was also added before initiation of the 
assay by addition of recombinant MtbLcp1 WT and SDMs. The products of the assay were 
then solvent extracted through a complex fractionation process (Section 5.23.4.) before 
analysis. The first extraction from the assay mix was the aqueous fraction, which contained 
any remaining unused radiolabel. 
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The organic fraction contained samples extracted using CHCl3:CH3OH (2:1, v/v), which were 
analysed through TLC (Figure 3.16A) (Section 5.23.5.). This analysis revealed three major 
bands migrating towards the bottom of the plate, with bands corresponding to GL-3 and GL-4 
(Section 1.2.3.2.) and decaprenyl-pyrophosphoryl-GlcNAc-Rhap-galactan, which remained at 
the origin. Interestingly, the intensity of these bands decreased with an increase in the amount 
of MtbLcp1 present in the sample (Figure 3.16B). When the assay was repeated in the absence 
of PPG, the intensity of all bands appeared to remain at similar levels as those in the absence 
of MtbLcp1 (Figure 3.16A, Lanes 2 and 5). This was corroborated by densitometry of the TLC 
plate, and analysis of the radioactivity of each band (Figure 3.16B). Therefore, the data shows 
that with the addition of MtbLcp1, the relative amount of [14C]-Galf labelled material is 
reduced in the organic fraction. This trend is seen not just for MtbLcp1 WT (Figure 3.16) but 
also for all SDMs in repeated assays.  
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Figure 3.16: Organic solvent extraction analysis. A) Organic solvent extracted fraction from [14C]-
labelled assay analysed by TLC (Section 5.14.), developed in CHCl3:CH3OH:NH4OH:H2O (65:25:0.5:3.6, v/v/v/v). As Lcp1 concentration increases, the bands corresponding to GL-4 and GL-3 and mature galactan at the origin, appear less intense, suggesting radioactivity and therefore substrates are being utilised. When there is an absence of PPG, the bands are much more intense, regardless of Lcp1 concentration, suggesting reduction in radioactivity moving through the system. Bands present are a result of MtbLcp1 WT, but are representative of all SDMs. B) Radioactivity present in all bands, showing the true counts per minute (CPM) within each band from the total radioactivity in the sample. The radioactivity within each band decreases when the amount of Lcp1 is increased. However, in the absence of PPG in lane 5, the level of radioactivity within each band remains high, at comparable levels to the no Lcp1 control in lane 2. This corresponds with what can be seen on the TLC plate. 
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The H2O:C2H5OH:(C2H5)2O:C5H5N:NH4OH (15:15:5:1:0.017, v/v/v/v/v) extraction, termed 
‘E-soak’ fraction, was believed to contain free unbound AG generated by the biosynthetic 
enzymes within the assay mixture. This was analysed by western blot (Figure 3.17A), using a 
primary antibody (CS-35) that recognised and bound to the hexa-arabinofuranoside terminal 
motif ([β-Araf-(1→2)-α-Araf]2-3,5-α-Araf-(1→5)-α-Araf) of AG and LAM (Section 1.2.3.1., 
Section 5.23.5.). The secondary antibody had alkaline phosphatase activity and was visualised 
by development with BCIP solution (Sigma Aldrich), which identified bands of varying size 
(Figure 3.17A). This not only showed that arabinan was present in the ‘E-soak’ fraction, but 
also that these arabinan chains were “capped” with terminal Araf6 domains at varying lengths. 
The blot was then subjected to autoradiography, which showed the location of [14C]-Galf in 
relation to the developed arabinan bands (Figure 3.17B). The radiolabelled bands of the 
autoradiograph match the locations of the developed bands on the blot, indicating bound 
[14C]-galactan to arabinan, showing the presence of AG within the ‘E-soak’ fraction. 
Importantly, the intensity of the radioactive bands decreased with an increase in the amount of 
MtbLcp1, as proven using densitometry (Figure 3.17C). However, when the assay was repeated 
in the absence of PPG, the intensity of the [14C]-galactan bands increased (Figure 3.17B,C, 
Lane 5). Therefore, as MtbLcp1 is increased, the relative amount of [14C]-Galf labelled material 
within the ‘E-soak’ fraction becomes decreased, which is a trend that is followed when the 
assay is repeated using MtbLcp1 SDMs. 
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Figure 3.17: ‘E-soak’ extraction analysis. A) Western blot of ‘E-soak’ fraction after Tris-Tricine 
SDS-PAGE (Section 5.23.5.). Lane M is protein marker. The primary antibody used was CS-35, which binds to the terminal Araf6 motif of the arabinan of AG and LAM, the secondary antibody was SC-2070 which can be visualised using BCIP solution (Sigma Aldrich). Blot shows terminal domains of arabinan at varying lengths. B) Autoradiography of ‘E-soak’ western blot A. Bands show [14C]-galactan at the same locations as arabinan on the blot, indicating bound AG. C) Radioactivity present in each lane in counts per minute (CPM), based on the total radiation in the sample. Radioactivity decreases with increased Lcp1, whereas the absence of PPG causes an increase in remaining radioactivity, which corresponds with what is seen in B. 
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The final insoluble fraction contains PG and any PG linked [14C]-Galf labelled material. 
Analysis of per-O-acetylated alditol acetates of this material by TLC (Section 5.23.5.), 
revealed a major band which migrated to the position of per-O-acetylated galactitol acetate 
(Figure 3.18A). Bands were also identified to correspond with per-O-acetylated glucitol 
acetate, among others, which indicated that some UDP-[14C]-Gal had been metabolised into 
other sugars under these conditions, which is a phenomenon that has been previously reported 
(Yagi et al., 2003). The addition of MtbLcp1 into the assay mix resulted in an increase in 
intensity of the per-O-acetylated galactitol acetate band, which seemingly increased further 
with increased MtbLcp1 (Figure 3.18A, Lane 3 and 4). This was confirmed through 
densitometry, since there is higher radioactivity within these bands, than in the absence of 
MtbLcp1 (Figure 3.18B Lane 2, 3 and 4). However, when the assay was repeated in the 
absence of PPG, the incorporation of [14C]-Gal material had diminished, since the band 
corresponding to per-O-acetylated galactitol acetate was of very low intensity, once again 
confirmed by densitometry, showing much lower radioactivity within this band (Figure 
3.18A, B, Lane 5). The same trend continued for the SDMs of MtbLcp1 where the addition of 
MtbLcp1 led to an increase in intensity of per-O-acetylated galactitol acetate bands, except in 
absence of PPG (Figure 3.18, Lanes 6-8 (R70A), Lanes 9-11 (R118A), Lanes 12-14 
(R236A)).  
The assay data as a whole shows two major findings. Firstly, that the attachment of [14C]-Galf 
cell wall material to PG can be directly monitored. Secondly, that recombinant MtbLcp1 is able 
to utilise decaprenyl-pyrophosphoryl-GlcNAc-Rhap-[14C]-Galfn as a substrate for attachment 
to PG, which is unaffected by the presence of bound arabinan, or by mutations to predicted 
residues believed to be involved in polyisoprenoid-phosphate binding.  
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Figure 3.18: Insoluble material analysis. A) Insoluble pellet material was analysed by TLC, after hydrolysis, 
reduction and per-O-acetylation (Section 5.23.5.). The resulting per-O-acetylated alditol acetates were developed by TLC using ethyl acetate:hexane (4:6, v/v). As the amount of Lcp1 increases, so does the intensity of per-O-acetylated galactitol acetate bands. In the absence of PPG, the intensity of these bands diminish, suggesting both Lcp1 and PPG are required for addition of [14C]-Gal onto PG. B) Radioactivity present in all bands, showing the true counts per minute (CPM) within each band from the total radioactivity in the sample (No Lcp1 = purple, MtbLcp1 WT = black, R70A = red, R118A = blue, R236A = green). The same trend is seen across all varations of MtbLcp1, whereby an increase of Lcp1 corresponds to an increase of radioactivity (over that of the no Lcp1 control (Lane 2)), except when there is an absence of PPG. Lane 13 shows lower CPM than expected but still a higher amount of radioactivity than seen in Lane 2. 
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3.2.6. Phosphatase activity of MtbLcp1 
It has previously been shown that LCP proteins have a phosphatase activity, that is capable of 
producing inorganic phosphate (Pi) as a by-product of cleavage of the pyrophosphate head 
group of the bound polyisoprenoid, and the formation of the new phosphodiester bond (Kawai 
et al., 2011, Eberhardt et al., 2012). With this in mind, an assay was devised to assess whether 
recombinant MtbLcp1 also possessed phosphatase activity. 
Geranyl-pyrophosphate (G-P-P) and geranylgeranyl-pyrophosphate (GG-P-P) were utilised as 
decaprenyl-pyrophosphate mimics in a phosphate cleavage assay (Section 5.24.), the products 
of these assays were then analysed by TLC (Figure 3.19). In the absence of MtbLcp1, there is 
little to no cleavage of phosphate from the pyrophosphate head group of either G-P-P or GG-
P-P, despite degradation seen at the top of each TLC (Figure 3.19A, B). However, when the 
assay is repeated in the presence of MtbLcp1 (WT or SDM) an additional band appeared on 
each TLC plate, corresponding to geranyl-monophosphate (G-P) (Figure 3.19A) and 
geranylgeranyl-monophosphate (GG-P) (Figure 3.19B). Therefore, the data suggests that 
recombinant MtbLcp1 does possess phosphatase activity comparable to previously 
characterised LCP proteins 
Additional bands migrating toward the top of the TLC remain unidentified (Figure 3.19). 
Mass spectrometry of the products produced in each experiment provided inconclusive data as 
to the characteristics of these bands. However, the positions of G-PP, GG-PP, G-P and GG-P 
were identified by Rf values (Kawai et al., 2011). 
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Figure 3.19: Analysis of MtbLcp1 phosphatase assay products by TLC. TLC plate (Section 5.14.) 
developed in CHCl3:CH3OH:NH4OH:H2O (65:25:0.5:3.6, v/v/v/v). A) Analysis of G-P-P products shows a band for G-P present when MtbLcp1 is added to the assay mix, which is missing in the absence of the protein. B) Analysis of GG-P-P products shows a band for GG-P present when MtbLcp1 is added to the assay mix, which is missing in the absence of the protein. Both of these analyses suggest a phosphatase activity for MtbLcp1. 
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3.3. Discussion 
The LU of mycobacterial AG is remarkably similar to that of CWTA in Gram-positive 
bacteria, both sharing a common D-GlcNAc (1→P) at the PG bound end (Figure 3.1). These 
common LU are then both covalently bound to the C6-hydroxyl of specific muramyl residues 
of PG through a phosphodiester bond. Other commonalities exist between mycobacterial AG 
and Gram-positive CWTA, in that both biosynthetic pathways begin with assembly of 
polymers onto polyprenyl-pyrophosphate lipid carriers within the cytoplasm, before transport 
to the extracellular side of the membrane (Yokoyama et al., 1986, Jankute et al., 2015). A 
recently discovered superfamily of proteins was found to be responsible for the attachment of 
CWTA to PG through phosphotransferase activity, known as LCP proteins (Kawai et al., 
2011). In this regard, we hypothesised that M. tuberculosis may harbour a similar protein of 
the LCP family in order to attach AG to PG within its cell wall architecture. 
Through bioinformatic analysis of members of the Corynebacterineae suborder, we identified 
MtbLcp1 (Rv3267) as the primary putative LCP protein in M. tuberculosis, sharing 20 % 
sequence identity with Cps2A from S. pneumoniae. There are two additional putative LCP 
orthologs in M. tuberculosis, Rv3434 and Rv0822c, which share 15 % and 12 % identity with 
Cps2A from S. pneumoniae respectively and also share 36 % and 26 % identity with MtbLcp1, 
respectively. Furthermore, both orthologues of MtbLcp1 are predicted to contain a single N-
terminal α-helix, as well as LCP and LytR_C superfamily domains similar to MtbLcp1. 
Because lcp1 is found immediately downstream of two genes involved in LU biosynthesis, 
wbbL1 and rmlD, we decided to utilise M. smegmatis as a model system to investigate the 
molecular genetics of the gene, in order to assess its essentiality and role as a primary LCP 
orthologue involved in mycobacterial cell wall assembly.  
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Mtblcp1 was purported to be an essential gene through a high throughput screen of the M. 
tuberculosis H37Rv genome, however this needed to be examined experimentally (Xu et al., 
2013). M. smegmatis has been used previously as a model organism to successfully study the 
molecular genetics of mycobacterial cell wall biosynthesis and therefore a clean deletion of 
Mslcp1 in M. smegmatis was attempted (Birch et al., 2008, Bhatt and Jacobs, 2009). However, 
as anticipated, it was not possible to generate a direct null mutant, as this would result in a 
non-viable, lethal phenotype because of the essential nature of Mslcp1, as observed (Section 
3.2.2.). The essentiality of Mslcp1 was confirmed by performing a CESTET experiment 
(Figure 3.4, Figure 3.5). The generation of null mutants of genes involved in the biosynthesis 
of the cell wall is technically challenging, since a non-viable phenotype is often returned due 
to lesions within the essential cell envelope structure. In S. aureus, the first two genes 
involved in CWTA biosynthesis (tarO and tarA) are non-essential and can be deleted without 
altering growth (D'Elia et al., 2006a, D'Elia et al., 2009). Despite this, deletion of any 
subsequent CWTA synthesising enzyme (tarBDFIJH) resulted in a non-viable, lethal 
phenotype, unless the mutant also contained an inactivation of either tarO or tarA (D'Elia et 
al., 2006b). A proposed hypothesis for this lethality, which is overcome when CWTA 
synthesis is prevented (by inactivation of tarO),  is the sequestering of a scarce shared 
building block, such as the polyisoprenoid lipid carrier which is required not only for CWTA 
biosynthesis, but also the biosynthesis of “Lipid II” in PG assembly, (D'Elia et al., 2006b).  
The polyisoprenoid lipid carrier, decaprenyl-phosphate, in Corynebacterineae such as M. 
tuberculosis is required for not only “Lipid II” in PG biosynthesis, but also in the production 
of DPA required for arabinan biosynthesis. Benzothiazinones (BTZs) are a new class of 
compound that are potent anti-mycobacterial agents (Batt et al., 2012). They are particularly 
potent inhibitors of mycobacterial growth since they target DprE1, which is involved in the 
epimerisation of DPR to DPA, thus inhibiting arabinan biosynthesis (Section 1.2.3.2.). 
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However, it has recently been concluded that BTZs mode of action is through the blocking of 
decaprenyl-phosphate recycling, consequently preventing cell wall biosynthesis from 
occurring properly (Grover et al., 2014). With this in mind, the identification and 
characterisation of the enzyme responsible for the attachment of AG to PG in M. tuberculosis 
would likely be a potential drug target, since its inhibition would prevent cell wall maturation 
and reduce the availability of decaprenyl-phosphate, leading to cell lethality. 
The presence of a hydrophobic polyisoprenoid binding pocket within the MtbLcp1 homology 
model (Figure 3.2C) is consistent with similar conserved cavities within other LCP proteins 
(Kawai et al., 2011, Eberhardt et al., 2012). This is evident through biochemical analysis of 
recombinant MtbLcp1 which was shown to co-elute with decaprenyl-1-monophosphate, likely 
bound within this binding pocket (Figure 3.9). The biochemistry of MtbLcp1 was probed 
further with the use of a chemically synthesised panel of LU analogues, each representing 
chemical structures found near the start of the mycobacterial AG biosynthetic pathway 
(Section 1.2.3.2.). ITF was used to probe the ligand binding properties of these compounds 
against MtbLcp1, with compounds 1-3 showing a ligand binding relationship that reached 
saturation with a defined Bmax and binding affinity at the low µM range. Compound 1 was 
synthesised to represent the disaccharide ‘core’ of the LU, L-Rhap-(1→3)-D-GlcNAc, which 
recorded a Kd of 58.71 µM. However, with the addition of 2 Galf residues in the 
tetrasaccharide Galf2-Rha-GlcNAc-O-C8 (compound 2) the binding affinity increased 10-fold, 
giving a Kd of 5.13 µM. When this molecule was increased by a further Galf residue 
(compound 3) there was a 4-fold decrease in Kd to 20.39 µM (Figure 3.14). Due to technical 
reasons the chemical synthesis of Galf-Rha-GlcNAc-O-C8 was not possible, which meant the 
study of the ligand binding properties of this single Galf-LU structure were unable to be 
studied. A control experiment was performed with the use of compound 4, representing the 
LU in the absence of D-GlcNAc, which displayed very low binding affinity (Kd of 97.61 µM) 
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in comparison to the other compounds, as well as a diminished binding capacity, suggesting 
that D-GlcNAc is a vital residue in the biophysical interaction between MtbLcp1 and ligand. 
Since MtbLcp1 is capable of binding not only the LU (compound 1) but also LU plus multiple 
Galf residues (compound 2-3), the data suggests that it is highly likely that MtbLcp1 might 
catalyse the phosphotransfer of AG to PG upon encountering a true physiological substrate, 
consisting of decaprenyl-pyrophosphate-LU and at least one (if not two) Galf residues 
attached (Figure 3.21). 
Mutations to residues believed to be involved in polyisoprenoid-phosphate binding resulted in 
an overall reduction in binding capacity of both compounds 1 and 4, for each MtbLcp1 variant 
(Figure 3.15). In particular, the mutation of R118A resulted in MtbLcp1 displaying a much 
higher binding affinity for compound 1 than the WT protein, with a Kd 27.76 µM, yet also 
shows a much lower binding capacity, with a Bmax of 744.5, compared to 1,448 for WT 
(Figure 3.15A). This trend continued with compound 4, whereby MtbLcp1 R118A showed a 
further diminished binding capacity of 38.61 (Figure 3.15B). The fact that these mutations 
affect the binding of LU mimetics, as well as the fact that each mutant protein has been shown 
to co-elute with a bound decaprenyl-1-monophosphate, suggests that these specific residues 
actually have a larger role in LU recognition, rather than simply polyisoprenoid-phosphate 
binding. The position of these residues within the homology model of MtbLcp1 helps to 
support this, since the side chains of R118 and R236 in particular extend toward the 
phosphate head group of decaprenyl-phosphate when it is bound in its suspected binding 
pocket (Figure 3.20). Therefore it is likely that these residues would be capable of interaction 
with D-GlcNAc-P of the LU region and play a role in substrate binding (Figure 3.20). 
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We devised a cell-free functional assay to assess the activity of MtbLcp1 and measure its 
ability to attach AG to PG. Chemical analysis of fractionated samples from an assay mix 
containing [14C]-Gal radiolabelled products showed that lipid-linked AG precursors (Figure 
3.16), as well as lipid-linked mature AG (Figure 3.17) decrease in an inverse relationship to 
the amount of MtbLcp1 present. A similar pattern was displayed in the insoluble material, 
showing a titratable dependant increase in per-O-acetalyated-[14C]-galacitol acetate with an 
increase of MtbLcp1 in the assay mix. This was seen regardless of any mutations to residues 
potentially important in LU and polyisoprenoid-phosphate binding, and indicates an increase 
in AG bound to PG in these samples (Figure 3.18). Interestingly, it was seen that in the 
absence of PPG, there was little to no MtbLcp1 action seen throughout the assay. This is of 
Figure 3.20: Positions of R70, R118 and R236 within homology model of MtbLcp1 with bound 
decaprenyl-phosphate. All three arginine residues are within the vicinity of the phosphate head group of decaprenyl-phosphate, in particular R118 and R236 whose side chains extend toward the phosphate group. It is likely that theses residues could be involved in LU binding since they would be in the correct location to interact with D-GlcNAc-P of the LU.  
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note, as it has previously been suggested that attachment between AG and PG requires 
concomitant biosynthesis of both cell wall polymers in order to take place (Hancock et al., 
2002). It has also been shown that MtbLcp1 displays some phosphatase activity which is 
indicative of the action of LCP family proteins, since phosphate release would occur upon 
formation of a phosphodiester bond between CWTA/AG and PG (Figure 3.19). However, the 
results of our phosphatase assay are contrary to those shown by Kawai et al., 2011, since their 
results suggest that Cps2A is incapable of cleaving G-P-P, which is attributed to blockage of 
the active site by exogenous polyisoprenoid-pyrophosphate. Since we have shown that 
MtbLcp1 co-elutes with a bound decaprenyl-phosphate, our results seem to suggest that this 
bound lipid can be displaced easily in order to allow other substrates to bind (Figure 3.8, 
Figure 3.9). This is also evidenced by the fact that MtbLcp1 shows activity in the cell-free 
assay, proving its capability of binding to glycolipid 3/4 substrates and utilising them within 
the assay (Figure 3.16). Conversely, an alternative reason for the activity of MtbLcp1 may be 
that it could purify as a heterogeneous mix of both decaprenyl-phosphate bound and un-bound 
states, with the ‘un-bound’ protein providing the activity seen. 
We suggest a putative mechanism for phosphotransfer by MtbLcp1 (Figure 3.21), initiated by 
the hydroxyl group of the phosphate bound to the decaprenyl moiety of the LU becoming 
deprotonated by an as of yet unconfirmed arginine residue (R70, R118, R236 or R238). We 
propose the hydrogen of the phosphate group binds to the double bonded NH/NH2 of the 
arginine residue, with the resulting positive charge passing to the opposing NH2 group. A 
neighbouring aspartate residue (D97, D119 or D245) then removes the extra proton to balance 
the charge, whilst the electrons between the hydroxyl group pass to the oxygen, breaking the 
bond between the atoms (Figure 3.21). The oxygen of the C6 hydroxyl from a MurNAc 
residue within PG then attacks the LU phosphate bound to the GlcNAc moiety by 
nucleophilic substitution, resulting in electrons passing from phosphate to its bound oxygen to 
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break the bond (Figure 3.21). Meanwhile, the newly negatively charged oxygen from the 
neighbouring phosphate group attacks the hydrogen of the MurNAc C6 hydroxyl, removing it 
and culminating in the bond between the AG LU and PG and the liberation of decaprenyl-
monophosphate (Figure 3.21). However, this mechanism remains uncertain without the full 
structure of MtbLcp1 being solved. 
 
 
 
 
This study provides compelling genetic and biochemical evidence that MtbLcp1 is the enzyme 
responsible for the convergence of two major cell wall biosynthetic pathways, culminating in 
a phosphodiester bond between AG and PG in mycobacteria (Figure 3.22).The discovery of 
MtbLcp1 sheds new light on a key reaction during late stage cell wall assembly and is likely to 
Figure 3.21: Potential arrow pushing mechanism of ligase activity by MtbLcp1. 1) Deprotonation of 
phosphate group attached to the decaprenyl moiety (C50) (P2) by arginine of MtbLcp1 (either R70, R118, 
R236 or R238). Electrons are passed to oxygen of P2 to break bond as proton is attached to NH group of 
arginine. Proton is then removed from active arginine by neighbouring aspartate (either D97, D119 or 
D245). 2) The C6 hydroxyl of MurNAc from PG then acts as a nucleophile, attacking the phosphate attached 
to the LU moiety (P1). The negative charge attached to P2 then attacks the proton of the C6 hydroxyl , as the 
phosphodiester bond between the phosphate groups is broken. 3) P1 becomes covalently bound to C6 of 
MurNAc (PG) as decaprenyl-phosphate is liberated. 
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be a critical protein for all Corynebacterineae that possess cell walls containing AG attached 
to PG via a phosphodiester bound LU. However, this discovery does raise the issue of when 
arabinan becomes bound to galactan to form AG, before or after attachment to PG, since 
MtbLcp1 has been shown to be capable of utilising both arabinan bound and non-arabinan 
bound LU-galactan. As a consequence of this, the timing of mycolylation of the arabinan 
chains is also questioned. If arabinan is bound to galactan before “ligation” to PG, then it 
could also be mycolylated at this point with a potential interaction between MtbLcp1 and 
antigen 85 complex. Conversely, this could all occur once MtbLcp1 has completed the 
attachment of the LU-galactan to PG and has left the area.  
 
 
 
Figure 3.22: Proposed mechanism of action of Lcp1 for attachment of AG to PG in the latter stages 
of cell wall biosynthesis. 1) Translocation of galactan polymer across plasma membrane. Lcp1 then 
recognises and binds the decaprenyl-pyrophosphoryl-LU (i.e. represented by compounds 2 and 3). 2) 
Phosphotransferase activity links AG to the 6’-OH of muramyl residues, releasing decaprenyl-phosphate to 
be recycled. 3) Newly bound AG is released by Lcp1 to go on to form mature mAGP. Additional synthesis 
of new PG, requiring AG addition by Lcp1, takes place simultaneously. 
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4. GENERAL DISCUSSION 
4.1. Conclusions and Future perspectives 
TB remains a global health crisis, which is only becoming exacerbated in recent times with 
the rise of MDR, XDR and even TDR strains of M. tuberculosis around the world. The 
effectiveness of this pathogen is due, in part, to its intricate carbohydrate and lipid-rich cell 
wall, which not only provides protection to the bacterium, but also plays an important role in 
its virulence. It is therefore vital to have a complete understanding of the mycobacterial cell 
wall, not just to advance scientific understanding, but also to help assist in the ongoing 
chemotherapeutic effort against TB by identifying potential new drug targets. Although many 
of the biosynthetic pathways of the mycobacterial cell wall have been fairly well defined in 
recent years, numerous voids in knowledge still exist. Therefore, this thesis aims to address 
the key themes of regulation and completion of crucial aspects of mycobacterial cell wall 
biosynthesis, which have previously been overlooked by scientific investigation. 
In chapter 2, we investigated how M. tuberculosis can control PG biosynthesis and therefore 
cell wall assembly. We have proven that phosphorylation of M. tuberculosis MurC has an 
effect on protein kinetics and is capable of downregulating its activity. Pseudo-
phosphorylated mutants simulated phosphorylation of specific sites within MurC, through 
substitution of specific serine/threonine residues (homologous to those known to be 
phosphorylated in C. glutamicum by PknA) to aspartate (Fiuza et al., 2008). We used the I-
TASSER server to produce homology models of both C. glutamicum and M. tuberculosis 
MurC, which were subsequently analysed against the crystal structure of H. influenzae MurC 
(Mol et al., 2003). Both the Cg-MurC and Mtb-MurC models aligned against each other with 
a TM-score of 0.93544, indicating a good fit, with both the phosphorylated Cg-MurC residues 
occupying the same space as the homologous residues in the Mtb-MurC model. All of these 
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residues occupied space surrounding the ATP binding domain, suggesting that 
phosphorylation of these residues would likely interfere with ATP binding in vivo. 
The introduction of a negative charge at key residues of MurC, namely T116 and T357, has a 
profound effect on the Michaelis-Menten kinetics of the enzyme, reducing activity by least 
around 50 %, when compared to MurC WT. Conversely, pseudo-phosphorylation of S360 
resulted in a slight up-regulation of MurC activity of around 15-20 % when compared to 
MurC WT, as opposed to the down-regulation displayed by the mutation of some of the other 
selected residues. A similar trend was seen regardless of whether the UDP-Muramyl or ATP 
dependence of MurC was assayed. We also discovered that phosphorylation of the specific 
sites of M. tuberculosis MurC have the potential to increase co-operative binding of ATP, as 
well as binding affinity, when assayed by ITF. This increase in co-operation between binding 
sites could be explained by an increase in dimerisation of MurC, caused by the pseudo-
phosphorylation of T116, S163 and S360 residues, since E. coli MurC has shown the ability 
to form dimers in solution, yet retain functional activity (Das et al., 2011). Furthermore, we 
noted that M. tuberculosis MurC displayed a much higher affinity for UDP-MurNGlyc over 
UDP-MurNAc, showing a 30-fold difference between Km values. We suggested that this 
difference in affinity, along with de-phosphorylation of down-regulated MurC, could be 
utilised by M. tuberculosis as a means to exit dormancy and resume active replication upon 
the degradation of the granuloma.  
In chapter 3, we probed the final union of both the AG and PG biosynthetic pathways through 
the identification of a putative AG/PG ligase, Lcp1. Firstly, bioinformatic analysis of 
Corynebacterineae revealed Rv3267 (MtbLcp1) as the primary LCP homolog of S. pneumoniae 
Cps2A in M. tuberculosis and MSMEG1824 (MsLcp1) as the primary orthologue in M. 
smegmatis. We created a homology model of MtbLcp1 (using the I-TASSER server) and 
analysed it against the crystal structure of Cps2A (Fiuza et al., 2008). We saw that the model 
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complied with many of the structural features seen in other LCP proteins, only lacking the 
non-conserved accessory domain. The essentiality of Mslcp1 was proved through a CESTET 
experiment, by the creation of a conditional ΔMslcp1 knock-out mutant. Without the acetamide 
induced second copy of Mslcp1, the ΔMslcp1 cell viability rapidly diminished, proving how 
vital Mslcp1 is to the survival of M. smegmatis and in turn M. tuberculosis.  
The presence of co-eluted polyisoprenoid-phosphate is indicative of LCP proteins (Kawai et 
al., 2011) and as such, we identified that recombinant MtbLcp1 WT and three site-directed 
mutant proteins (MtbLcp1 R70A, R118A and R236A) all co-eluted with a bound decaprenyl-1-
monophosphate, despite the fact that the mutated residues were originally believed to be 
involved in polyisoprenoid-phosphate binding. Each of these MtbLcp1 variants were also 
shown to be capable of in vitro phosphatase activity, able to cleave the pyrophosphate bond of 
G-P-P and GG-P-P, an ability which Cps2A was shown incapable of (Kawai et al., 2011). It is 
possible that the co-eluted decaprenyl-1-monophosphate is easily displaced from MtbLcp1, 
allowing for surrogate polyisoprenoid-phosphate binding and permitting phosphate cleavage. 
However, it is equally likely that MtbLcp1 is purified as a mixture of both decaprenyl-1-
monophosphate bound and un-bound units and it is the ‘un-bound’ protein that displays this 
activity.  
The ideal MtbLcp1 LU substrate structure was investigated using both ITF and a panel of 
synthetic LU analogues. We were able to show that the preferred substrate was Galf2-Rha-
GlcNAc-O-C8 (compound 2), which displayed a binding affinity 4 times higher than any other 
compound. However, in a control experiment using compound 4, representing the LU without 
D-GlcNAc, the binding affinity diminished, indicating the importance of this conserved 
monosaccharide to substrate recognition. The ligand binding properties of each MtbLcp1 SDM 
were also probed, revealing a reduced binding capacity of each mutant protein for compounds 
1 and 4, suggesting a role in LU binding for the mutated residues. This data shows that it is 
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highly likely in vivo, that MtbLcp1 action would depend on encountering a true physiological 
substrate consisting of decaprenyl-pyrophosphate-LU and a galactan chain consisting of at 
least one, if not two, Galf residues. 
We were able to prove the ability of MtbLcp1 to ‘ligate’ AG to PG by developing a cell-free 
radiolabelled functional assay. In the absence of recombinant MtbLcp1, a build-up of [14C]-
Galf labelled substrates was seen, including both GL-4 and AG, whereas an increase in 
MtbLcp1 correlated with a large decrease in these substrates. Likewise, the addition of 
recombinant MtbLcp1 correlated with an increase of [14C]-Galf labelled products within the 
final insoluble material (the PG), therefore indicating that the increased presence of MtbLcp1 
results in an increase of radiolabelled AG addition to PG. We also discovered that in the 
absence of PPG within the starting assay mix, MtbLcp1 activity was abolished, demonstrating 
that MtbLcp1 activity is dependent upon pre-existing PG.  
Both of the major proteins discussed in this thesis play an important role in M. tuberculosis 
cell wall biosynthesis, which is a major factor during cell division. Being a rod-shaped 
organism, M. tuberculosis traditionally divides symmetrically at the septum formed at the mid 
cell (Hett and Rubin, 2008). However, it has recently been shown that around 20 % of mid-
log replicating M. tuberculosis divides asymmetrically, due to deviation in septum location, 
resulting in viable, but non-identical short/long daughter cells (Vijay et al., 2014). It has also 
been noted that in cases of drug-resistant M. tuberculosis, cells are capable of branching 
division, whereby daughter cells begin to grow on the sides of mother cells, rather than 
splitting at the septum. In XDR and TDR strains, this branched replication becomes further 
adapted as daughter cells become small and spherical in shape, believed to be due to harsh 
environmental conditions (Farnia et al., 2010). Septum formation is initiated by FtsZ, a 
tubulin-like homolog, which binds GTP to form protofilaments, which then become 
polymerised to form a complex known as the Z-ring (Margolin, 2005). In M. tuberculosis, 
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FtsZ has been shown to display slower GTP-dependent polymerisation, as well as weaker 
GTPase activity by polymers than other bacteria. These polymers of FtsZ were also seen to be 
much more stable than the homologous polymers in E. coli (White et al., 2000). Once the Z-
ring has formed, it begins recruitment of membrane-associated cell division proteins, with 
one, FtsW, forming a unique interaction with FtsZ in M. tuberculosis, believed to be 
responsible for anchoring the Z-ring to the plasma membrane (Datta et al., 2002). PG 
formation then begins at the septum, as the Z-ring begins to contract, believed to be possibly 
down to loss of FtsZ subunits in the polymer (Margolin, 2005, Hett and Rubin, 2008). This 
completes the septum and results in the sealing of the daughter cells (Hett and Rubin, 2008). 
The daughter cells separate as a V-shape, due to the growth of the cell wall at the septum, 
with PG hydrolysis allowing the cells to ‘snap’ apart from one another. This results in the 
outer layer of the cell wall becoming ruptured which ‘scars’ the new cell (Dahl, 2004, Thanky 
et al., 2007).  
Opposed to most rod shaped bacteria, such as E. coli, which have nascent PG continuing 
through the cell and inert PG at the poles, mycobacteria grow with nascent PG being at their 
poles and inert PG running throughout the length of the cell (Thanky et al., 2007). Therefore, 
PG biosynthetic machinery would also be located at the poles of the cell where PG synthesis 
is taking place. It is therefore highly likely that other enzymes involved in cell wall 
biosynthesis would also locate to the poles where cell growth is occurring. Since the FtsZ 
polymer or Z-ring causes constriction and pinches the septum, as well as recruitment of the 
cell wall assembly machinery, it is probable that FtsZ remains at the poles long after cell 
division (Hett and Rubin, 2008). Since there is no cytoskeletal MreB homolog in 
mycobacteria to compete with FtsZ for cell shape definition, as well as the fact that the Z-ring 
is highly stable, could mean that FtsZ is responsible for recruiting and maintaining the cell 
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wall biosynthetic enzymes at the poles of the cell, allowing for nascent PG to form at each 
end of the cell (Thanky et al., 2007, Hett and Rubin, 2008).  
It would be of interest to the outcomes of this thesis to see where Lcp1 is localised throughout 
the mycobacterial cell. We would assume that it would be located at the poles of the cell, 
where cell wall biosynthesis occurs to drive cellular growth, perhaps recruited by FtsZ if it 
truly does remain at the poles past cell division. This could be investigated by the creation of 
an Lcp1-GFP conjugation, which could then be visualised by fluorescence microscopy in 
order to track Lcp1 within live cells. This method could perhaps be utilised to see whether 
Lcp1 interacts with other cell wall biosynthetic enzymes by creating various coloured 
fluorescent tag conjugations of proteins such as members of the antigen 85 complex or 
Wzt/Wzm, etc. It would then be interesting to see whether these additionally tagged proteins 
co-locate with Lcp1. Furthermore, if the FtsZ polymer does remain at the poles of the cell to 
orchestrate cell wall growth, then the constriction of the Z-ring during cell division would 
create a ‘pinch point’ within the cell wall, which would likely be carried forward past the 
point of cell separation. In terms of the dimensions of the mycobacterial cell wall (Section 
1.2.1.), this ‘pinch point’ would bring the components of the cell wall much closer to the 
plasma membrane. This would be in important consideration for membrane anchored 
proteins, such as Lcp1, since there would be no way that these proteins could act upon mAGP 
components across a 14-17 nm periplasmic space. With a pinching of the cell wall, these 
proteins would then be able to reach their sites of action and perform their roles in cell wall 
assembly. 
We do not know how mycobacterial cells perform the regulation of such an important cell 
wall assembly protein as Lcp1. However, since we have proven that M. tuberculosis MurC 
can be phosphorylated in order to regulate its activity, it is likely that, if phosphorylation of 
MurC does indeed occur in vivo, Lcp1 would indirectly be regulated by MurC action. This 
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would likely transpire since we have proven that Lcp1 requires pre-existing PG for protein 
action, so if MurC is down-regulated by phosphorylation of key residues (T116 or T357), then 
the down-regulation of PG biosynthesis would also lead to the consequence of reduced Lcp1 
activity, as there would be no PG to “ligate” AG to. It is likely however, that there are many 
more measures M. tuberculosis takes to regulate the protein that combines two crucial, 
nutrient demanding cell wall biosynthesis pathways. 
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5. MATERIALS AND METHODS 
5.1. General chemical and media preparation 
All Chemicals and Solvents were from Sigma-Aldrich, Bio-Rad or Fisher Chemicals, unless 
otherwise stated. Restriction enzymes were from Thermo Scientific. 
5.1.1. Luria-Bertani (LB) Broth 
37 g of LB Broth (Merck Millipore) in 1 L Water (H2O), autoclaved at 121 °C for 15 min.   
5.1.2. Luria-Bertani (LB) Agar 
37 g of LB Broth (Merck Millipore), 15 g Bacto Agar (BD, Difco) in 1 L H2O, autoclaved at 
121 °C for 15 min. Incubated at 55 °C, then poured into petri dishes (25 mL/plate). 
5.1.3. Terrific Broth  
47.6 g Terrific Broth (Merck Millipore) in 1 L H2O, with additional 4 mL glycerol (100 % 
v/v). Autoclaved at 121 °C for 15 min. 
5.1.4. NZY+ Broth 
10 g NZ amine (casein hydrolysate), 5 g yeast extract, 5 g Sodium Chloride (NaCl) in 1 L 
H2O, autoclaved at 121 °C for 15 min. Once cooled, 12.5 mL Magnesium Chloride (MgCl2) 
(1 M), 12.5 mL Magnesium Sulfate (MgSO4) (1 M) and 10 mL glucose (2 M) were filter 
sterilised (through 0.2 µm filter), and supplemented into media. 
5.1.5. Tryptic Soy Broth (TSB) 
30 g of TSB (BD, Difco) in 1 L H2O, autoclaved at 121 °C for 15 min. 
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5.1.6. Tryptic Soy Agar (TSA) 
30 g of TSB (BD, Difco), 15 g Bacto Agar (BD, Difco) in 1 L H2O, autoclaved at 121 °C for 
15 min. Incubated at 55 °C, then poured into petri dishes (25 mL/plate). 
5.1.7. Middlebrook 7H9 Basal Agar 
4.7 g Middlebrook 7H9 Broth (BD, Difco), 15 g Bacto Agar (BD, Difco) in 1 L H2O (without 
ADC supplement). Autoclaved at 121 °C for 15 min. Incubated at 55 °C, then poured into 
petri dishes (20 mL/plate). 
5.1.8. Middlebrook 7H9 ‘Top’ Agar 
4.7 g Middlebrook 7H9 Broth (BD, Difco), 6 g Bacto Agar (BD, Difco) in 1 L H2O (without 
ADC supplement). Autoclaved at 121 °C for 15 min.  
5.1.9. Transformation Buffers 
5.1.9.1. Transformation Buffer 1 (TFB1)  
100 mM Rubidium Chloride (RbCl2), 50 mM Manganese Chloride (MnCl2), 30 mM 
Potassium Acetate (KAc), 10 mM Calcium Chloride (CaCl2), 15 % glycerol (v/v), pH 5.8. 
5.1.9.2. Transformation Buffer 2 (TFB2)  
10 mM MOPS, 10 mM RbCl2, 75 mM CaCl2, 15 % glycerol (v/v), pH 6.8. 
5.1.10. Protein Purification Buffer (2 ×) 
100 mM Potassium Phosphate (KH2PO4), 600 mM NaCl, pH 7.9 
5.1.10.1. Lysis Buffer  
50 mM KH2PO4, 300 mM NaCl, 20 mM Imidazole, pH 7.9. 
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5.1.11. Dialysis Buffers 
MurC ‘Storage’ Buffer - 30 mM HEPES pH 7.6, 50 mM Potassium Chloride (KCl), 1 mM 
MgCl2, 1 mM EDTA, 50 % glycerol (v/v), made up to 2 L.  
Lcp1 Buffer - 25 mM Tris HCl pH 7.9, 10 mM NaCl, 10 % glycerol (v/v), made up to 2 L. 
5.1.12. MurC Reaction Buffer 
50 mM HEPES pH 7.6, 10 mM MgCl2. 
5.1.13. Mycobacteriophage (MP) Buffer 
50 mM Tris HCl pH 7.6, 150 mM NaCl, 10 mM MgCl2, 2 mM CaCl2, sterilised through a 0.2 
µm filter. 
5.1.14. Buffer ‘A’ 
50 mM MOPS (NaOH pH 7.9), 10 mM MgCl2, 5 mM β-Mercaptoethanol. 
5.1.15. Western Transfer Buffer 
25 mM Tris, 190 mM Glycine pH 7.5, 10 % Methanol in 1 L H2O. 
5.1.16. Tris Buffered Saline (TBS) 
20 mM Tris pH 7.5, 150 mM NaCl in 1 L H2O. Can be made with 0.05 % Tween 20 (TBS-T).  
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5.2. Bacterial Strains and Conditions 
E. coli Top 10 cells were used for propagation of plasmid DNA. These cells were routinely 
grown in LB broth, or LB agar at 37 °C. E. coli BL21 (DE3) cells were used for the 
overproduction of recombinant protein, grown in Terrific Broth at 37 °C. E. coli XL10 Gold 
cells were used during site-directed mutagenesis protocols, grown in NYZ+ broth, and LB 
agar at 37 °C. M. smegmatis mc2155 was grown in TSB (containing Tween 80 (0.05 % v/v)) 
and TSA at 37 °C. All cells were supplemented with the appropriate antibiotics (50 µg/mL 
Kanamycin (Kan) and/or 100 µg/mL Hygromycin (Hyg)) when required.  
5.3. Preparation of competent cells 
5.3.1. E. coli chemically competent cells 
E. coli cells were grown at 37 °C to OD600 = 0.4-0.5, before incubation on ice for 10 min. 
Cells were pelleted by centrifugation at 3,300 × g for 15 min and the supernatant was 
discarded. From this point, pelleted cells were kept on ice and were then re-suspended in 0.4 
volume of ice cold TFB1 (Section 5.1.9.1.). The suspension was then incubated on ice for 15 
min, before centrifugation at 3,300 × g for 15 min at 4 °C. The supernatant was discarded, and 
the cells were re-suspended in 0.02 volume of ice cold TFB2 (Section 5.1.9.2.).  The 
suspension was then incubated on ice for 30-60 min, before being aliquoted into 
microcentrifuge tubes. Each aliquot was then flash frozen in liquid nitrogen (N2) and stored at 
-80 °C. 
5.3.2. M. smegmatis electrocompetent cells 
M. smegmatis cells were grown at 37 °C to OD600 = 0.4-0.5, then pelleted by centrifugation at 
3,300 × g for 15 min at 4 °C. The supernatant was discarded, and the pellet was re-suspended 
in 0.5 volume of ice cold 10 % glycerol (v/v). The suspension was then incubated on ice for 
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10 min. Cells were pelleted by centrifugation at 3,300 × g for 15 min at 4 °C, before being re-
suspended in 0.3 volume of ice cold 10 % glycerol (v/v). The suspension was incubated on ice 
for 10 min. This trend of centrifugation, resuspension and incubation continued, reducing the 
volume of 10 % glycerol in each round (0.15 volume, 0.1 volume and 0.04 volume 
successively). Once the cells had been incubated in 0.04 volume 10 % glycerol (v/v), cells 
were aliquoted into microcentrifuge tubes. Each aliquot was then flash frozen in liquid N2 and 
stored at -80 °C. 
5.4. Transformation of bacterial cells 
5.4.1. Transformation of E. coli cells by heat shock method 
Chemically competent E. coli cells (100 µL) (Section 5.3.1.) were added on top of 1 µL 
plasmid DNA and incubated on ice for 15 min. The cell suspension was then subjected to 
‘heat shock’, incubation at 42 °C for 1 min. Cells were then returned to ice for a further 2 min, 
before 250 µL LB broth was added and the suspension was incubated at 37 °C for 1 h. The 
suspension was then plated onto LB agar plates (supplemented with correct antibiotic) and 
incubated overnight at 37 °C. 
5.4.2. Transformation of M. smegmatis cells by electroporation 
Electrocompetent M. smegmatis cells (Section 5.3.2.) and plasmid DNA were incubated on 
ice until thawed. After this, 2 µL of plasmid DNA was inserted into a 1 mm electroporation 
cuvette (Cell Projects) and incubated on ice for 20 min. Then 200 µL of M. smegmatis cells 
were added to the cuvette and incubated on ice for 30 min. The cuvette was then inserted into 
an electroporator 2510 (Eppendorf) and pulsed at 1,800 V before incubation on ice for 15 
min. Cells were rescued by the addition of 250 µL TSB and incubation at 37 °C for 4 h. After 
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incubation, cells were plated onto TSA plates (supplemented with correct antibiotic) and 
incubated at 37 °C for 2-3 days.  
5.5. Polymerase Chain Reaction (PCR) 
PCR was performed in 20 µL reactions, consisting of 0.5 µM forward primer, 0.5 µM reverse 
primer (Section 5.5.1.), 250 ng genomic DNA (M. smegmatis/M. tuberculosis), 200 µM dNTP 
mix, 1.5 mM MgCl2, 3 % dimethyl sulfoxide (DMSO), 1 U/(50 µL reaction) Phusion DNA 
polymerase (New England Biolabs), 1× Phusion 5× GC buffer (New England Biolabs) and 
made up to 20 µL with nuclease free H2O. Each reaction was then subjected to cycling 
conditions (Table 5.1) for gene amplification, inside a Mastercycler Gradient thermocycler 
(Eppendorf).  
 
Cycle Temp (°C) Time (sec) 
1 98 30 
2 98 10 
3 72* 30 
 Back to cycle 2 × 35 times 
4 72 600 
Hold at 4 °C 
 
 
 
 
 
Table 5.1: PCR cycling conditions for MSMEG1824 amplification. * R = 3 deg/s + G = 8 deg. 
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5.5.1. Primers used for PCR 
 
Forward 5’-GATCGATCGATATCTTGATCAGGTCCATTGCTGTGGCCGCA-3’ 
Reverse 5’-GATCGATCAAGCTTTCAGTTCACGCACTGCGGGTCGTTGGC-3’ 
 
 
Forward 5’-GATCGATCCATATGGTGATGTCTGCGCAACGTGTGGTTCGT-3’ 
Reverse 5’-GATCGATCAAGCTTTCAGTTGATGCACTCCGGCGCGTCGGA-3’ 
 
 
TB Forward 5’-GATCGATCCATATGGTGAGCACCGAGCAGTTGCCGCCCGAT-3’ 
TB Reverse 5’-GATCGATCAAGCTTTCATCCCAGCACCCCCGGACGGCCGGG-3’ 
MS Forward 5’-GATCGATCCATATGATGACGGGCATCTCGCTGCCACCGGAG-3’ 
MS Reverse 5’-GATCGATCAAGCTTTCACGACGCGCCCGCTCCCGGCATACC-3’ 
 
 
F-LL 5’-TTTTTTTTCCATAAATTGGCGACCACCAGGGGGCGGGCATCGTCCA-3’ 
R-LR 5’-TTTTTTTTCCATTTCTTGGACCGGGGCAGGCGGCATGGTCGGGCGC-3’ 
F-RL 5’-TTTTTTTTCCATAGATTGGACGACGCCACCGGTGAACGCATCGAGC-3’ 
R-RR 5’-TTTTTTTTCCATCTTTTGGGCCGACGACAGGCTGCTCGACGACTAC-3’ 
 
 
Table 5.2: Primers designed for amplification of MSMEG1824 from M. smegmatis 
Table 5.3: Primers designed for amplification of rv3267 from M. tuberculosis 
Table 5.4: Primers designed for amplification of murC from M. tuberculosis (TB) and M. smegmatis (MS) 
Table 5.5: Primers designed for Mslcp1 Van91I-containing flanking regions. For creation of ΔMslcp1 
phasmid (Section 5.19.) and for confirmation of genetic knock-out, through PCR of ΔMslcp1 genomic DNA.  
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5.6. Site-Directed Mutagenesis (SDM) 
Site-Directed Mutagenesis (SDM) was performed using Quikchange II XL kit (Agilent 
Technologies). Reaction mixtures were made, consisting of 0.5 µL (10 ng) double-stranded 
DNA template (plasmid-gene DNA), 1 µL (125 ng) forward primer, 1 µL (125 ng) reverse 
primer (Section 5.6.1.), 1 µL dNTP mix, 5 µL 10 × reaction buffer (Agilent Technologies), 3 
µL QuikSolution (Agilent Technologies) and 38.5 µL nuclease-free H2O to give a final 
volume of 50 µL. Once mixed, 1 µL (2.5 U/µL) pfuUltra high fidelity polymerase (Agilent 
Technologies) was added and the reaction was subjected to cycling conditions (Table 5.6) 
inside a Mastercycler Gradient thermocycler (Eppendorf). Reactions were immediately 
incubated on ice following cycling conditions to cool to ≤ 37 °C, before 1 µL DpnI (Agilent 
Technologies) was added to reactions, and incubated at 37 °C for 1 h. E. coli XL10 Gold cells 
were then transformed (Section 5.4.1.) using 2 µL of DpnI-digested DNA mixture. After 
plasmid extraction (Section 5.10.), samples were submitted for DNA sequencing to confirm 
SDM (MWG Eurofins).  
 
Segment Cycles Temp (°C) Time 
1 1 95 1 min 
2 18 95 50 sec 
60 50 sec 
68 7 min* 
3 1 68 7 min 
 
 
Table 5.6: PCR cycling conditions for Quikchange II XL protocol. *pET28b = 5.3 kb, murC/lcp1 = 
1.5 kb. Therefore total size is 6.8 kb = 7 minutes elongation step.  
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5.6.1. Primers used for SDM 
5.6.1.1. MurC primers 
 
T116D Forward 5’-GTTGATGGCCGGGCGCGACACATTGATGGTCACCG-3’ 
T116D Reverse 5’-CGGTGACCATCAATGTGTCGCGCCCGGCCATCAAC-3’ 
T129D Forward 5’-GCACGGCAAGACAACGGACACGTCCATGCTGATCG-3’ 
T129D Reverse 5’-CGATCAGCATGGACGTGTCCGTTGTCTTGCCGTGC-3’ 
S163D Forward 5’-CAACGCCCATCACGGCGATGGCGACTGTTTCGTCG-3’ 
S163D Reverse 5’-CGACGAAACAGTCGCCATCGCCGTGATGGGCGTTG-3’ 
T357D Forward 5’-CTACGCCCACCACCCGGACGAGATCAGCGCGACAC-3’ 
T357D Reverse 5’-GTGTCGCGCTGATCTCGTCCGGGTGGTGGGCGTAG-3’ 
S360D Forward 5’-CCACCCGACGGAGATCGACGCGACACTGGCGGCGG-3’ 
S360D Reverse 5’-CCGCCGCCAGTGTCGCGTCGATCTCCGTCGGGTGG-3’ 
 
5.6.1.2. Lcp1 primers 
R70A Forward 5’-GGTCGGCCTGGACAGCGCTACCGACGCGCACGGCA-3’ 
R70A Reverse 5’-TGCCGTGCGCGTCGGTAGCGCTGTCCAGGCCGACC-3’ 
R118A Forward 5’-CGCAATCTCTATACCGGCGGACTCCTACGTCGCGG-3’ 
R118A Reverse 5’-CCGCGACGTAGGAGTCCGCCGGTATAGAGATTGCG-3’ 
R236A Forward 5’-AGCGCTCAGCTTCGTTGCCCAGCGGCATGATCTGC-3’ 
R236A Reverse 5’-GCAGATCATGCCGCTGGGCAACGAAGCTGAGCGCT-3’ 
R238A Forward 5’-CAGCTTCGTTCGCCAGGCGCATGATCTGCCCCGCG-3’ 
R238A Reverse 5’-CGCGGGGCAGATCATGCGCCTGGCGAACGAAGCTG-3’ 
 
Table 5.7: Primers designed to produce Serine/Threonine to Aspartate mutants of M. tuberculosis murC. 
Table 5.8: Primers designed to produce Arginine to Alanine mutants of M. tuberculosis lcp1. 
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5.7. Agarose gel DNA electrophoresis 
DNA samples were added to Loading Dye (5 % glycerol (v/v), 0.04 % Bromophenol Blue), 
and loaded onto 1 % TAE (40 mM Tris-acetate, 1 mM EDTA, pH 8.0) agarose gel, containing 
5 % Midori Green dye (v/v) (Nippon Genetics) alongside 1 kb DNA ladder (New England 
Biolabs). Gel was run in 1 × TAE buffer at 140 V, 400 mA for 50 min. The gel was then 
visualised using a Gel Doc XR (Bio-Rad) with Image Lab software.  
5.8. DNA extraction from agarose gel 
DNA was extracted from agarose gel with the use of QIAquick gel extraction kit (Qiagen). 
The DNA band was excised from the agarose gel using a scalpel, but by minimising the 
amount of excess agarose in the slice. The agarose slice was then weighed and 3 volumes of 
Buffer QG was added to every 1 volume of agarose (3 µL: 1 mg). The agarose was then 
incubated at 50 °C for 10 min, until the agarose had dissolved. The pH of the solution was 
then checked, by assuring the mixture was yellow in colour (indicator shows pH ≤ 7.5). One 
gel volume of isopropanol was added to the solution and mixed, before being transferred to a 
QIAquick spin column. The column was centrifuged at 18,000 × g for 1 min, and the flow 
through was discarded. This was repeated until all the sample was passed through the spin 
column. The spin column was then washed with 500 µL Buffer QG and centrifuged at 18,000 
× g for 1 min. The flow through was discarded before 750 µL Buffer PE (Qiagen) was added 
to the spin column and was centrifuged at 18,000 × g for 1 min. The flow through was 
discarded and the spin column was again centrifuged at 18,000 × g for 1 min, to extract any 
residual flow through, which was then also discarded. The spin column was then inserted into 
a microcentrifuge tube, with 50 µL H2O being added to the column for 2 min. The tube was 
then centrifuged at 18,000 × g for 1 min and the DNA in the flow through was retained and 
stored at -20 °C. 
Chapter 5   Materials and Methods  
138  
5.8.1. ‘DNA clean up’ 
DNA that contained enzymes and buffers was cleaned by making use of QIAquick gel 
extraction kit (Qiagen). The DNA sample was mixed with 500 µL Buffer QG (Qiagen) and 
transferred to a QIAquick spin column. The column was then centrifuged at 18,000 × g for 1 
min and the flow through was discarded. The spin column was then washed with 750 µL 
Buffer PE (Qiagen) by centrifugation at 18,000 × g for 1 min. The flow through was 
discarded and the spin column was again centrifuged at 18,000 × g for 1 min, to extract any 
residual flow through, which was then also discarded. The spin column was then inserted into 
a microcentrifuge tube, with 50 µL H2O being added to the column for 2 min. The tube was 
then centrifuged at 18,000 × g for 1 min and the cleaned DNA in the flow through was 
retained and stored at -20 °C. 
5.9. Genomic DNA extraction 
Genomic DNA was extracted from 10 mL of bacterial culture, centrifuged at 3,300 × g for 15 
min. Cells were re-suspended in 450 µL Buffer P1 (Qiagen) (or 50 mM Tris HCl pH 8, 10 
mM EDTA and 100 µg/mL RNase A) and 50 µL of 10 mg/mL lysozyme, incubated at 37 °C 
overnight. 100 µL 10 % SDS was added to the suspension, alongside 50 µL 10 mg/mL 
proteinase K. The suspension was gently mixed and incubated at 55 °C for 4 h. 200 µL 5 M 
NaCl was added to the suspension, and was incubated at 65 °C for 15 min. Once the 
suspension was cooled, 500 µL chloroform (CHCl3) was added, gently mixed for 5 min, and 
then centrifuged at 18,000 × g for 5 min. The aqueous layer was taken, 350 µL ice cold 
isopropanol added and gently mixed by inversion until DNA precipitation. Mixture was 
centrifuged at 18,000 × g for 10 min at 4 °C. The supernatant was removed, 1 mL ice cold 70 
% ethanol (C2H5OH) was added and the tube was inverted gently. Sample was centrifuged at 
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18,000 × g for 5 min at 4 °C. Supernatant was removed and the DNA pellet was dried at room 
temperature for 20 min. The DNA was re-suspended in 50 µL H2O.  
5.10. Plasmid DNA extraction 
Plasmid DNA was extracted from 5 mL bacterial culture with use of QIAprep spin miniprep 
kit (Qiagen). Cells were pelleted by centrifugation at 3,300 × g for 15 min and supernatant 
discarded. Pellets were re-suspended in 250 µL Buffer P1 containing RNAse A (Qiagen) and 
transferred into microcentrifuge tubes. After this, 250 µL Buffer P2 (Qiagen) was added and 
mixed by tube inversion, before the addition of 350 µL Buffer N3 (Qiagen) which was also 
mixed by tube inversion. Mixtures were then centrifuged at 18,000 × g for 10 min, and the 
supernatant was extracted and transferred into a miniprep spin column (Qiagen). The spin 
column was centrifuged at 18,000 × g for 1 min and the flow through was discarded. The spin 
column was then washed with 500 µL Buffer PB (Qiagen), by centrifugation at 18,000 × g for 
1 min and the flow through was discarded. A final wash step of 750 µL Buffer PE (Qiagen) 
was then added to the spin column, and was centrifuged at 18,000 × g for 1 min, with the flow 
through being discarded. The spin column was again centrifuged at 18,000 × g for 1 min, to 
extract any residual flow through, which was then discarded. The spin column was then 
inserted into a microcentrifuge tube, with 50 µL H2O being added to the column for 2 min. 
The tube was then centrifuged at 18,000 × g for 1 min and the plasmid DNA in the flow 
through was retained and stored at -20 °C. 
5.11. Recombinant protein purification 
Transformed E. coli BL21(DE3) were induced for protein production, once OD600 = 0.5 was 
reached, by the addition of 1 mL 1 M IPTG (0.1 M final concentration). Cultures were then 
incubated at 16 °C overnight with shaking. Cells were then harvested from via centrifugation 
at 6,000 × g for 15 min at 4 °C. The supernatant was discarded and the pellet was re-
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suspended in Phosphate Buffered Saline (PBS). The re-suspended cells were then centrifuged 
at 3,300 × g for 18 min at 4 °C. The supernatant was once again discarded and the cell pellets 
were stored at -20 °C.  
An imidazole gradient was produced from ‘Purification Buffer’ (2 ×) (Section 5.1.10.) and 2 
M Imidazole pH 7.9. Protein containing pellet was defrosted then re-suspended in 20-30 mL 
‘lysis buffer’ (Section 5.1.10.1.), with a proteinase inhibitor tablet (Roche) added. The 
mixture was subsequently sonicated using a soniprep 150 (MSE) (30 sec on, 30 sec off, 10 
cycles). The solution was then centrifuged at 21,000 × g for 40 min at 4 °C, and the 
supernatant was retained (clarified lysate). Protein was purified using a HisTrap 1 mL/5 mL 
chelating HP column (GE healthcare) charged with 0.1 M NiCl2 (binds to 6x Histidine tag). 
The clarified lysate/flow-through and imidazole fractions were collected.   
Fractions that required further purification were loaded onto a 1 mL Q HP (anion exchange) 
column (GE healthcare) after dialysis. Protein was eluted using a NaCl gradient, made up 
from the same buffer system as the protein dialysis buffer (Section 5.1.11.). All fractions were 
collected.  
5.12. SDS-PAGE  
Protein fractions were mixed with SDS loading dye (2 % SDS, 125 mM Tris pH 6.8, 715 mM 
β-mercaptoethanol, 20 % glycerol made up to 1 mL with H2O) and incubated at 100 °C for 10 
min. Boiled samples, alongside PageRuler (Thermo Scientific) protein marker, were then ran 
on mini-PROTEAN TGX precast (Bio-Rad) gels at 200 V, 50 mA for 30 min. Gels were then 
incubated in Instant Blue stain (Expedeon) at room temperature with shaking for 1 h.  
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5.13. Western Blot 
Once subjected to SDS-PAGE (Section 5.12.) samples are transferred onto nitrocellulose 
membrane in Western transfer buffer (Section 5.1.15.) at 20 V, 300 mA for 1 h. The 
membrane was then blocked with 5 % milk (Source of Bovine Serum Albumin (BSA)) in 
TBS-T (Section 5.1.16.) or Western blocking buffer (Roche), before incubation at room 
temperature with 0.1 % milk. The primary antibody (mouse anti-His, Qiagen) was added 
(1:1,000), the membrane was then washed in TBS-T (Section 5.1.16) and the secondary 
antibody (goat anti-mouse, Sigma Aldrich) was added (1:25,000). The membrane was further 
washed in TBS-T and then in TBS (Section 5.1.16.) only. Bands were then developed by 
incubation in BCIP solution.  
5.14. Thin Layer Chromatography (TLC) 
Samples were re-suspended in 10 µL solvent and loaded onto aluminium-backed silica gel 
plates (5735 silica gel 60 F254, Merck). The plates were then placed into a running tank 
containing 0.5 cm depth of appropriate solvent mixture for samples to migrate across the 
plate. The plates were removed from the running tank once the solvent front had reached 
around 1 cm from the top of the plate, before being left to dry. Once dry, plates were 
visualised using phosphomolybdic acid and heat. In the case of radiolabelled TLC, the plates 
were developed on a storage phosphor screen (Kodak). Bands were then visualised on a 
Personal Molecular Imager (Bio-Rad) and compared to known standards. 
5.15. Ligand Binding Assays 
Purified protein, total volume of 400 µL in a quartz cuvette, was allowed to equilibrate to 25 
°C, inside a Fluorescence Spectrophotometer (Hitachi F-7000), with magnetic stirring (10 
min). Intrinsic Tryptophan Fluorescence (ITF) was measured at excitation wavelength of 280 
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nm, and emission wavelength of 300-400 nm (Femission), with an excitation and emission slit 
width of 5 nm. An emission maximum (Femissionmax) was recorded at 340 nm. Ligands were 
added to the cuvette in increasing concentration by 1 µL additions. The change in 
fluorescence emission (ΔFemission) was calculated by the subtraction of Femission (recorded 2 min 
after addition of ligand) from Femissionmax, this data was then plotted against ligand 
concentration [L]. Data analysis was performed using Microsoft Excel and then by fitting 
ΔFemission at 340 nm vs [L] to a one-site specific binding equation using Graphpad Prism 5: 
ΔFemission = Fmax × [L]/(Kd + [L]). 
5.16. Kinetic analysis of MurC site-directed mutants 
The assay mixture for the kinetic analysis of MurC was made up to a total volume of 200 µL 
in a quartz cuvette, with 1 mm path length. The assay mixture consisted of  MurC ‘Reaction 
buffer’ (Section 5.1.12.), 50 mM KCl, 1 mM dithiothreitol (DTT), 0.2 mM nicotinamide 
adenine dinucleotide (NADH), 2 mM phosphoenolpyruvate (PEP),  2 µL Pyruvate 
Kinase/Lactate Dehydrogenase (PKLDH, PK = 600-1000 U/mL,  LDH = 900-1400 U/mL), 
10 mM L-alanine, 0.1 µM MurC enzyme. In assays to assess the dependence of MurC on 
UDP-muramyl substrate, adenosine triphosphate (ATP), pH 7.5, was fixed at 1 mM. Assays 
to assess the dependence of MurC on ATP concentration fixed UDP-N-acetylmuramic acid at 
1.5 mM and UDP-N-glycolylmuramic acid at 100 µM. The variable substrate concentration 
ranged between 10-400 µM. All assays were made up to final volume with H2O, where L-
alanine was added as the final component to initiate reactions. UDP-muramyl substrates were 
provided by BacWAN (University of Warwick). All assays were perfomed at the University 
of Warwick using a Cary 100 UV/Visible double beam spectrophotometer (Varian/Agilent) 
equipped with a thermostatically controlled cell changer, set to 37 °C, reading at 340 nm. 
Data collection was performed using Cary WinUV software. Data analysis was performed 
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using Microsoft Excel and by fitting to a Michaelis-Menten model using Graphpad Prism 
software (Y = Vmax × X / (Km + X)).  
5.17. Bioinformatic analytical tools 
Homologous genes were identified using BLAST analysis against known search sequences 
(Altschul et al., 1990). Protein sequences were submitted to the I-TASSER server for 3D 
modelling prediction (Zhang, 2008, Roy et al., 2010, Yang et al., 2015, Yang and Zhang, 
2015), as well as to the TMHMM server for transmembrane helix prediction (Sonnhammer et 
al., 1998). 3D models were then analysed against known homologous x-ray crystal structures 
using UCSF Chimera software (Pettersen et al., 2004). Multiple protein sequences were then 
aligned for comparison using ClustalW2 (Goujon et al., 2010), which could then be used to 
identify residues of interest within the protein sequences. 
5.18. Production of plasmid vectors 
5.18.1. Expression vectors 
The gene to be expressed was amplified via PCR (Section 5.5.) with restriction sites 
corresponding to the selected expression plasmid. The gene product was then ran on 1 % TAE 
agarose gel electrophoresis (Section 5.7.). Bands at the correct molecular weight were excised 
and extracted (Section 5.8.). The extracted gene product as well as the expression plasmid was 
digested with the corresponding restriction enzymes for 1 h at 37 °C. A ‘DNA clean-up’ 
(Section 5.8.1.) was performed to remove the enzymes and buffer. A ligation was then 
performed between the gene product and expression vector using T4 DNA ligase (New 
England Biolabs) and the ligation mixtures were then transformed into E. coli Top 10 cells 
(Section 5.4.1.). Colonies that grew were selected and grown in 5 mL LB broth (50 µg/mL 
Kan) at 37 °C for 18 h, with shaking. The following day, plasmid DNA was extracted 
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(Section 5.10.) and the vector was digested using the corresponding restriction enzymes for 1 
h at 37 °C. Samples were ran on 1 % TAE agarose gel electrophoresis (Section 5.7.). Lanes 
that showed bands at the correct molecular weight (for plasmid and gene product) were 
successful ligations and were therefore retained. Samples were submitted for DNA 
sequencing for confirmation of complete vector (MWG Eurofins). 
5.18.2. Genetic knock-out mutant ‘rescue’ plasmid 
The gene of interest (GOI) was amplified via PCR (Section 5.5.), with restriction sites for 
HindIII and EcoRV, with the product being ran on 1 % TAE agarose gel electrophoresis 
(Section 5.7.). Bands at the correct molecular weight were excised and extracted (Section 
5.8.). The extracted gene was then digested with HindIII/EcoRV restriction enzymes for 1 h at 
37 °C. A ‘DNA clean-up’ (Section 5.8.1.) was performed to remove the enzymes and buffer. 
The plasmids pSD26 and pMV306 were both double digested (pSD26 – EcoRV/XbaI, 
pMV306 – XbaI/HindIII) for 1 h at 37 °C. The digestion was then ran on 1 % TAE agarose 
gel electrophoresis (Section 5.7.) and bands at the correct molecular weight for the 
acetamidase gene (from pSD26) and cut pMV306 were excised and extracted (Section 5.8.)  
A triple ligation between cut pMV306, acetamidase gene and GOI was performed using T4 
DNA ligase (New England Biolabs). The ligation mixtures were then transformed into E. coli 
Top 10 cells (Section 5.4.1.) and colonies that grew were selected and grown in 5 mL LB 
broth (50 µg/mL Kan) at 37 °C for 18 h, with shaking. The following day, plasmid DNA was 
extracted (Section 5.10.) and the vector was triple digested using XbaI/HindIII/EcoRV 
enzymes for 1 h at 37 °C. Samples were ran on 1 % TAE agarose gel electrophoresis (Section 
5.7.). Lanes that showed bands at the correct molecular weight (for plasmid, acetamidase gene 
and GOI) were successful ligations and were therefore retained. Samples were submitted for 
DNA sequencing for confirmation of complete vector (MWG Eurofins). 
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5.19. Production of genetic knock-out conditional mutant 
Electrocompetent M. smegmatis MC2 155 (5.3.2.) were electroporated (Section 5.4.2.) with 
the ‘rescue’ plasmid construct (Section 5.18.), as well as the original uncut pMV306 plasmid. 
The electroporated cells were plated onto TSA plates (50 µg/mL Kan) and incubated at 37 °C 
for 4 days. Successfully electroporated cells containing the construct were stored as a glycerol 
stock (500 µL) at -80 °C. The remaining cell culture were once again made electrocompetent 
(Section 5.3.2.) and also stored at -80 °C. 
For the generation of the ΔGOI phasmid, around 1 kb of flanking region sequences both up 
and downstream of the GOI were cloned (with primers containing Van91I restriction sites on 
5’ ends (Section 5.5.1.)). These fragments were then digested with Van91I, ligated into 
Van91I digested p0004S (A gift from T. Hsu and W.R. Jacobs Jr., Albert Einstein College of 
Medicine, NY) and subsequently sequenced, by Dr G.S. Lloyd. The correctly sequenced DNA 
was then linearised by PacI digestion and packaged into the temperature sensitive 
mycobacteriophage phAE159 by Mr Albel Singh, to yield the knockout phage phΔGOI 
phasmid DNA. 
In order to produce high-titre phage for transduction, phΔGOI phasmid was electoporated into 
electrocompetent M. smegmatis WT cells (Section 5.4.2.), which were then incubated in 1 mL 
TSB at 30 °C for 4 h. After this, 100 µL of electroporated cells were added to 0.5 mL pre-
grown M. smegmatis culture (OD600=0.8-1), whilst the remaining cells were added to 100 µL 
of the pre-grown M. smegmatis culture. Both mixtures were added to separate tubes each 
containing 4 mL ‘top agar’ (Section 5.1.8.) molten at around 50 °C. This ‘top agar’ mixture is 
then added atop of 7H9 basal agar plates (Section 5.1.7.) and incubated at 30 °C for 3 days. 
After this, 1-2 plaques were extracted and added to 200 µL MP buffer (Section 5.1.13.) and 
phage was extracted by incubation at room temperature for at least 3 h. Once extracted, 5 µL 
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of lysate (as well as 5 µL of a 1:5 dilution in a separate tube) was added to 4 mL ‘top agar’ 
(containing M. smegmatis WT), which was added on top of 7H9 basal agar plates, and then 
incubated at 30 °C for 3 days. The plate containing around 1000 plaques (known as ‘lacy’ 
pattern) was selected and 5 mL MP buffer was added atop of the plate for at least 4 h at room 
temperature, to extract phage. Lysate was then filtered through a 0.2 µm syringe filter, and 
stored at 4 °C. The titre of the phage was checked by producing a 10-fold dilution series, 
whereby 100 µL of each dilution was spotted onto M. smegmatis WT containing ‘top agar’, 
on top of 7H9 basal agar. These plates were then incubated at 30 °C for 2-3 days, and the 
numbers of plaques were counted, to calculate the number of plaque forming units (PFU) titre 
of the lysate. 
Electroporated M. smegmatis (containing ‘rescue’ plasmid (Section 5.18.)) was streaked from 
glycerol stock onto TSA plates (containing 50 µg/mL Kan) alongside M. smegmatis WT 
which were streaked onto antibiotic free TSA plates. All plates were incubated at 37 °C for 2 
days. Colonies were picked using a sterile loop, and used to inoculate 5 mL TSB containing 
Tween 80 (0.05 % v/v) (+ Kan for vector containing cells). These cultures were then 
incubated at 37 °C with shaking for 2 days. Once grown, 500 µL of each 5 mL culture was 
used to seed into 50 mL TSB (containing the same additives as 5 mL cultures). These were 
incubated at 37 °C with shaking overnight. The following day, 50 mL cultures were 
centrifuged at 3,300 × g for 15 min, supernatant discarded and the pellet was washed twice 
with MP buffer to remove Tween 80 (3,300 × g for 15 min performed between washes). The 
pellets were then re-suspended in 2 mL MP buffer, with the addition of 1 mL MP buffer 
containing high-titre phΔGOI. The suspensions were then incubated at 37 °C overnight, to 
induce lysogeny. The following day suspensions were centrifuged at 3,300 × g for 15 min, 
and the pellets were re-suspended in 2 mL TSB containing Tween 80 (0.05 % v/v) and 
acetamide (acet) (0.2 % w/v) each and incubated at 37 °C for 5 h. Cells were then plated 
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across TSB agar plates containing either Hyg only for WT, or Hyg, Kan and acet for ‘rescue’ 
plasmid containing cells. All plates were incubated at 37 °C for 3 days. 
5.20. Growth of mutant strains for validation of genetic knock out 
Hyg and Kan resistant colonies from knock out plates (Section 5.19.) were streaked onto TSB 
agar containing Kan, Hyg and acet and incubated at 37 °C for 3 days. Single colonies from 
these plates were looped and used to inoculate 5 mL TSB containing Kan, Hyg, acet and +/- 
Tween 80 (0.05 %). Cultures were incubated at 37 °C for 2 days. 2 mL of culture was 
centrifuged at 3,300 × g for 15 min and the pellet was twice washed in 10 mL TSB containing 
Tween 80 (0.05 %) (to remove acet). The pellet was re-suspended in 2 mL TSB with Tween 
80 (0.05 %), and mixed with 8 mL TSB containing Hyg, Kan and Tween. Cultures were then 
incubated at 37 °C for 1-2 days to deplete intracellular GOI. 30 µL of the 10 mL culture was 
used to inoculate separate 3 mL TSB (containing Hyg, Kan and Tween 80) with +/- acet. 
Cultures were incubated at 37 °C overnight, and the following day were checked for growth.  
5.21. Extraction of bound decaprenyl-1-monophosphate from MtbLcp1 
2 mL of recombinant MtbLcp1 (41.2 µM) (WT and site-directed mutants) was mixed with 2 
mL CHCl3 and 1 mL methanol (CH3OH) and incubated at 60 °C for 2 h. The samples were 
then centrifuged at 5,000 × g for 10 min. The lower organic phase was then collected and 
dried under nitrogen, before being re-suspended in 100 µL CHCl3:CH3OH (2:1, v/v). Samples 
were then analysed by TLC (Section 5.14.) and electrospray mass spectrometry (ES-MS) in 
the negative mode using a Micromass LCT mass spectrometer.  
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5.22. Biophysical analysis of MtbLcp1 
Circular Dichroism (CD) was performed on WT and mutant MtbLcp1 at a concentration of 
around 2 µM. CD was recorded using a Jasco J-715 spectropolarimeter, using 300 µL protein 
sample in a 1 mm quartz cuvette. Spectra were recorded at 1 nm bandwidth, at 50 nm/min 
between a range of 260-190 nm. Once the spectra were recorded, 9 pt Savitzky-Golay 
smoothing was applied. CD was performed by the Birmingham Biophysical Characterisation 
Facility (BBCF). Data was analysed using Microsoft Excel software.  
Analytical ultracentrifugation (AUC) was performed using WT and mutant MtbLcp1, as well 
as MtbLcp1 WT with increasing concentration of ‘Compound 1’ ligand (2, 4 and 6 mM 
respectively). All samples were between 13-19 µM of protein (between 0.35 and 0.5 
absorbance at A280). 500 µL of each sample was centrifuged at 110,000 × g inside a 
Beckman XLI Ultracentrifuge. AUC was performed by the BBCF. All data was analysed 
using SEDFIT and Microsoft Excel software.  
5.23. Cell-free MtbLcp1 protein activity assay 
5.23.1. Extraction of M. smegmatis membranes 
M. smegmatis WT was grown in 1 L TSB at 37 °C for 2 days. Cells were then harvested via 
centrifugation at 6,000 × g for 20 min at 4 °C. Supernatant was discarded, and cells were re-
suspended in 30 mL PBS. Suspended cells were centrifuged at 3,300 × g for 15 min and the 
supernatant was discarded. M. smegmatis pellet was re-suspended in 24 mL ‘Buffer A’ 
(Section 5.1.14.), and then sonicated (60 on, 90 off, 15 cycles). Lysate was then centrifuged at 
21,000 × g for 30 min at 4 °C. Supernatant and pellet were then split, but retained (pellet used 
for P60 cell wall fraction (Section 5.23.2.)). The supernatant was then centrifuged at 100,000 
× g for 1 h 30 min. The supernatant was then discarded and 200 µL ‘Buffer A’ was added to 
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the top of the pellet and left on ice overnight. Pellets were then homogenised and transferred 
into a microcentrifuge tube. The suspension was further homogenised into a uniform 
preparation (not containing bubbles). Membrane preparation was aliquoted into 4 x 250 µL 
and stored at -20 °C. 
 5.23.2. Extraction of P60 cell wall fraction 
The separated pellet (Section 5.23.1.) was re-suspended in 24 mL ‘Buffer A’ (Section 5.1.14.) 
and split into 2 centrifuge tubes (12 mL in each) and 18 mL Percoll (60 %) was added to each. 
Samples were centrifuged at 15,000 × g for 50 min. The middle layer was then extracted from 
each tube and combined using a plastic pipette. Combined samples were then equally 
separated into 2 centrifuge tubes and made up to 30 mL with ‘Buffer A’, and centrifuged at 
39,000 × g for 20 min. Supernatant was discarded and pellet washed with 30 mL ‘Buffer A’. 
Centrifugation at 39,000 × g for 20 min was repeated twice more with 30 mL ‘Buffer A’ 
washes in-between. Pellets were finally combined in 5 mL ‘Buffer A’ and stored at -20 °C.  
5.23.3. Preparation of nascent mycobacterial peptidoglycan 
M. smegmatis WT was grown to 1 L in TSB (Section 5.23.1.), and harvested via 
centrifugation at 6,000 × g for 15 min. Pelleted M. smegmatis was re-suspended in H2O 
before addition of CHCl3:CH3OH (1:1 v/v) to create a CHCl3:CH3OH:H2O (10:10:3 v/v/v) 
single phase. The suspension was centrifuged at 3,300 × g for 15 min, the resulting 
supernatant was discarded and the remaining pellet was re-suspended in 30-40 mL H2O. The 
cell suspension was sonicated (Soniprep 150, MSE) (60 on, 90 off, 15 cycles), before the 
addition of 1 % (v/v) Triton X100 and incubation at room temperature for 16 h. The 
suspension was then centrifuged at 3,300 × g for 15 min. The remaining insoluble material 
was extracted three times with 2 % (w/v) SDS in PBS at 95 °C for 1 h, before being 
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consecutively washed with H2O, 80 % (v/v) (CH3)2CO  in H2O,  then 100 % (CH3)2CO and 
finally lyophilised to yield purified cell wall mAGP preparation.  
Mycolic acids were removed from the mAGP by addition of 0.5 % (w/v) KOH in CH3OH, 
incubated at 37 °C for 4 days. The suspension was then centrifuged at 27,000 × g for 20 min 
in order to collect the treated mAGP, which was then washed repeatedly with 100 % CH3OH 
before the pellet was finally recovered by centrifugation at 27,000 × g for 20 min. The 
mycolic acids were then extracted from the pellet by treatment with diethyl ether ((C2H5)2O) 
and then centrifugation at 27,000 × g, which was repeated three times to result in supernatant 
containing mycolic acid methyl esters, and pellet containing the remaining AGP complex. 
The pellet material was then hydrolysed with 0.2 M H2SO4 at 85 °C for 30 min, then 
neutralised with BaCO3. After centrifugation at 27,000 × g for 30 min, the supernatant 
(containing solubilised arabinogalactan (AG)) was removed and the remaining insoluble 
pellet material (containing highly purified peptidoglycan (PPG)) was repeatedly washed with 
H2O, before being lyophilised and stored at -20 °C. 
5.23.4. Assay procedure 
The assay mixture consisted of 0.5 mg purified M. smegmatis membranes (Section 5.23.1.), 1 
mg P60 cell wall fraction (Section 5.23.2.), 0.2 mM ATP, 0.2 mM NADH, 15 mg PPG 
(Section 5.23.3.), MtbLcp1 (0.3 µM (+) or 0.9 µM (++)) and reactions were initiated by the 
addition of 0.1 µCi UDP-[14C]-D-Galactose (Specific activity 300 mCi/mmol, ARC 
radiochemicals) (final volume 200 µL, made up with ‘Buffer A’ (Section 5.1.14.)). All 
reactions were incubated at 37 °C for 17 h. Reactions were quenched by the addition of 1333 
µL of CHCl3:CH3OH (1:1 v/v) to form a CHCl3:CH3OH:H2O (10:10:3 v/v/v) single phase. 
Samples were centrifuged at 18,000 × g for 15 min, supernatant was extracted, and the pellet 
retained for further processing. The supernatant was dried under nitrogen, before re-
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suspension in 2 mL CHCl3:H2O (1:1 v/v). The lower organic phase was separated from the 
upper aqueous phase, and both extractions were retained for later analysis (Figure 5.1). The 
earlier insoluble pellet was re-suspended in 1 mL 
H2O:C2H5OH:(C2H5)2O:pyridine(C5H5N):NH4OH (15:15:5:1:0.017, v/v/v/v/v) (named ‘E-
soak’), and incubated at room temperature for 2 h. Samples were then centrifuged at 18,000 × 
g for 15 min and the supernatant was extracted and kept for later analysis (Figure 5.1). The 
remaining insoluble pellet was re-suspended in 200 µL H2O for further analysis. Each 
extraction stage (Upper aqueous, Lower organic, ‘E-soak’ and insoluble pellet) were 
quantified for radioactivity through liquid scintillation counting, by using 10 % of material 
with 5 mL EcoScintA (National Diagnostics). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: A flow-chart showing the fractionation steps of Lcp1 activity assay. The assay mixture was incubated at 37 °C for 18 h before being quenched with CHCl3:CH3OH (1:1 v/v) to form a CHCl3:CH3OH:H2O (10:10:3 v/v/v) single phase. This was then separated into soluble and insoluble fractions. The soluble fraction was again separated into aqueous and organic fractions using CHCl3:H2O (1:1 v/v). The insoluble fraction was solubilised in ‘E-soak’, before once again being separated into soluble and insoluble fractions. 
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5.23.5. Analysis of assay extractions 
The Lower organic and ‘E-soak’ samples were dried under nitrogen. The Lower organic 
material samples were then re-suspended in 10 µL CHCl3. This resuspension as well as 10 µL 
of the Upper aqueous material were ran on TLC plates (Section 5.14.). 
‘E-soak’ material was re-suspended in 30 µL LDS loading dye with DTT (Expedeon), before 
being loaded onto mini-PROTEAN Tris-Tricine (Bio-Rad) SDS-PAGE (200 V, 80 mA, 1.5 
h). The gel was then transferred onto a 0.2 µm nitrocellulose membrane. Transfer was run at 
20 V, 300 mA for 1.5 h. Western blot was performed (Section 5.13.), but the primary 
antibody used was CS-35 (mouse anti-hexa-arabinofuranoside) (1:1000 dilution)) and the 
secondary antibody was goat anti-mouse SC-2070 (1:25,000). After visualisation, the blot was 
then additionally visualised by autoradiography, through exposure to X-ray film (Kodak X-
Omat). Bands on the membrane and film were then analysed against each other.   
The insoluble material was hydrolysed in 2 M trifluoroacetic acid at 120 °C for 2 h, before 
being dried under nitrogen. Samples were then reduced by addition of 100 µL sodium 
borohydride (NaBH4) (10 mg/mL in 1 M NH4OH:C2H5OH (1:1 v/v)) incubated at room 
temperature for 2 h. Glacial acetic acid was then added (3 drops) before being dried under 
nitrogen. A further 3 drops of 10 % glacial acetic acid in CH3OH was added to samples before 
being dried under nitrogen. 100 % CH3OH was then added by 3 drops before being dried 
under nitrogen, which was repeated, in order to thoroughly dry samples. Once dry, samples 
were per-O-acetylated by the addition of 100 µL acetic anhydride and incubation at 120 °C 
for 1 h. Once cooled, 100 µL toluene was added and samples were dried under nitrogen. 
Samples were then re-suspended in 4 mL CHCl3:H2O (1:1 v/v) and centrifuged at 3,300 × g 
for 15 min. The lower phase was extracted and dried under nitrogen. The resulting per-O-
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acetylated alditol acetates were re-suspended in 10 µL CHCl3 and ran on a TLC plate (Section 
5.14.). 
5.24. Phosphatase activity assay 
Geranyl pyrophosphate (GPP) and Geranylgeranyl pyrophosphate (GGPP) ammonium salts 
were added to separate tubes (25 µL of 1 mg/mL stock, Sigma Aldrich) and dried under 
nitrogen. Samples were then re-suspended in ‘Buffer A’ (Section 5.1.14.) before the addition 
of MtbLcp1 WT and site-directed mutants to a final volume of 200 µL. Samples were then 
incubated at 37 °C for 3 h, before the addition of 1 mL CHCl3. The lower phase was then 
extracted from each sample, and dried under nitrogen. Each sample was then re-suspended in 
10 µL CHCl3 and ran on a TLC plate (Section 5.14.). 
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